JP6817952B2 - ピリミジン誘導体 - Google Patents
ピリミジン誘導体 Download PDFInfo
- Publication number
- JP6817952B2 JP6817952B2 JP2017547876A JP2017547876A JP6817952B2 JP 6817952 B2 JP6817952 B2 JP 6817952B2 JP 2017547876 A JP2017547876 A JP 2017547876A JP 2017547876 A JP2017547876 A JP 2017547876A JP 6817952 B2 JP6817952 B2 JP 6817952B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- oxo
- isobutyramide
- dihydropyrimidine
- benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000003230 pyrimidines Chemical class 0.000 title description 12
- 150000001875 compounds Chemical class 0.000 claims description 488
- -1 N-(3- [4- [6- (2-ethoxyethoxy) Pyridine-3-yl] -6-oxo-1,6-dihydropyrimidine-2-yl] -4- (trifluoromethyl) benzyl) isobutyramide Amide Chemical class 0.000 claims description 319
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 113
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 92
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 claims description 87
- 125000001424 substituent group Chemical group 0.000 claims description 51
- 229940047889 isobutyramide Drugs 0.000 claims description 48
- 150000003839 salts Chemical class 0.000 claims description 39
- 125000000217 alkyl group Chemical group 0.000 claims description 33
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 30
- 229920006395 saturated elastomer Polymers 0.000 claims description 24
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 23
- 125000005843 halogen group Chemical group 0.000 claims description 23
- 229960002986 dinoprostone Drugs 0.000 claims description 22
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims description 22
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 19
- 125000000623 heterocyclic group Chemical group 0.000 claims description 17
- 208000002193 Pain Diseases 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 206010061218 Inflammation Diseases 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 13
- 230000004054 inflammatory process Effects 0.000 claims description 13
- 125000002950 monocyclic group Chemical group 0.000 claims description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 11
- 125000005842 heteroatom Chemical group 0.000 claims description 11
- 239000003112 inhibitor Substances 0.000 claims description 11
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 9
- FPZWZCWUIYYYBU-UHFFFAOYSA-N 2-(2-ethoxyethoxy)ethyl acetate Chemical group CCOCCOCCOC(C)=O FPZWZCWUIYYYBU-UHFFFAOYSA-N 0.000 claims description 7
- 206010037660 Pyrexia Diseases 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 230000001629 suppression Effects 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 6
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 6
- 201000008482 osteoarthritis Diseases 0.000 claims description 6
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 5
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 5
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 5
- 208000017442 Retinal disease Diseases 0.000 claims description 5
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 5
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 5
- 125000002252 acyl group Chemical group 0.000 claims description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 5
- 230000000302 ischemic effect Effects 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- 125000002837 carbocyclic group Chemical group 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- XTXMIGGTHGFYRN-UHFFFAOYSA-N C1(CC1)COC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C(=C(CNC(C(C)C)=O)C=CC=1F)F Chemical compound C1(CC1)COC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C(=C(CNC(C(C)C)=O)C=CC=1F)F XTXMIGGTHGFYRN-UHFFFAOYSA-N 0.000 claims description 3
- IFXRFOKFQWSNPB-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C1=NC=C(C=C1)C(F)(F)F)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C1=NC=C(C=C1)C(F)(F)F)=O IFXRFOKFQWSNPB-UHFFFAOYSA-N 0.000 claims description 3
- JRKXIIABPAKMQZ-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)C#CC1CC1)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)C#CC1CC1)=O JRKXIIABPAKMQZ-UHFFFAOYSA-N 0.000 claims description 3
- HJMNPQXVGODGAL-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OC(F)F)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OC(F)F)=O HJMNPQXVGODGAL-UHFFFAOYSA-N 0.000 claims description 3
- DXPHEQNKXKVMQP-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC1CC1)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC1CC1)=O DXPHEQNKXKVMQP-UHFFFAOYSA-N 0.000 claims description 3
- AQFUJTCOZAMFNA-UHFFFAOYSA-N FC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C1=NC=C(C=C1)C(F)(F)F)=O)C(F)(F)F Chemical compound FC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C1=NC=C(C=C1)C(F)(F)F)=O)C(F)(F)F AQFUJTCOZAMFNA-UHFFFAOYSA-N 0.000 claims description 3
- AOCHGQRPWAMLQI-UHFFFAOYSA-N FC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)OC)=O)C(F)(F)F Chemical compound FC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)OC)=O)C(F)(F)F AOCHGQRPWAMLQI-UHFFFAOYSA-N 0.000 claims description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 2
- HYNKMWIUMSRCSU-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C1=NC=C(C=C1)Cl)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C1=NC=C(C=C1)Cl)=O HYNKMWIUMSRCSU-UHFFFAOYSA-N 0.000 claims description 2
- QKWNCQMDBXPIGF-UHFFFAOYSA-N ClC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C1=NC=C(C=C1)C(F)(F)F)=O)F Chemical compound ClC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C1=NC=C(C=C1)C(F)(F)F)=O)F QKWNCQMDBXPIGF-UHFFFAOYSA-N 0.000 claims description 2
- 206010011796 Cystitis interstitial Diseases 0.000 claims description 2
- NFIRWPIZBJBUCD-UHFFFAOYSA-N FC(OC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C(=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)F)F Chemical compound FC(OC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C(=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)F)F NFIRWPIZBJBUCD-UHFFFAOYSA-N 0.000 claims description 2
- 206010020853 Hypertonic bladder Diseases 0.000 claims description 2
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims description 2
- 206010029279 Neurogenic bladder Diseases 0.000 claims description 2
- HAFTZDQOLSDINN-UHFFFAOYSA-N O=C1C=C(N=C(N1)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)C=1C=NC(=CC=1)OCC1CCOCC1 Chemical compound O=C1C=C(N=C(N1)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)C=1C=NC(=CC=1)OCC1CCOCC1 HAFTZDQOLSDINN-UHFFFAOYSA-N 0.000 claims description 2
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims description 2
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 claims description 2
- 208000009911 Urinary Calculi Diseases 0.000 claims description 2
- 206010046543 Urinary incontinence Diseases 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 230000000422 nocturnal effect Effects 0.000 claims description 2
- 208000020629 overactive bladder Diseases 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 101710096361 Prostaglandin E synthase Proteins 0.000 claims 1
- 208000025844 Prostatic disease Diseases 0.000 claims 1
- 206010013990 dysuria Diseases 0.000 claims 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 394
- 238000000034 method Methods 0.000 description 348
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 311
- GZVUWANWWQXKQR-UHFFFAOYSA-N 2-methylpropanamide;hydrochloride Chemical compound Cl.CC(C)C(N)=O GZVUWANWWQXKQR-UHFFFAOYSA-N 0.000 description 157
- 238000006243 chemical reaction Methods 0.000 description 68
- 239000000203 mixture Substances 0.000 description 64
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 60
- 239000000243 solution Substances 0.000 description 48
- 239000002904 solvent Substances 0.000 description 45
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 36
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 33
- 238000010898 silica gel chromatography Methods 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 28
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- 238000000746 purification Methods 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 26
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 24
- 239000012299 nitrogen atmosphere Substances 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- ARUJJNVNLJPSDO-UHFFFAOYSA-N butanamide;hydrochloride Chemical compound Cl.CCCC(N)=O ARUJJNVNLJPSDO-UHFFFAOYSA-N 0.000 description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 19
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 18
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 17
- PDOIMVAAISWSFS-UHFFFAOYSA-N 3-chloro-2-fluoro-6-(trifluoromethyl)benzenecarboximidamide hydrochloride Chemical compound Cl.NC(=N)c1c(F)c(Cl)ccc1C(F)(F)F PDOIMVAAISWSFS-UHFFFAOYSA-N 0.000 description 16
- NRGBKYVUEUMGTE-UHFFFAOYSA-N 6-(difluoromethoxy)pyridine-3-carbaldehyde Chemical compound FC(F)OC1=CC=C(C=O)C=N1 NRGBKYVUEUMGTE-UHFFFAOYSA-N 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 16
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 16
- 238000001816 cooling Methods 0.000 description 16
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 16
- MRPAGRCGPAXOGS-UHFFFAOYSA-N 6-(trifluoromethyl)pyridine-3-carbaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)C=N1 MRPAGRCGPAXOGS-UHFFFAOYSA-N 0.000 description 15
- 239000012044 organic layer Substances 0.000 description 15
- 229910000027 potassium carbonate Inorganic materials 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 13
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 13
- 235000019341 magnesium sulphate Nutrition 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 230000035484 reaction time Effects 0.000 description 12
- QSVPMTXHKPJXIR-UHFFFAOYSA-N 6-(2-propoxyethoxy)pyridine-3-carbaldehyde Chemical compound C(CC)OCCOC1=CC=C(C=N1)C=O QSVPMTXHKPJXIR-UHFFFAOYSA-N 0.000 description 11
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 10
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 10
- 125000001544 thienyl group Chemical group 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 9
- VHWJSJBTUWUEAL-UHFFFAOYSA-N propanamide;hydrochloride Chemical compound Cl.CCC(N)=O VHWJSJBTUWUEAL-UHFFFAOYSA-N 0.000 description 9
- JJDDVGAESNBKMY-UHFFFAOYSA-N 5-(trifluoromethyl)pyridine-2-carbaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)N=C1 JJDDVGAESNBKMY-UHFFFAOYSA-N 0.000 description 8
- YYLBDBOSXXSZQQ-UHFFFAOYSA-N 5-chloropyridine-2-carbaldehyde Chemical compound ClC1=CC=C(C=O)N=C1 YYLBDBOSXXSZQQ-UHFFFAOYSA-N 0.000 description 8
- RZRCCVPCOBSNON-UHFFFAOYSA-N 6-(2-ethoxyethoxy)pyridine-3-carbaldehyde Chemical compound CCOCCOC1=CC=C(C=O)C=N1 RZRCCVPCOBSNON-UHFFFAOYSA-N 0.000 description 8
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 7
- 125000001819 4H-chromenyl group Chemical group O1C(=CCC2=CC=CC=C12)* 0.000 description 7
- KVAFDURIBQGXOV-UHFFFAOYSA-N 5-(2-cyclopropylethynyl)pyridine-2-carbaldehyde Chemical compound C1(CC1)C#CC=1C=CC(=NC=1)C=O KVAFDURIBQGXOV-UHFFFAOYSA-N 0.000 description 7
- MDPHMVYKMRFNPC-UHFFFAOYSA-N 6-(2-propan-2-yloxyethoxy)pyridine-3-carbaldehyde Chemical compound CC(C)OCCOC1=CC=C(C=O)C=N1 MDPHMVYKMRFNPC-UHFFFAOYSA-N 0.000 description 7
- JAZGZNUKSCDSDF-UHFFFAOYSA-N 6-(cyclopropylmethoxy)pyridine-3-carbaldehyde Chemical compound N1=CC(C=O)=CC=C1OCC1CC1 JAZGZNUKSCDSDF-UHFFFAOYSA-N 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 6
- CTNMHLKNBBSQOH-UHFFFAOYSA-N 6-(2-cyclopropylethynyl)pyridine-3-carbaldehyde Chemical compound C1(CC1)C#CC1=CC=C(C=N1)C=O CTNMHLKNBBSQOH-UHFFFAOYSA-N 0.000 description 6
- ROARRKDOMGZNFY-UHFFFAOYSA-N 6-ethoxypyridine-3-carbaldehyde Chemical compound CCOC1=CC=C(C=O)C=N1 ROARRKDOMGZNFY-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 6
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 6
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 6
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 5
- WXLCDTBTIVJDCE-UHFFFAOYSA-N 1,4-oxazepine Chemical compound O1C=CC=NC=C1 WXLCDTBTIVJDCE-UHFFFAOYSA-N 0.000 description 5
- QPPOMEOQNLTFRU-UHFFFAOYSA-N 1,4-thiazepine Chemical compound S1C=CC=NC=C1 QPPOMEOQNLTFRU-UHFFFAOYSA-N 0.000 description 5
- JGQPSDIWMGNAPE-UHFFFAOYSA-N 2,1-benzothiazole Chemical compound C1=CC=CC2=CSN=C21 JGQPSDIWMGNAPE-UHFFFAOYSA-N 0.000 description 5
- FZKCAHQKNJXICB-UHFFFAOYSA-N 2,1-benzoxazole Chemical compound C1=CC=CC2=CON=C21 FZKCAHQKNJXICB-UHFFFAOYSA-N 0.000 description 5
- BCELHNLIYYAOLV-UHFFFAOYSA-N 5-chloropyridine-3-carbaldehyde Chemical compound ClC1=CN=CC(C=O)=C1 BCELHNLIYYAOLV-UHFFFAOYSA-N 0.000 description 5
- ZKUVXNUOOFYCIE-UHFFFAOYSA-N 6-(2,2-difluoroethoxy)pyridine-3-carbaldehyde Chemical compound FC(F)COC1=CC=C(C=O)C=N1 ZKUVXNUOOFYCIE-UHFFFAOYSA-N 0.000 description 5
- WTUULYKWJAFCTQ-UHFFFAOYSA-N 6-[2-(2,2,2-trifluoroethoxy)ethoxy]pyridine-3-carbaldehyde Chemical compound FC(COCCOC1=CC=C(C=N1)C=O)(F)F WTUULYKWJAFCTQ-UHFFFAOYSA-N 0.000 description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 5
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 125000001309 chloro group Chemical group Cl* 0.000 description 5
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 125000001153 fluoro group Chemical group F* 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 150000007530 organic bases Chemical class 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 4
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 4
- XZSQOQJHPJRFBG-UHFFFAOYSA-N 2-(2-cyclopropylethynyl)-1,3-thiazole-5-carbaldehyde Chemical compound C1(CC1)C#CC=1SC(=CN=1)C=O XZSQOQJHPJRFBG-UHFFFAOYSA-N 0.000 description 4
- IOSOHXWZMSCSEJ-UHFFFAOYSA-N 2-(cyclopropylmethoxy)pyrimidine-5-carbaldehyde Chemical compound N1=CC(C=O)=CN=C1OCC1CC1 IOSOHXWZMSCSEJ-UHFFFAOYSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 4
- XHELRKTWQYMJJH-UHFFFAOYSA-N 5-(cyclopropylmethoxy)pyridine-2-carbaldehyde Chemical compound C1=NC(C=O)=CC=C1OCC1CC1 XHELRKTWQYMJJH-UHFFFAOYSA-N 0.000 description 4
- UQJXXLAPNMGZDF-UHFFFAOYSA-N 5-(difluoromethoxy)pyridine-2-carbaldehyde Chemical compound FC(F)OC1=CC=C(C=O)N=C1 UQJXXLAPNMGZDF-UHFFFAOYSA-N 0.000 description 4
- FEPXZFGQVDIXMZ-UHFFFAOYSA-N 5-fluoropyridine-3-carbaldehyde Chemical compound FC1=CN=CC(C=O)=C1 FEPXZFGQVDIXMZ-UHFFFAOYSA-N 0.000 description 4
- XKOBNYABZGUMQN-UHFFFAOYSA-N 6-(2,2,2-trifluoroethoxy)pyridine-3-carbaldehyde Chemical compound FC(F)(F)COC1=CC=C(C=O)C=N1 XKOBNYABZGUMQN-UHFFFAOYSA-N 0.000 description 4
- YQORPWDERUJAEL-UHFFFAOYSA-N 6-(oxan-4-ylmethoxy)pyridine-3-carbaldehyde Chemical compound O1CCC(CC1)COC1=CC=C(C=N1)C=O YQORPWDERUJAEL-UHFFFAOYSA-N 0.000 description 4
- HQULYFAKUZDRPB-UHFFFAOYSA-N 6-bromo-2-[4-(trifluoromethoxy)phenoxy]-1,3-benzothiazole Chemical compound BrC1=CC2=C(N=C(S2)OC2=CC=C(C=C2)OC(F)(F)F)C=C1 HQULYFAKUZDRPB-UHFFFAOYSA-N 0.000 description 4
- AFWWKZCPPRPDQK-UHFFFAOYSA-N 6-chloropyridine-3-carbaldehyde Chemical compound ClC1=CC=C(C=O)C=N1 AFWWKZCPPRPDQK-UHFFFAOYSA-N 0.000 description 4
- CTAIEPPAOULMFY-UHFFFAOYSA-N 6-methoxypyridine-3-carbaldehyde Chemical compound COC1=CC=C(C=O)C=N1 CTAIEPPAOULMFY-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- OULBWXQESPQCJR-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC(=NC=C1)C(F)(F)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC(=NC=C1)C(F)(F)F)=O OULBWXQESPQCJR-UHFFFAOYSA-N 0.000 description 4
- OWXPDSXENTXKIY-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=NC=1)C(F)(F)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=NC=1)C(F)(F)F)=O OWXPDSXENTXKIY-UHFFFAOYSA-N 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- NCYMYLUDQDWAHU-UHFFFAOYSA-N FC(C1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)C(F)(F)F)=O)F Chemical compound FC(C1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)C(F)(F)F)=O)F NCYMYLUDQDWAHU-UHFFFAOYSA-N 0.000 description 4
- 208000010412 Glaucoma Diseases 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 4
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 4
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 150000001340 alkali metals Chemical class 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- NPTDXPDGUHAFKC-UHFFFAOYSA-N ethynylcyclopropane Chemical group C#CC1CC1 NPTDXPDGUHAFKC-UHFFFAOYSA-N 0.000 description 4
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 4
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 3
- CPTUUXGFFRYFKP-UHFFFAOYSA-N 3-(aminomethyl)-6-chloro-2-fluorobenzonitrile Chemical compound NCC=1C(=C(C#N)C(=CC=1)Cl)F CPTUUXGFFRYFKP-UHFFFAOYSA-N 0.000 description 3
- KESSGSGWVZVSBE-UHFFFAOYSA-N 4-(trifluoromethyl)-1,3-thiazole-2-carbaldehyde Chemical compound FC(F)(F)C1=CSC(C=O)=N1 KESSGSGWVZVSBE-UHFFFAOYSA-N 0.000 description 3
- MRMKKOBVCYQHDQ-UHFFFAOYSA-N 5-(2-cyclopropylethynyl)-1,3-thiazole-2-carbaldehyde Chemical compound C1(CC1)C#CC1=CN=C(S1)C=O MRMKKOBVCYQHDQ-UHFFFAOYSA-N 0.000 description 3
- WFDUNOOWOFZPII-UHFFFAOYSA-N 5-(2-cyclopropylethynyl)pyridine-3-carbaldehyde Chemical compound C1(CC1)C#CC=1C=C(C=NC=1)C=O WFDUNOOWOFZPII-UHFFFAOYSA-N 0.000 description 3
- VRSKZZIXPDVEFN-UHFFFAOYSA-N 5-(aminomethyl)-2-fluorobenzonitrile Chemical compound NCC1=CC=C(F)C(C#N)=C1 VRSKZZIXPDVEFN-UHFFFAOYSA-N 0.000 description 3
- KIEHHNVILFHOIG-UHFFFAOYSA-N 5-(trifluoromethyl)pyridine-3-carbaldehyde Chemical compound FC(F)(F)C1=CN=CC(C=O)=C1 KIEHHNVILFHOIG-UHFFFAOYSA-N 0.000 description 3
- POPXBLXAVUEVOL-UHFFFAOYSA-N 5-ethynylpyridine-3-carbaldehyde Chemical compound O=CC1=CN=CC(C#C)=C1 POPXBLXAVUEVOL-UHFFFAOYSA-N 0.000 description 3
- BCSGDXYJDSJMFA-UHFFFAOYSA-N 5-methylpyridine-3-carbaldehyde Chemical compound CC1=CN=CC(C=O)=C1 BCSGDXYJDSJMFA-UHFFFAOYSA-N 0.000 description 3
- VHDPSELCEVSNJV-UHFFFAOYSA-N 5-prop-1-ynylpyridine-2-carbaldehyde Chemical compound C(#CC)C=1C=CC(=NC=1)C=O VHDPSELCEVSNJV-UHFFFAOYSA-N 0.000 description 3
- LDOIFJPPQNFGQE-UHFFFAOYSA-N 6-(3,3,3-trifluoropropoxy)pyridine-3-carbaldehyde Chemical compound FC(F)(F)CCOC1=CC=C(C=O)C=N1 LDOIFJPPQNFGQE-UHFFFAOYSA-N 0.000 description 3
- NKAXMLFBCJTZIK-UHFFFAOYSA-N 6-(3-ethoxypropoxy)pyridine-3-carbaldehyde Chemical compound C(C)OCCCOC1=CC=C(C=N1)C=O NKAXMLFBCJTZIK-UHFFFAOYSA-N 0.000 description 3
- WVSPCILXJHJCEQ-UHFFFAOYSA-N 6-(3-fluoropropoxy)pyridine-3-carbaldehyde Chemical compound FCCCOC1=CC=C(C=N1)C=O WVSPCILXJHJCEQ-UHFFFAOYSA-N 0.000 description 3
- QSIBXECVYFNZLJ-UHFFFAOYSA-N 6-(3-methoxypropoxy)pyridine-3-carbaldehyde Chemical compound COCCCOC1=CC=C(C=N1)C=O QSIBXECVYFNZLJ-UHFFFAOYSA-N 0.000 description 3
- XVRRWGYFWONCPL-UHFFFAOYSA-N 6-(pyridin-2-ylmethoxy)pyridine-3-carbaldehyde Chemical compound N1=CC(C=O)=CC=C1OCC1=CC=CC=N1 XVRRWGYFWONCPL-UHFFFAOYSA-N 0.000 description 3
- PVUKGNBRJFTFNJ-UHFFFAOYSA-N 6-bromopyridine-3-carbaldehyde Chemical compound BrC1=CC=C(C=O)C=N1 PVUKGNBRJFTFNJ-UHFFFAOYSA-N 0.000 description 3
- VZPQVEBWGXXTOC-UHFFFAOYSA-N 6-cyclopropylpyridine-3-carbaldehyde Chemical compound N1=CC(C=O)=CC=C1C1CC1 VZPQVEBWGXXTOC-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 229910000906 Bronze Inorganic materials 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 101150058514 PTGES gene Proteins 0.000 description 3
- 102100033076 Prostaglandin E synthase Human genes 0.000 description 3
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 3
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 3
- 150000008041 alkali metal carbonates Chemical class 0.000 description 3
- 150000001409 amidines Chemical class 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 3
- 239000010974 bronze Substances 0.000 description 3
- DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical compound CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 description 3
- 150000001735 carboxylic acids Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- KUNSUQLRTQLHQQ-UHFFFAOYSA-N copper tin Chemical compound [Cu].[Sn] KUNSUQLRTQLHQQ-UHFFFAOYSA-N 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- WPFGFHJALYCVMO-UHFFFAOYSA-L rubidium carbonate Chemical compound [Rb+].[Rb+].[O-]C([O-])=O WPFGFHJALYCVMO-UHFFFAOYSA-L 0.000 description 3
- 229910000026 rubidium carbonate Inorganic materials 0.000 description 3
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 3
- 150000003460 sulfonic acids Chemical class 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- DCGLONGLPGISNX-UHFFFAOYSA-N trimethyl(prop-1-ynyl)silane Chemical compound CC#C[Si](C)(C)C DCGLONGLPGISNX-UHFFFAOYSA-N 0.000 description 3
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 2
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical compound C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 2
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 2
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 description 2
- STYQRAZUBODKCA-UHFFFAOYSA-N 1-butyl-2-oxopyridine-4-carbaldehyde Chemical compound CCCCN1C=CC(C=O)=CC1=O STYQRAZUBODKCA-UHFFFAOYSA-N 0.000 description 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 2
- LFNCODRCVBGYJX-UHFFFAOYSA-N 2-(3,3-dimethylbut-1-ynyl)pyrimidine-5-carbaldehyde Chemical compound CC(C)(C)C#CC1=NC=C(C=O)C=N1 LFNCODRCVBGYJX-UHFFFAOYSA-N 0.000 description 2
- FXOZGZJPMYTZKC-UHFFFAOYSA-N 2-(4-methylpent-1-ynyl)pyrimidine-5-carbaldehyde Chemical compound CC(CC#CC1=NC=C(C=N1)C=O)C FXOZGZJPMYTZKC-UHFFFAOYSA-N 0.000 description 2
- VIMQVDDXZNCLDZ-UHFFFAOYSA-N 2-(cyclopropylmethoxy)pyridine-4-carbaldehyde Chemical compound C1(CC1)COC1=NC=CC(=C1)C=O VIMQVDDXZNCLDZ-UHFFFAOYSA-N 0.000 description 2
- KWRMQSHHGQEUIF-UHFFFAOYSA-N 2-(difluoromethoxy)pyridine-4-carbaldehyde Chemical compound FC(F)OC1=CC(C=O)=CC=N1 KWRMQSHHGQEUIF-UHFFFAOYSA-N 0.000 description 2
- CBHUHUQPLDWHIO-UHFFFAOYSA-N 2-(trifluoromethyl)pyridine-4-carbaldehyde Chemical compound FC(F)(F)C1=CC(C=O)=CC=N1 CBHUHUQPLDWHIO-UHFFFAOYSA-N 0.000 description 2
- NAIGKGQHPIGYBB-UHFFFAOYSA-N 2-amino-7,9-dimethylpurin-9-ium-6-olate Chemical compound NC1=NC([O-])=C2N(C)C=[N+](C)C2=N1 NAIGKGQHPIGYBB-UHFFFAOYSA-N 0.000 description 2
- DJUWIZUEHXRECB-UHFFFAOYSA-N 2-bromo-1,3-thiazole-5-carbaldehyde Chemical compound BrC1=NC=C(C=O)S1 DJUWIZUEHXRECB-UHFFFAOYSA-N 0.000 description 2
- MERUNNHMVZFFRE-UHFFFAOYSA-N 2-methoxypyrimidine-5-carbaldehyde Chemical compound COC1=NC=C(C=O)C=N1 MERUNNHMVZFFRE-UHFFFAOYSA-N 0.000 description 2
- QSMYNJRJUCKDCB-UHFFFAOYSA-N 2-oxo-1-pentylpyridine-4-carbaldehyde Chemical compound O=C1N(C=CC(=C1)C=O)CCCCC QSMYNJRJUCKDCB-UHFFFAOYSA-N 0.000 description 2
- CIAMJLHLWBXCNE-UHFFFAOYSA-N 2-prop-1-ynyl-1,3-thiazole-5-carbaldehyde Chemical compound C(#CC)C=1SC(=CN=1)C=O CIAMJLHLWBXCNE-UHFFFAOYSA-N 0.000 description 2
- OQOHGVWVMHTFTP-UHFFFAOYSA-N 3-(bromomethyl)-2-chloro-6-fluorobenzonitrile Chemical compound BrCC=1C(=C(C#N)C(=CC=1)F)Cl OQOHGVWVMHTFTP-UHFFFAOYSA-N 0.000 description 2
- OWPGEEFYRJJYFX-UHFFFAOYSA-N 3-(bromomethyl)-6-chloro-2-fluorobenzonitrile Chemical compound BrCC=1C(=C(C#N)C(=CC=1)Cl)F OWPGEEFYRJJYFX-UHFFFAOYSA-N 0.000 description 2
- VGEXDTFRSYZMCB-UHFFFAOYSA-N 4-(2-cyclopropylethynyl)-1,3-thiazole-2-carbaldehyde Chemical compound C1(CC1)C#CC=1N=C(SC=1)C=O VGEXDTFRSYZMCB-UHFFFAOYSA-N 0.000 description 2
- XEKCMBCZVBRSCM-UHFFFAOYSA-N 4-(2-ethoxyethoxy)-2-fluorobenzaldehyde Chemical compound C(C)OCCOC1=CC(=C(C=O)C=C1)F XEKCMBCZVBRSCM-UHFFFAOYSA-N 0.000 description 2
- ZRRWOZZZOISMIQ-UHFFFAOYSA-N 4-(2-pyridin-2-ylethynyl)benzaldehyde Chemical compound C1=CC(C=O)=CC=C1C#CC1=CC=CC=N1 ZRRWOZZZOISMIQ-UHFFFAOYSA-N 0.000 description 2
- JDUXMFGFGCJNGO-UHFFFAOYSA-N 4-bromo-1,3-thiazole-2-carbaldehyde Chemical compound BrC1=CSC(C=O)=N1 JDUXMFGFGCJNGO-UHFFFAOYSA-N 0.000 description 2
- UVGYSEIWAOOIJR-UHFFFAOYSA-N 4-chloro-2-fluorobenzaldehyde Chemical compound FC1=CC(Cl)=CC=C1C=O UVGYSEIWAOOIJR-UHFFFAOYSA-N 0.000 description 2
- WZWIQYMTQZCSKI-UHFFFAOYSA-N 4-cyanobenzaldehyde Chemical compound O=CC1=CC=C(C#N)C=C1 WZWIQYMTQZCSKI-UHFFFAOYSA-N 0.000 description 2
- RXRYFFTVFMQTKA-UHFFFAOYSA-N 4-formyl-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=C(C=O)C=C1 RXRYFFTVFMQTKA-UHFFFAOYSA-N 0.000 description 2
- KUSDDEPOUVZOCG-UHFFFAOYSA-N 4-piperidin-1-ylsulfonylbenzaldehyde Chemical compound C1=CC(C=O)=CC=C1S(=O)(=O)N1CCCCC1 KUSDDEPOUVZOCG-UHFFFAOYSA-N 0.000 description 2
- PWQLTSSDLXDTEZ-UHFFFAOYSA-N 4-prop-1-ynyl-1,3-thiazole-2-carbaldehyde Chemical compound C(#CC)C=1N=C(SC=1)C=O PWQLTSSDLXDTEZ-UHFFFAOYSA-N 0.000 description 2
- LLXRHAKGKJMNRR-UHFFFAOYSA-N 4-pyrimidin-5-ylpyrimidine Chemical compound C1=NC=CC(C=2C=NC=NC=2)=N1 LLXRHAKGKJMNRR-UHFFFAOYSA-N 0.000 description 2
- XXYVDNSLGDYGHJ-UHFFFAOYSA-N 5-(2,2,2-trifluoroethyl)pyridine-2-carbaldehyde Chemical compound FC(CC=1C=CC(=NC=1)C=O)(F)F XXYVDNSLGDYGHJ-UHFFFAOYSA-N 0.000 description 2
- BGWFVVJSWCZOTF-UHFFFAOYSA-N 5-(aminomethyl)-2-(difluoromethoxy)benzonitrile Chemical compound NCC=1C=CC(=C(C#N)C=1)OC(F)F BGWFVVJSWCZOTF-UHFFFAOYSA-N 0.000 description 2
- ZZRHOOSPEZUCDV-UHFFFAOYSA-N 5-(aminomethyl)-2-(trifluoromethyl)benzonitrile Chemical compound NCC=1C=CC(=C(C#N)C=1)C(F)(F)F ZZRHOOSPEZUCDV-UHFFFAOYSA-N 0.000 description 2
- YBAVDMUZYWKFRR-UHFFFAOYSA-N 5-(aminomethyl)-2-chlorobenzonitrile Chemical compound NCC1=CC=C(Cl)C(C#N)=C1 YBAVDMUZYWKFRR-UHFFFAOYSA-N 0.000 description 2
- ZQVLPMNLLKGGIU-UHFFFAOYSA-N 5-bromopyridine-2-carbaldehyde Chemical compound BrC1=CC=C(C=O)N=C1 ZQVLPMNLLKGGIU-UHFFFAOYSA-N 0.000 description 2
- NGUVGKAEOFPLDT-UHFFFAOYSA-N 5-bromopyridine-3-carbaldehyde Chemical compound BrC1=CN=CC(C=O)=C1 NGUVGKAEOFPLDT-UHFFFAOYSA-N 0.000 description 2
- YOVIXSRXKCZJRN-UHFFFAOYSA-N 5-methoxypyridine-3-carbaldehyde Chemical compound COC1=CN=CC(C=O)=C1 YOVIXSRXKCZJRN-UHFFFAOYSA-N 0.000 description 2
- FCFGPUJASPCBTE-UHFFFAOYSA-N 5-prop-1-ynylpyridine-3-carbaldehyde Chemical compound C(#CC)C=1C=C(C=NC=1)C=O FCFGPUJASPCBTE-UHFFFAOYSA-N 0.000 description 2
- MKJPDLQQQCBDKZ-UHFFFAOYSA-N 5-propylpyridine-2-carbaldehyde Chemical compound CCCC1=CC=C(C=O)N=C1 MKJPDLQQQCBDKZ-UHFFFAOYSA-N 0.000 description 2
- XLDXZUVARXHHLJ-UHFFFAOYSA-N 6-(2-butoxyethoxy)pyridine-3-carbaldehyde Chemical compound CCCCOCCOC1=CC=C(C=O)C=N1 XLDXZUVARXHHLJ-UHFFFAOYSA-N 0.000 description 2
- VPDWXBRWCBSFQV-UHFFFAOYSA-N 6-(2-cyclopropylethynyl)pyridine-2-carbaldehyde Chemical compound C1(CC1)C#CC1=CC=CC(=N1)C=O VPDWXBRWCBSFQV-UHFFFAOYSA-N 0.000 description 2
- HBNZTKJBICPHMF-UHFFFAOYSA-N 6-(2-fluoroethoxy)pyridine-3-carbaldehyde Chemical compound FCCOC1=CC=C(C=O)C=N1 HBNZTKJBICPHMF-UHFFFAOYSA-N 0.000 description 2
- OMFVRHWVFINADV-UHFFFAOYSA-N 6-(trifluoromethyl)pyridine-2-carbaldehyde Chemical compound FC(F)(F)C1=CC=CC(C=O)=N1 OMFVRHWVFINADV-UHFFFAOYSA-N 0.000 description 2
- ALGQMDSUKOCCHT-UHFFFAOYSA-N 6-[(3-ethyloxetan-3-yl)methoxy]pyridine-3-carbaldehyde Chemical compound C(C)C1(COC1)COC1=CC=C(C=N1)C=O ALGQMDSUKOCCHT-UHFFFAOYSA-N 0.000 description 2
- WLLVCVASYAYTGW-UHFFFAOYSA-N 6-[(3-methyloxetan-3-yl)methoxy]pyridine-3-carbaldehyde Chemical compound CC1(COc2ccc(C=O)cn2)COC1 WLLVCVASYAYTGW-UHFFFAOYSA-N 0.000 description 2
- PIXNVMIQHIBNQV-UHFFFAOYSA-N 6-[(6-methylpyridin-2-yl)methoxy]pyridine-3-carbaldehyde Chemical compound CC1=CC=CC(=N1)COC1=CC=C(C=N1)C=O PIXNVMIQHIBNQV-UHFFFAOYSA-N 0.000 description 2
- SBCJVBYTXLMYIT-UHFFFAOYSA-N 6-[(6-methylpyridin-3-yl)methoxy]pyridine-3-carbaldehyde Chemical compound CC1=CC=C(C=N1)COC1=CC=C(C=N1)C=O SBCJVBYTXLMYIT-UHFFFAOYSA-N 0.000 description 2
- OKLRZTSZXXPVBF-UHFFFAOYSA-N 6-[2-(2-butoxyethoxy)ethoxy]pyridine-3-carbaldehyde Chemical compound C(CCC)OCCOCCOC1=CC=C(C=N1)C=O OKLRZTSZXXPVBF-UHFFFAOYSA-N 0.000 description 2
- XHUHMNNNBOYATQ-UHFFFAOYSA-N 6-[2-[2-(2-ethoxyethoxy)ethoxy]ethoxy]pyridine-3-carbaldehyde Chemical compound C(C)OCCOCCOCCOC1=CC=C(C=N1)C=O XHUHMNNNBOYATQ-UHFFFAOYSA-N 0.000 description 2
- YDNWTNODZDSPNZ-UHFFFAOYSA-N 6-methoxypyridine-2-carbaldehyde Chemical compound COC1=CC=CC(C=O)=N1 YDNWTNODZDSPNZ-UHFFFAOYSA-N 0.000 description 2
- FXDRWINQDOISOO-UHFFFAOYSA-N 6-prop-1-ynylpyridine-3-carbaldehyde Chemical compound C(#CC)C1=CC=C(C=N1)C=O FXDRWINQDOISOO-UHFFFAOYSA-N 0.000 description 2
- FKWPVUNGBPPVTL-UHFFFAOYSA-N 6-propylpyridine-3-carbaldehyde Chemical compound CCCC1=CC=C(C=O)C=N1 FKWPVUNGBPPVTL-UHFFFAOYSA-N 0.000 description 2
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 2
- JYTNKVZJJWOHQH-UHFFFAOYSA-N C(C)OC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C(=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)F Chemical compound C(C)OC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C(=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)F JYTNKVZJJWOHQH-UHFFFAOYSA-N 0.000 description 2
- GZUQVHJDHKJARZ-UHFFFAOYSA-N C(C)OC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C Chemical compound C(C)OC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C GZUQVHJDHKJARZ-UHFFFAOYSA-N 0.000 description 2
- OLKOXVSSQBHVGN-UHFFFAOYSA-N C(C)OC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F Chemical compound C(C)OC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F OLKOXVSSQBHVGN-UHFFFAOYSA-N 0.000 description 2
- FSCFIPFIHXVZPA-UHFFFAOYSA-N C(C)OCCOC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C(=C(CNC(C(C)C)=O)C=CC=1F)F Chemical compound C(C)OCCOC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C(=C(CNC(C(C)C)=O)C=CC=1F)F FSCFIPFIHXVZPA-UHFFFAOYSA-N 0.000 description 2
- YQEJYOUHVIIZOZ-UHFFFAOYSA-N C(CCC)OC1=CC=C(N=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F Chemical compound C(CCC)OC1=CC=C(N=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F YQEJYOUHVIIZOZ-UHFFFAOYSA-N 0.000 description 2
- KLYJQUOUBZVKAB-UHFFFAOYSA-N C(CCC)OCCOCCOC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1Cl Chemical compound C(CCC)OCCOCCOC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1Cl KLYJQUOUBZVKAB-UHFFFAOYSA-N 0.000 description 2
- KKFKLNCBZDSZBO-UHFFFAOYSA-N C1(CC1)C#CC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C(=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)F Chemical compound C1(CC1)C#CC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C(=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)F KKFKLNCBZDSZBO-UHFFFAOYSA-N 0.000 description 2
- QCKGWLKDKSRING-UHFFFAOYSA-N C1(CC1)C#CC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C(=C(CNC(C(C)C)=O)C=CC=1F)F Chemical compound C1(CC1)C#CC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C(=C(CNC(C(C)C)=O)C=CC=1F)F QCKGWLKDKSRING-UHFFFAOYSA-N 0.000 description 2
- FBBSHYPVXUZUCT-UHFFFAOYSA-N C1(CC1)C#CC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F Chemical compound C1(CC1)C#CC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F FBBSHYPVXUZUCT-UHFFFAOYSA-N 0.000 description 2
- ZWNDAZDUAHFGLJ-UHFFFAOYSA-N C1(CC1)C#CC1=CC=CC(=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F Chemical compound C1(CC1)C#CC1=CC=CC(=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F ZWNDAZDUAHFGLJ-UHFFFAOYSA-N 0.000 description 2
- ABXPGZPALIWSHB-UHFFFAOYSA-N C1(CC1)C#CC1=CN=C(S1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F Chemical compound C1(CC1)C#CC1=CN=C(S1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F ABXPGZPALIWSHB-UHFFFAOYSA-N 0.000 description 2
- NBSPHCKYOXWBAW-UHFFFAOYSA-N C1(CC1)C#CC=1C=C(C=NC=1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F Chemical compound C1(CC1)C#CC=1C=C(C=NC=1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F NBSPHCKYOXWBAW-UHFFFAOYSA-N 0.000 description 2
- DNBUAENTNDWUJD-UHFFFAOYSA-N C1(CC1)C#CC=1C=CC(=NC=1)C=1N=C(NC(C=1)=O)C=1C(=C(CNC(C(C)C)=O)C=CC=1F)F Chemical compound C1(CC1)C#CC=1C=CC(=NC=1)C=1N=C(NC(C=1)=O)C=1C(=C(CNC(C(C)C)=O)C=CC=1F)F DNBUAENTNDWUJD-UHFFFAOYSA-N 0.000 description 2
- KCLLAPMKTMEGIH-UHFFFAOYSA-N C1(CC1)C#CC=1C=CC(=NC=1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(CCC)=O)C=CC=1C(F)(F)F Chemical compound C1(CC1)C#CC=1C=CC(=NC=1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(CCC)=O)C=CC=1C(F)(F)F KCLLAPMKTMEGIH-UHFFFAOYSA-N 0.000 description 2
- HDSAFJLLAHOQOU-UHFFFAOYSA-N C1(CC1)COC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F Chemical compound C1(CC1)COC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F HDSAFJLLAHOQOU-UHFFFAOYSA-N 0.000 description 2
- UBZKDWIUUVCDRO-UHFFFAOYSA-N C1(CC1)COC1=CC=C(N=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F Chemical compound C1(CC1)COC1=CC=C(N=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F UBZKDWIUUVCDRO-UHFFFAOYSA-N 0.000 description 2
- QGMRQZBAGLKJHP-UHFFFAOYSA-N C1(CC1)COC1=NC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F Chemical compound C1(CC1)COC1=NC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F QGMRQZBAGLKJHP-UHFFFAOYSA-N 0.000 description 2
- GLFQXQZFYZFGRV-UHFFFAOYSA-N C1(CC1)COC1=NC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(CCC)=O)C=CC=1C(F)(F)F Chemical compound C1(CC1)COC1=NC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(CCC)=O)C=CC=1C(F)(F)F GLFQXQZFYZFGRV-UHFFFAOYSA-N 0.000 description 2
- AWMZHMWVSQNZAQ-UHFFFAOYSA-N C1(CC1)COC1=NC=CC(=C1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F Chemical compound C1(CC1)COC1=NC=CC(=C1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F AWMZHMWVSQNZAQ-UHFFFAOYSA-N 0.000 description 2
- RUZMUZZAKJBWJT-UHFFFAOYSA-N C1(CC1)COC=1C=CC(=NC=1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F Chemical compound C1(CC1)COC=1C=CC(=NC=1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F RUZMUZZAKJBWJT-UHFFFAOYSA-N 0.000 description 2
- CYGHCELGFUXSIU-UHFFFAOYSA-N C1(CC1)COC=1N=CC(=NC=1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F Chemical compound C1(CC1)COC=1N=CC(=NC=1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F CYGHCELGFUXSIU-UHFFFAOYSA-N 0.000 description 2
- MLYRAUBKMOCQRA-UHFFFAOYSA-N CC(CC#CC1=NC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)C Chemical compound CC(CC#CC1=NC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)C MLYRAUBKMOCQRA-UHFFFAOYSA-N 0.000 description 2
- LIVMBPRBPAGDGK-UHFFFAOYSA-N CC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)C(F)(F)F)=O Chemical compound CC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)C(F)(F)F)=O LIVMBPRBPAGDGK-UHFFFAOYSA-N 0.000 description 2
- AGQUGACDFSEHKY-UHFFFAOYSA-N CC=1C=C(C=NC=1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F Chemical compound CC=1C=C(C=NC=1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F AGQUGACDFSEHKY-UHFFFAOYSA-N 0.000 description 2
- SCYYJPMFXSPYRJ-UHFFFAOYSA-N COC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F Chemical compound COC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F SCYYJPMFXSPYRJ-UHFFFAOYSA-N 0.000 description 2
- NIMDOKOVINWZIW-UHFFFAOYSA-N COC1=NC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F Chemical compound COC1=NC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F NIMDOKOVINWZIW-UHFFFAOYSA-N 0.000 description 2
- ZJLOIHOLUODZQT-UHFFFAOYSA-N COC=1C=C(C=NC=1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F Chemical compound COC=1C=C(C=NC=1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F ZJLOIHOLUODZQT-UHFFFAOYSA-N 0.000 description 2
- QBOWLOVYTHMSTF-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C1=CC=C(C=C1)C#N)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C1=CC=C(C=C1)C#N)=O QBOWLOVYTHMSTF-UHFFFAOYSA-N 0.000 description 2
- LFOILIYVCVTOIX-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C1=CN=C(S1)C#CC)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C1=CN=C(S1)C#CC)=O LFOILIYVCVTOIX-UHFFFAOYSA-N 0.000 description 2
- VKVQOGCWDUBMQD-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C1=CN=C(S1)C#CC1CC1)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C1=CN=C(S1)C#CC1CC1)=O VKVQOGCWDUBMQD-UHFFFAOYSA-N 0.000 description 2
- DADVDTIBQOIZRV-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C1=NC(=CC=C1)C(F)(F)F)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C1=NC(=CC=C1)C(F)(F)F)=O DADVDTIBQOIZRV-UHFFFAOYSA-N 0.000 description 2
- BJOKYGPRBIWQHQ-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C1=NC(=CC=C1)OC)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C1=NC(=CC=C1)OC)=O BJOKYGPRBIWQHQ-UHFFFAOYSA-N 0.000 description 2
- YFDVEBSALLJFON-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C1=NC=C(C=C1)C#CC)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C1=NC=C(C=C1)C#CC)=O YFDVEBSALLJFON-UHFFFAOYSA-N 0.000 description 2
- VKDJROZSQWIPHP-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C1=NC=C(C=C1)C#CC1CC1)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C1=NC=C(C=C1)C#CC1CC1)=O VKDJROZSQWIPHP-UHFFFAOYSA-N 0.000 description 2
- PPCIAVKRYARHNY-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C1=NC=C(C=C1)C(F)F)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C1=NC=C(C=C1)C(F)F)=O PPCIAVKRYARHNY-UHFFFAOYSA-N 0.000 description 2
- XNEHZUJJRJKQDI-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C1=NC=C(C=C1)CCC)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C1=NC=C(C=C1)CCC)=O XNEHZUJJRJKQDI-UHFFFAOYSA-N 0.000 description 2
- MKPXLTOXDTUJJQ-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C1=NC=C(C=C1)F)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C1=NC=C(C=C1)F)=O MKPXLTOXDTUJJQ-UHFFFAOYSA-N 0.000 description 2
- YPVVNXGCYAOYIU-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C1=NC=C(C=C1)OC(F)F)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C1=NC=C(C=C1)OC(F)F)=O YPVVNXGCYAOYIU-UHFFFAOYSA-N 0.000 description 2
- BDVOGGPCGWESKU-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C1=NC=C(C=C1)OCC1CC1)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C1=NC=C(C=C1)OCC1CC1)=O BDVOGGPCGWESKU-UHFFFAOYSA-N 0.000 description 2
- AJYXEVCMOFSGCN-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)C#CC)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)C#CC)=O AJYXEVCMOFSGCN-UHFFFAOYSA-N 0.000 description 2
- HYTZUJYONWACRK-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)C(F)(F)F)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)C(F)(F)F)=O HYTZUJYONWACRK-UHFFFAOYSA-N 0.000 description 2
- PKPOYKOROVYXLB-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)C(F)F)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)C(F)F)=O PKPOYKOROVYXLB-UHFFFAOYSA-N 0.000 description 2
- JOZAQNBIBSDURV-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)C1=CC=CC=C1)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)C1=CC=CC=C1)=O JOZAQNBIBSDURV-UHFFFAOYSA-N 0.000 description 2
- KBZDBRFARIDLPI-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC)=O KBZDBRFARIDLPI-UHFFFAOYSA-N 0.000 description 2
- YBXNWBJTFGETJR-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOCC(F)(F)F)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOCC(F)(F)F)=O YBXNWBJTFGETJR-UHFFFAOYSA-N 0.000 description 2
- ZQPCBFLFGRAQRV-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=NC=1)OCC1CC1)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=NC=1)OCC1CC1)=O ZQPCBFLFGRAQRV-UHFFFAOYSA-N 0.000 description 2
- XTYBUIYGLOZEPX-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC=C(C=1)C#C)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC=C(C=1)C#C)=O XTYBUIYGLOZEPX-UHFFFAOYSA-N 0.000 description 2
- ZCEWMRPUSYRYNJ-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC=C(C=1)C)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC=C(C=1)C)=O ZCEWMRPUSYRYNJ-UHFFFAOYSA-N 0.000 description 2
- WGTMNAXRQZCOAO-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC=C(C=1)F)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC=C(C=1)F)=O WGTMNAXRQZCOAO-UHFFFAOYSA-N 0.000 description 2
- CVPMBDKNOPHOSA-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1SC(=CN=1)C#CC1CC1)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1SC(=CN=1)C#CC1CC1)=O CVPMBDKNOPHOSA-UHFFFAOYSA-N 0.000 description 2
- BUUDEPYTHLETAI-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1SC=C(N=1)C#CC)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1SC=C(N=1)C#CC)=O BUUDEPYTHLETAI-UHFFFAOYSA-N 0.000 description 2
- INWORUBHXJIGPK-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1SC=C(N=1)C#CC1CC1)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1SC=C(N=1)C#CC1CC1)=O INWORUBHXJIGPK-UHFFFAOYSA-N 0.000 description 2
- LTHYZGIFNBTVTH-UHFFFAOYSA-N ClC1=C(C(=C(CNC(CCC)=O)C=C1)F)C=1NC(C=C(N=1)C1=NC=C(C=C1)C#CC1CC1)=O Chemical compound ClC1=C(C(=C(CNC(CCC)=O)C=C1)F)C=1NC(C=C(N=1)C1=NC=C(C=C1)C#CC1CC1)=O LTHYZGIFNBTVTH-UHFFFAOYSA-N 0.000 description 2
- IZMQCAVOCAXTPO-UHFFFAOYSA-N ClC1=C(C(=C(CNC(CCC)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)C(F)(F)F)=O Chemical compound ClC1=C(C(=C(CNC(CCC)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)C(F)(F)F)=O IZMQCAVOCAXTPO-UHFFFAOYSA-N 0.000 description 2
- NYURTSKYTBNFQD-UHFFFAOYSA-N ClC1=C(C(=C(CNC(CCC)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OC(F)F)=O Chemical compound ClC1=C(C(=C(CNC(CCC)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OC(F)F)=O NYURTSKYTBNFQD-UHFFFAOYSA-N 0.000 description 2
- UNBAVVUZRPXULU-UHFFFAOYSA-N ClC1=C(C(=C(CNC(CCC)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=NC=1)OCC1CC1)=O Chemical compound ClC1=C(C(=C(CNC(CCC)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=NC=1)OCC1CC1)=O UNBAVVUZRPXULU-UHFFFAOYSA-N 0.000 description 2
- XAUBIFQDERDDIQ-UHFFFAOYSA-N ClC1=C(C=C(C=C1)CNC(C(C(F)(F)F)(C)C)=O)C=1NC(C=C(N=1)C1=CC=C(C(=O)N(C)C)C=C1)=O Chemical compound ClC1=C(C=C(C=C1)CNC(C(C(F)(F)F)(C)C)=O)C=1NC(C=C(N=1)C1=CC=C(C(=O)N(C)C)C=C1)=O XAUBIFQDERDDIQ-UHFFFAOYSA-N 0.000 description 2
- AQRQHKLWWVPWCU-UHFFFAOYSA-N ClC1=C(C=C(C=C1)CNC(C(C)C)=O)C=1NC(C=C(N=1)C1=CC=C(C(=O)N(C)C)C=C1)=O Chemical compound ClC1=C(C=C(C=C1)CNC(C(C)C)=O)C=1NC(C=C(N=1)C1=CC=C(C(=O)N(C)C)C=C1)=O AQRQHKLWWVPWCU-UHFFFAOYSA-N 0.000 description 2
- SVWYVHCAPHZETM-UHFFFAOYSA-N ClC1=C(C=C(CNC(=O)C2CC2)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)C(F)(F)F)=O Chemical compound ClC1=C(C=C(CNC(=O)C2CC2)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)C(F)(F)F)=O SVWYVHCAPHZETM-UHFFFAOYSA-N 0.000 description 2
- DBCIHKMSKRVDLD-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C(F)(F)F)(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)C(F)(F)F)=O Chemical compound ClC1=C(C=C(CNC(C(C(F)(F)F)(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)C(F)(F)F)=O DBCIHKMSKRVDLD-UHFFFAOYSA-N 0.000 description 2
- LUTYTZMHBQTNQE-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C(F)(F)F)(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OC(F)F)=O Chemical compound ClC1=C(C=C(CNC(C(C(F)(F)F)(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OC(F)F)=O LUTYTZMHBQTNQE-UHFFFAOYSA-N 0.000 description 2
- WTAHSELPBRFGEZ-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)(C)OC)=O)C=C1)C=1NC(C=C(N=1)C1=NC=C(C=C1)Cl)=O Chemical compound ClC1=C(C=C(CNC(C(C)(C)OC)=O)C=C1)C=1NC(C=C(N=1)C1=NC=C(C=C1)Cl)=O WTAHSELPBRFGEZ-UHFFFAOYSA-N 0.000 description 2
- KSDAGQDXYWTDJU-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C(=C(N=1)C1=CSC=C1)C#N)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C(=C(N=1)C1=CSC=C1)C#N)=O KSDAGQDXYWTDJU-UHFFFAOYSA-N 0.000 description 2
- UXKDVDPDMYRJTJ-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C(=C(N=1)C1=CSC=C1)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C(=C(N=1)C1=CSC=C1)F)=O UXKDVDPDMYRJTJ-UHFFFAOYSA-N 0.000 description 2
- NISDBTHBYBZSGM-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C(=C(N=1)C=1SC=CC=1)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C(=C(N=1)C=1SC=CC=1)F)=O NISDBTHBYBZSGM-UHFFFAOYSA-N 0.000 description 2
- BBSBHDMKBDGLRI-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=C(C(=CC=C1)Cl)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=C(C(=CC=C1)Cl)F)=O BBSBHDMKBDGLRI-UHFFFAOYSA-N 0.000 description 2
- OCKAHLAETYBLQF-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=C(C=C(C=C1)C)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=C(C=C(C=C1)C)F)=O OCKAHLAETYBLQF-UHFFFAOYSA-N 0.000 description 2
- WQMJRJPKDHADLM-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=C(C=C(C=C1)Cl)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=C(C=C(C=C1)Cl)F)=O WQMJRJPKDHADLM-UHFFFAOYSA-N 0.000 description 2
- VZPPVHGFHRVPDA-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=C(C=C(C=C1)F)Cl)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=C(C=C(C=C1)F)Cl)=O VZPPVHGFHRVPDA-UHFFFAOYSA-N 0.000 description 2
- IHDWZSMELYSHSI-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=C(C=C(C=C1)F)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=C(C=C(C=C1)F)F)=O IHDWZSMELYSHSI-UHFFFAOYSA-N 0.000 description 2
- BTPOCOBHJYSCGP-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=C(C=C(C=C1)OC(F)(F)F)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=C(C=C(C=C1)OC(F)(F)F)F)=O BTPOCOBHJYSCGP-UHFFFAOYSA-N 0.000 description 2
- ILYWJWACHDGELS-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=C(C=C(C=C1)OC(F)F)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=C(C=C(C=C1)OC(F)F)F)=O ILYWJWACHDGELS-UHFFFAOYSA-N 0.000 description 2
- DKKDIXDKYHSEIE-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=C(C=C(C=C1)OC)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=C(C=C(C=C1)OC)F)=O DKKDIXDKYHSEIE-UHFFFAOYSA-N 0.000 description 2
- WAAHIFZWPNTFDI-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=C(C=CC(=C1)Cl)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=C(C=CC(=C1)Cl)F)=O WAAHIFZWPNTFDI-UHFFFAOYSA-N 0.000 description 2
- DDJVLBUPRVEDBW-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=C(C=CC(=C1)OC)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=C(C=CC(=C1)OC)F)=O DDJVLBUPRVEDBW-UHFFFAOYSA-N 0.000 description 2
- NIXIHPBAPUYLJI-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=C(C=CC=C1)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=C(C=CC=C1)F)=O NIXIHPBAPUYLJI-UHFFFAOYSA-N 0.000 description 2
- JVYXNYCJTYCIDS-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=C(SC=C1)Cl)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=C(SC=C1)Cl)=O JVYXNYCJTYCIDS-UHFFFAOYSA-N 0.000 description 2
- ISOFDZLFMNGZBR-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC(=C(C=C1)C)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC(=C(C=C1)C)F)=O ISOFDZLFMNGZBR-UHFFFAOYSA-N 0.000 description 2
- RUGJTLIBOYCFNU-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC(=C(C=C1)Cl)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC(=C(C=C1)Cl)F)=O RUGJTLIBOYCFNU-UHFFFAOYSA-N 0.000 description 2
- JZPOADYKVCOCAE-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC(=C(C=C1)OC)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC(=C(C=C1)OC)F)=O JZPOADYKVCOCAE-UHFFFAOYSA-N 0.000 description 2
- LEFGYJFYVMADNU-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC(=CC=C1)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC(=CC=C1)F)=O LEFGYJFYVMADNU-UHFFFAOYSA-N 0.000 description 2
- ADCRRUSCFSDAPF-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC(=NC=C1)OC(F)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC(=NC=C1)OC(F)F)=O ADCRRUSCFSDAPF-UHFFFAOYSA-N 0.000 description 2
- JZVJWLRJLWDHSD-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC(=NC=C1)OCC1CC1)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC(=NC=C1)OCC1CC1)=O JZVJWLRJLWDHSD-UHFFFAOYSA-N 0.000 description 2
- VSQMEKFVFXVPTE-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC=C(C=C1)C#CC1=NC=CC=C1)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC=C(C=C1)C#CC1=NC=CC=C1)=O VSQMEKFVFXVPTE-UHFFFAOYSA-N 0.000 description 2
- BAJXZZNXFHBTEN-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC=C(C=C1)C(F)(F)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC=C(C=C1)C(F)(F)F)=O BAJXZZNXFHBTEN-UHFFFAOYSA-N 0.000 description 2
- WEVSVVWSPYPAHR-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC=C(C=C1)C(F)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC=C(C=C1)C(F)F)=O WEVSVVWSPYPAHR-UHFFFAOYSA-N 0.000 description 2
- LHOCKLPKVLEYMP-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC=C(C=C1)C1CC1)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC=C(C=C1)C1CC1)=O LHOCKLPKVLEYMP-UHFFFAOYSA-N 0.000 description 2
- WQDMKMDBGAYDIC-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC=C(C=C1)Cl)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC=C(C=C1)Cl)=O WQDMKMDBGAYDIC-UHFFFAOYSA-N 0.000 description 2
- RTOKDBKMYGZKAD-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC=C(C=C1)OC(F)(F)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC=C(C=C1)OC(F)(F)F)=O RTOKDBKMYGZKAD-UHFFFAOYSA-N 0.000 description 2
- MUCBXJGLMPFGNB-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC=C(C=C1)OC(F)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC=C(C=C1)OC(F)F)=O MUCBXJGLMPFGNB-UHFFFAOYSA-N 0.000 description 2
- IODNYINYRRMQRR-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC=C(C=C1)OC)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC=C(C=C1)OC)=O IODNYINYRRMQRR-UHFFFAOYSA-N 0.000 description 2
- RLUAAJNEKAPKBZ-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC=C(C=C1)OCCOC)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC=C(C=C1)OCCOC)=O RLUAAJNEKAPKBZ-UHFFFAOYSA-N 0.000 description 2
- PDVMCRNLMRGRKY-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC=C(C=C1)S(=O)(=O)N1CCCCC1)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC=C(C=C1)S(=O)(=O)N1CCCCC1)=O PDVMCRNLMRGRKY-UHFFFAOYSA-N 0.000 description 2
- KVOGSJWWMUEQDX-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC=C(C=C1)S(N(CC)CC)(=O)=O)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC=C(C=C1)S(N(CC)CC)(=O)=O)=O KVOGSJWWMUEQDX-UHFFFAOYSA-N 0.000 description 2
- MGWANSLKDFYBAG-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CN=C(S1)C(F)(F)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CN=C(S1)C(F)(F)F)=O MGWANSLKDFYBAG-UHFFFAOYSA-N 0.000 description 2
- NGCQRMBNZFAEBF-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CN=C(S1)OC)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CN=C(S1)OC)=O NGCQRMBNZFAEBF-UHFFFAOYSA-N 0.000 description 2
- CRDXMCRQYDSVKX-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CSC=C1)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CSC=C1)=O CRDXMCRQYDSVKX-UHFFFAOYSA-N 0.000 description 2
- TWJPRCZADVEKAD-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=NC(=CC=C1)C(F)(F)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=NC(=CC=C1)C(F)(F)F)=O TWJPRCZADVEKAD-UHFFFAOYSA-N 0.000 description 2
- DSORADJIGKVYCX-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=NC=C(C=C1)C(F)(F)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=NC=C(C=C1)C(F)(F)F)=O DSORADJIGKVYCX-UHFFFAOYSA-N 0.000 description 2
- JFIFCMTXZIHFGE-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=NC=C(C=C1)C)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=NC=C(C=C1)C)=O JFIFCMTXZIHFGE-UHFFFAOYSA-N 0.000 description 2
- VZSUXKZDHGDBEK-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=NC=C(C=C1)Cl)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=NC=C(C=C1)Cl)=O VZSUXKZDHGDBEK-UHFFFAOYSA-N 0.000 description 2
- QQCGMZLLFIRGPK-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=NC=C(C=C1)OC)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=NC=C(C=C1)OC)=O QQCGMZLLFIRGPK-UHFFFAOYSA-N 0.000 description 2
- MZTKIZKYHYJXHT-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=NC=C(C=C1)OCC1CC1)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=NC=C(C=C1)OCC1CC1)=O MZTKIZKYHYJXHT-UHFFFAOYSA-N 0.000 description 2
- HHRFCIIDZREQQO-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1CCCC1)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1CCCC1)=O HHRFCIIDZREQQO-UHFFFAOYSA-N 0.000 description 2
- XZRDYPQHHIBIGM-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1CCCCC1)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1CCCCC1)=O XZRDYPQHHIBIGM-UHFFFAOYSA-N 0.000 description 2
- CZRHGKCORBLEFT-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)C(F)(F)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)C(F)(F)F)=O CZRHGKCORBLEFT-UHFFFAOYSA-N 0.000 description 2
- MWDPHPPVXXPIRT-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)C1CC1)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)C1CC1)=O MWDPHPPVXXPIRT-UHFFFAOYSA-N 0.000 description 2
- ZQMYVORBQPHFQV-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OC(C)C)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OC(C)C)=O ZQMYVORBQPHFQV-UHFFFAOYSA-N 0.000 description 2
- QIDNCEBDSLQSKR-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OC(F)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OC(F)F)=O QIDNCEBDSLQSKR-UHFFFAOYSA-N 0.000 description 2
- WLTYTFOWQCLGDN-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC(F)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC(F)F)=O WLTYTFOWQCLGDN-UHFFFAOYSA-N 0.000 description 2
- KXTGXHXCMBRJLY-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC)=O KXTGXHXCMBRJLY-UHFFFAOYSA-N 0.000 description 2
- AXIYTFSQCZPDEO-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC1=NC=CC=C1)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC1=NC=CC=C1)=O AXIYTFSQCZPDEO-UHFFFAOYSA-N 0.000 description 2
- OXSSUVAGPXDOAP-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC1CC1)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC1CC1)=O OXSSUVAGPXDOAP-UHFFFAOYSA-N 0.000 description 2
- HSDFPKJRGQTCSF-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC1CCOCC1)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC1CCOCC1)=O HSDFPKJRGQTCSF-UHFFFAOYSA-N 0.000 description 2
- LGDSWSBOGAYIIR-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=NC=1)C1CC1)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=NC=1)C1CC1)=O LGDSWSBOGAYIIR-UHFFFAOYSA-N 0.000 description 2
- GKHJZGWBLNOZHH-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC=C(C=1)C#CC)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC=C(C=1)C#CC)=O GKHJZGWBLNOZHH-UHFFFAOYSA-N 0.000 description 2
- PFUQEBSYPBGXGX-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC=C(C=1)C#CC1CC1)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC=C(C=1)C#CC1CC1)=O PFUQEBSYPBGXGX-UHFFFAOYSA-N 0.000 description 2
- ZDMXJKVNFYYXGT-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC=C(C=1)C(F)(F)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC=C(C=1)C(F)(F)F)=O ZDMXJKVNFYYXGT-UHFFFAOYSA-N 0.000 description 2
- LHVQYWXSZVAHAP-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC=C(C=1)C)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC=C(C=1)C)=O LHVQYWXSZVAHAP-UHFFFAOYSA-N 0.000 description 2
- JEUQWBJPZDMAMU-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC=C(C=1)Cl)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC=C(C=1)Cl)=O JEUQWBJPZDMAMU-UHFFFAOYSA-N 0.000 description 2
- ZWQAUZVJBYAMSD-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC=C(C=1)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC=C(C=1)F)=O ZWQAUZVJBYAMSD-UHFFFAOYSA-N 0.000 description 2
- YHAPDLMJTDTJQZ-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC=C(C=1)OC)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC=C(C=1)OC)=O YHAPDLMJTDTJQZ-UHFFFAOYSA-N 0.000 description 2
- QSNXLDNEPLREAJ-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NN(C=1)C(C)C)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NN(C=1)C(C)C)=O QSNXLDNEPLREAJ-UHFFFAOYSA-N 0.000 description 2
- GTNLQMVEZFGPGP-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NN(C=1)CC(C)C)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NN(C=1)CC(C)C)=O GTNLQMVEZFGPGP-UHFFFAOYSA-N 0.000 description 2
- DSUDKRCAUITMBW-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NN(C=1)CCC)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NN(C=1)CCC)=O DSUDKRCAUITMBW-UHFFFAOYSA-N 0.000 description 2
- SZYXKLARWWIZGH-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1SC(=CC=1)C(F)(F)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1SC(=CC=1)C(F)(F)F)=O SZYXKLARWWIZGH-UHFFFAOYSA-N 0.000 description 2
- SVSLMHSWGMBSIR-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1SC=CC=1)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1SC=CC=1)=O SVSLMHSWGMBSIR-UHFFFAOYSA-N 0.000 description 2
- SCHJNCACRHPQIG-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1SC=CC=1F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1SC=CC=1F)=O SCHJNCACRHPQIG-UHFFFAOYSA-N 0.000 description 2
- BYJCJTSEWNWWGZ-UHFFFAOYSA-N ClC1=C(C=C(CNC(CC)=O)C=C1)C=1NC(C=C(N=1)C1=NC=C(C=C1)OC(F)F)=O Chemical compound ClC1=C(C=C(CNC(CC)=O)C=C1)C=1NC(C=C(N=1)C1=NC=C(C=C1)OC(F)F)=O BYJCJTSEWNWWGZ-UHFFFAOYSA-N 0.000 description 2
- ISEPYSYWXZGMCB-UHFFFAOYSA-N ClC1=C(C=C(CNC(CC)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OC(F)F)=O Chemical compound ClC1=C(C=C(CNC(CC)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OC(F)F)=O ISEPYSYWXZGMCB-UHFFFAOYSA-N 0.000 description 2
- LHEJPSKCQPSLPJ-UHFFFAOYSA-N ClC1=C(C=C(CNC(CC)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC(F)F)=O Chemical compound ClC1=C(C=C(CNC(CC)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC(F)F)=O LHEJPSKCQPSLPJ-UHFFFAOYSA-N 0.000 description 2
- WKFMJWCMWJUBAL-UHFFFAOYSA-N ClC1=C(C=C(CNC(CC)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC1CC1)=O Chemical compound ClC1=C(C=C(CNC(CC)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC1CC1)=O WKFMJWCMWJUBAL-UHFFFAOYSA-N 0.000 description 2
- ZPZZRJJOMANNBM-UHFFFAOYSA-N ClC1=C(C=C(CNC(CC)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCC)=O Chemical compound ClC1=C(C=C(CNC(CC)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCC)=O ZPZZRJJOMANNBM-UHFFFAOYSA-N 0.000 description 2
- HFNPVHATRUNZPD-UHFFFAOYSA-N ClC1=C(C=C(CNC(CC)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCCF)=O Chemical compound ClC1=C(C=C(CNC(CC)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCCF)=O HFNPVHATRUNZPD-UHFFFAOYSA-N 0.000 description 2
- GZRRVEPXHBEILI-UHFFFAOYSA-N ClC1=C(C=C(CNC(CC)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOCCC)=O Chemical compound ClC1=C(C=C(CNC(CC)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOCCC)=O GZRRVEPXHBEILI-UHFFFAOYSA-N 0.000 description 2
- NPIVSEKOZYYUHP-UHFFFAOYSA-N ClC1=C(C=C(CNC(CCC)=O)C=C1)C=1NC(C=C(N=1)C1=NC=C(C=C1)OC(F)F)=O Chemical compound ClC1=C(C=C(CNC(CCC)=O)C=C1)C=1NC(C=C(N=1)C1=NC=C(C=C1)OC(F)F)=O NPIVSEKOZYYUHP-UHFFFAOYSA-N 0.000 description 2
- RZIDABWCQNLDDD-UHFFFAOYSA-N ClC1=C(C=C(CNC(CCC)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OC(F)F)=O Chemical compound ClC1=C(C=C(CNC(CCC)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OC(F)F)=O RZIDABWCQNLDDD-UHFFFAOYSA-N 0.000 description 2
- CAXTXSCRTNXOHN-UHFFFAOYSA-N ClC1=C(C=C(CNC(CCC)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC1CCOCC1)=O Chemical compound ClC1=C(C=C(CNC(CCC)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC1CCOCC1)=O CAXTXSCRTNXOHN-UHFFFAOYSA-N 0.000 description 2
- PQEAKYZMCKKSBG-UHFFFAOYSA-N ClC1=C(C=C(CNC(CCC)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCF)=O Chemical compound ClC1=C(C=C(CNC(CCC)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCF)=O PQEAKYZMCKKSBG-UHFFFAOYSA-N 0.000 description 2
- SOUPXKBLSZKHGA-UHFFFAOYSA-N ClC1=C(C=C(CNC(CCC)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOCC)=O Chemical compound ClC1=C(C=C(CNC(CCC)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOCC)=O SOUPXKBLSZKHGA-UHFFFAOYSA-N 0.000 description 2
- XEBINXDZAQTRJQ-UHFFFAOYSA-N ClC1=C(C=C(CNC(CCC)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOCCC)=O Chemical compound ClC1=C(C=C(CNC(CCC)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOCCC)=O XEBINXDZAQTRJQ-UHFFFAOYSA-N 0.000 description 2
- HFPYCTYOVWLSFO-UHFFFAOYSA-N ClC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C1=CN=C(S1)C#CC1CC1)=O)F Chemical compound ClC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C1=CN=C(S1)C#CC1CC1)=O)F HFPYCTYOVWLSFO-UHFFFAOYSA-N 0.000 description 2
- AWEZMVNLFCBCIB-UHFFFAOYSA-N ClC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C1=NC=C(C=C1)C#CC1CC1)=O)F Chemical compound ClC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C1=NC=C(C=C1)C#CC1CC1)=O)F AWEZMVNLFCBCIB-UHFFFAOYSA-N 0.000 description 2
- IWFRBCCYGUWWEX-UHFFFAOYSA-N ClC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C1=NC=C(C=C1)Cl)=O)F Chemical compound ClC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C1=NC=C(C=C1)Cl)=O)F IWFRBCCYGUWWEX-UHFFFAOYSA-N 0.000 description 2
- GIKILPGYMBDKAQ-UHFFFAOYSA-N ClC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C1=NC=C(C=C1)OCC1CC1)=O)F Chemical compound ClC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C1=NC=C(C=C1)OCC1CC1)=O)F GIKILPGYMBDKAQ-UHFFFAOYSA-N 0.000 description 2
- YLEMNKYRDDRZLS-UHFFFAOYSA-N ClC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)C#CC1CC1)=O)F Chemical compound ClC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)C#CC1CC1)=O)F YLEMNKYRDDRZLS-UHFFFAOYSA-N 0.000 description 2
- LSBJTMKXDQYFEE-UHFFFAOYSA-N ClC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)OC(F)F)=O)F Chemical compound ClC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)OC(F)F)=O)F LSBJTMKXDQYFEE-UHFFFAOYSA-N 0.000 description 2
- OHUDYZVSHQKXGP-UHFFFAOYSA-N ClC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC(F)F)=O)F Chemical compound ClC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC(F)F)=O)F OHUDYZVSHQKXGP-UHFFFAOYSA-N 0.000 description 2
- CVVHYSHIANJPGU-UHFFFAOYSA-N ClC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC1CC1)=O)F Chemical compound ClC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC1CC1)=O)F CVVHYSHIANJPGU-UHFFFAOYSA-N 0.000 description 2
- CBIAQROOJWFYFM-UHFFFAOYSA-N ClC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOCC(F)(F)F)=O)F Chemical compound ClC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOCC(F)(F)F)=O)F CBIAQROOJWFYFM-UHFFFAOYSA-N 0.000 description 2
- NWRWTTKCUGOAHS-UHFFFAOYSA-N ClC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1SC=C(N=1)C(F)(F)F)=O)F Chemical compound ClC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1SC=C(N=1)C(F)(F)F)=O)F NWRWTTKCUGOAHS-UHFFFAOYSA-N 0.000 description 2
- TWSCUJKNEAPIKD-UHFFFAOYSA-N ClC=1C(=C(C(=CC=1)C(F)(F)F)C1=NC(=CC(N1)=O)C1=CN=C(S1)C#CC1CC1)F Chemical compound ClC=1C(=C(C(=CC=1)C(F)(F)F)C1=NC(=CC(N1)=O)C1=CN=C(S1)C#CC1CC1)F TWSCUJKNEAPIKD-UHFFFAOYSA-N 0.000 description 2
- AIPLAWMCLCZUAV-UHFFFAOYSA-N ClC=1C(=C(C(=CC=1)C(F)(F)F)C1=NC(=CC(N1)=O)C1=NC=C(C=C1)C#CC)F Chemical compound ClC=1C(=C(C(=CC=1)C(F)(F)F)C1=NC(=CC(N1)=O)C1=NC=C(C=C1)C#CC)F AIPLAWMCLCZUAV-UHFFFAOYSA-N 0.000 description 2
- OPNHZNXGCDKAFP-UHFFFAOYSA-N ClC=1C(=C(C(=CC=1)C(F)(F)F)C1=NC(=CC(N1)=O)C1=NC=C(C=C1)C#CC1CC1)F Chemical compound ClC=1C(=C(C(=CC=1)C(F)(F)F)C1=NC(=CC(N1)=O)C1=NC=C(C=C1)C#CC1CC1)F OPNHZNXGCDKAFP-UHFFFAOYSA-N 0.000 description 2
- NQHNUCJMDCUUJP-UHFFFAOYSA-N ClC=1C(=C(C(=CC=1)C(F)(F)F)C1=NC(=CC(N1)=O)C1=NC=C(C=C1)C(F)(F)F)F Chemical compound ClC=1C(=C(C(=CC=1)C(F)(F)F)C1=NC(=CC(N1)=O)C1=NC=C(C=C1)C(F)(F)F)F NQHNUCJMDCUUJP-UHFFFAOYSA-N 0.000 description 2
- VEVDJSAEBFXNBT-UHFFFAOYSA-N ClC=1C(=C(C(=CC=1)C(F)(F)F)C1=NC(=CC(N1)=O)C1=NC=C(C=C1)Cl)F Chemical compound ClC=1C(=C(C(=CC=1)C(F)(F)F)C1=NC(=CC(N1)=O)C1=NC=C(C=C1)Cl)F VEVDJSAEBFXNBT-UHFFFAOYSA-N 0.000 description 2
- KDLSYXGXHRUOFA-UHFFFAOYSA-N ClC=1C(=C(C(=CC=1)C(F)(F)F)C1=NC(=CC(N1)=O)C=1C=NC(=CC=1)C#CC1CC1)F Chemical compound ClC=1C(=C(C(=CC=1)C(F)(F)F)C1=NC(=CC(N1)=O)C=1C=NC(=CC=1)C#CC1CC1)F KDLSYXGXHRUOFA-UHFFFAOYSA-N 0.000 description 2
- NPPLZUIJKHSZFQ-UHFFFAOYSA-N ClC=1C(=C(C(=CC=1)C(F)(F)F)C1=NC(=CC(N1)=O)C=1C=NC(=CC=1)C(F)(F)F)F Chemical compound ClC=1C(=C(C(=CC=1)C(F)(F)F)C1=NC(=CC(N1)=O)C=1C=NC(=CC=1)C(F)(F)F)F NPPLZUIJKHSZFQ-UHFFFAOYSA-N 0.000 description 2
- UDYCWMKYXQJFBR-UHFFFAOYSA-N ClC=1C(=C(C(=CC=1)C(F)(F)F)C1=NC(=CC(N1)=O)C=1C=NC(=CC=1)OC(F)F)F Chemical compound ClC=1C(=C(C(=CC=1)C(F)(F)F)C1=NC(=CC(N1)=O)C=1C=NC(=CC=1)OC(F)F)F UDYCWMKYXQJFBR-UHFFFAOYSA-N 0.000 description 2
- QJGKWMUQGQEHHK-UHFFFAOYSA-N ClC=1C(=C(C(=CC=1)C(F)(F)F)C1=NC(=CC(N1)=O)C=1C=NC(=CC=1)OC)F Chemical compound ClC=1C(=C(C(=CC=1)C(F)(F)F)C1=NC(=CC(N1)=O)C=1C=NC(=CC=1)OC)F QJGKWMUQGQEHHK-UHFFFAOYSA-N 0.000 description 2
- NVCVWZLBJDPRMQ-UHFFFAOYSA-N ClC=1C(=C(C(=CC=1)C(F)(F)F)C1=NC(=CC(N1)=O)C=1C=NC(=CC=1)OCC)F Chemical compound ClC=1C(=C(C(=CC=1)C(F)(F)F)C1=NC(=CC(N1)=O)C=1C=NC(=CC=1)OCC)F NVCVWZLBJDPRMQ-UHFFFAOYSA-N 0.000 description 2
- QXITYGRGPAKCOF-UHFFFAOYSA-N ClC=1C(=C(C(=CC=1)C(F)(F)F)C1=NC(=CC(N1)=O)C=1C=NC(=CC=1)OCCOC(C)C)F Chemical compound ClC=1C(=C(C(=CC=1)C(F)(F)F)C1=NC(=CC(N1)=O)C=1C=NC(=CC=1)OCCOC(C)C)F QXITYGRGPAKCOF-UHFFFAOYSA-N 0.000 description 2
- DAAXQKMFLWOYIP-UHFFFAOYSA-N ClC=1C(=C(C(=CC=1)C(F)(F)F)C1=NC(=CC(N1)=O)C=1C=NC(=CC=1)OCCOCC)F Chemical compound ClC=1C(=C(C(=CC=1)C(F)(F)F)C1=NC(=CC(N1)=O)C=1C=NC(=CC=1)OCCOCC)F DAAXQKMFLWOYIP-UHFFFAOYSA-N 0.000 description 2
- HNPGQPRWQACYRK-UHFFFAOYSA-N ClC=1C(=C(C(=CC=1)C(F)(F)F)C1=NC(=CC(N1)=O)C=1C=NC(=CC=1)OCCOCCC)F Chemical compound ClC=1C(=C(C(=CC=1)C(F)(F)F)C1=NC(=CC(N1)=O)C=1C=NC(=CC=1)OCCOCCC)F HNPGQPRWQACYRK-UHFFFAOYSA-N 0.000 description 2
- UXEUQWAEWCMALE-UHFFFAOYSA-N ClC=1C(=C(C(=CC=1)C(F)(F)F)C1=NC(=CC(N1)=O)C=1C=NC=C(C=1)F)F Chemical compound ClC=1C(=C(C(=CC=1)C(F)(F)F)C1=NC(=CC(N1)=O)C=1C=NC=C(C=1)F)F UXEUQWAEWCMALE-UHFFFAOYSA-N 0.000 description 2
- QGRWATOBASGOAW-UHFFFAOYSA-N ClC=1C=C(C=NC=1)C=1N=C(NC(C=1)=O)C=1C(=C(CNC(C(C)C)=O)C=CC=1F)F Chemical compound ClC=1C=C(C=NC=1)C=1N=C(NC(C=1)=O)C=1C(=C(CNC(C(C)C)=O)C=CC=1F)F QGRWATOBASGOAW-UHFFFAOYSA-N 0.000 description 2
- JZLDHVLQRWUZJB-UHFFFAOYSA-N ClC=1C=C(C=NC=1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F Chemical compound ClC=1C=C(C=NC=1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F JZLDHVLQRWUZJB-UHFFFAOYSA-N 0.000 description 2
- AOYUFYMONJCIFA-UHFFFAOYSA-N ClC=1C=C(C=NC=1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1F Chemical compound ClC=1C=C(C=NC=1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1F AOYUFYMONJCIFA-UHFFFAOYSA-N 0.000 description 2
- PQRMZAZILPYKLC-UHFFFAOYSA-N ClC=1C=CC(=NC=1)C=1N=C(NC(C=1)=O)C=1C(=C(CNC(C(C)C)=O)C=CC=1F)F Chemical compound ClC=1C=CC(=NC=1)C=1N=C(NC(C=1)=O)C=1C(=C(CNC(C(C)C)=O)C=CC=1F)F PQRMZAZILPYKLC-UHFFFAOYSA-N 0.000 description 2
- ROTZGDVLVYKEHV-UHFFFAOYSA-N ClC=1C=CC(=NC=1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1 Chemical compound ClC=1C=CC(=NC=1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1 ROTZGDVLVYKEHV-UHFFFAOYSA-N 0.000 description 2
- QAZHHDSFIOWBEL-UHFFFAOYSA-N ClC=1C=CC(=NC=1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F Chemical compound ClC=1C=CC(=NC=1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F QAZHHDSFIOWBEL-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 2
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- LOQJVZMCINQIGS-UHFFFAOYSA-N FC(OC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OC(F)F)=O)F Chemical compound FC(OC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OC(F)F)=O)F LOQJVZMCINQIGS-UHFFFAOYSA-N 0.000 description 2
- ZECFAKRXPJJQAK-UHFFFAOYSA-N FC(OC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)F Chemical compound FC(OC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)F ZECFAKRXPJJQAK-UHFFFAOYSA-N 0.000 description 2
- USJVCWGKTBBVQB-UHFFFAOYSA-N FC(OC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)F)F Chemical compound FC(OC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)F)F USJVCWGKTBBVQB-UHFFFAOYSA-N 0.000 description 2
- KWFUOPWFZPTRTR-UHFFFAOYSA-N FC(OC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C)F Chemical compound FC(OC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C)F KWFUOPWFZPTRTR-UHFFFAOYSA-N 0.000 description 2
- ZJMNTFGAZMONQA-UHFFFAOYSA-N FC(OC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1F)F Chemical compound FC(OC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1F)F ZJMNTFGAZMONQA-UHFFFAOYSA-N 0.000 description 2
- LINXKOSEMFHDAU-UHFFFAOYSA-N FC(OC1=NC=CC(=C1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)F Chemical compound FC(OC1=NC=CC(=C1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)F LINXKOSEMFHDAU-UHFFFAOYSA-N 0.000 description 2
- RFPNSVDCRZBJLG-UHFFFAOYSA-N FC(OC=1C=CC(=NC=1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)F Chemical compound FC(OC=1C=CC(=NC=1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)F RFPNSVDCRZBJLG-UHFFFAOYSA-N 0.000 description 2
- HPPIJKRHFBUVMB-UHFFFAOYSA-N FC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)C(F)(F)F)=O Chemical compound FC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)C(F)(F)F)=O HPPIJKRHFBUVMB-UHFFFAOYSA-N 0.000 description 2
- HXUCZKXWQIRBCD-UHFFFAOYSA-N FC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C1=NC=C(C=C1)C(F)(F)F)=O)F Chemical compound FC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C1=NC=C(C=C1)C(F)(F)F)=O)F HXUCZKXWQIRBCD-UHFFFAOYSA-N 0.000 description 2
- XFGTZWPRDKRDPW-UHFFFAOYSA-N FC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)C(F)(F)F)=O)C(F)(F)F Chemical compound FC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)C(F)(F)F)=O)C(F)(F)F XFGTZWPRDKRDPW-UHFFFAOYSA-N 0.000 description 2
- HHBVMJMXNMZVMY-UHFFFAOYSA-N FC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOC(C)C)=O)F Chemical compound FC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOC(C)C)=O)F HHBVMJMXNMZVMY-UHFFFAOYSA-N 0.000 description 2
- UELHLLBFEVQTEF-UHFFFAOYSA-N FC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOCC(F)(F)F)=O)F Chemical compound FC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOCC(F)(F)F)=O)F UELHLLBFEVQTEF-UHFFFAOYSA-N 0.000 description 2
- MAWFSGKQHGLQIH-UHFFFAOYSA-N FC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOCCC)=O)F Chemical compound FC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOCCC)=O)F MAWFSGKQHGLQIH-UHFFFAOYSA-N 0.000 description 2
- CRHYAMDJICALGX-UHFFFAOYSA-N FC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC=C(C=1)F)=O)C(F)(F)F Chemical compound FC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC=C(C=1)F)=O)C(F)(F)F CRHYAMDJICALGX-UHFFFAOYSA-N 0.000 description 2
- RRVDYWSZJISAHN-UHFFFAOYSA-N FC=1C=C(C=NC=1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F Chemical compound FC=1C=C(C=NC=1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F RRVDYWSZJISAHN-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Natural products COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 2
- PKENCSOZODLGMM-UHFFFAOYSA-N N-[(2-chloro-3-cyano-4-fluorophenyl)methyl]-2-methylpropanamide Chemical compound ClC1=C(CNC(C(C)C)=O)C=CC(=C1C#N)F PKENCSOZODLGMM-UHFFFAOYSA-N 0.000 description 2
- ABEBQFMMVVGZNN-UHFFFAOYSA-N N-[(3-bromo-4-methylphenyl)methyl]-2-methylpropanamide Chemical compound BrC=1C=C(CNC(C(C)C)=O)C=CC=1C ABEBQFMMVVGZNN-UHFFFAOYSA-N 0.000 description 2
- JZOJAYKFJLDKAB-UHFFFAOYSA-N N-[(3-cyano-2,4-difluorophenyl)methyl]-2-methylpropanamide Chemical compound C(#N)C=1C(=C(CNC(C(C)C)=O)C=CC=1F)F JZOJAYKFJLDKAB-UHFFFAOYSA-N 0.000 description 2
- SETFBNFDDDBUIE-UHFFFAOYSA-N N-[(3-cyano-4-fluorophenyl)methyl]-2,2-dimethylpropanamide Chemical compound C(#N)C=1C=C(CNC(C(C)(C)C)=O)C=CC=1F SETFBNFDDDBUIE-UHFFFAOYSA-N 0.000 description 2
- XZBAUNOJLPRAKO-UHFFFAOYSA-N N-[(3-cyano-4-fluorophenyl)methyl]-2-methylpropanamide Chemical compound C(#N)C=1C=C(CNC(C(C)C)=O)C=CC=1F XZBAUNOJLPRAKO-UHFFFAOYSA-N 0.000 description 2
- MDEOFGJEQRUZNN-UHFFFAOYSA-N N-[(3-cyano-4-methylphenyl)methyl]-2-methylpropanamide Chemical compound C(#N)C=1C=C(CNC(C(C)C)=O)C=CC=1C MDEOFGJEQRUZNN-UHFFFAOYSA-N 0.000 description 2
- SZFLPLIIMVPEBT-UHFFFAOYSA-N N-[(4-chloro-3-cyano-2-fluorophenyl)methyl]-2-methylpropanamide Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C#N SZFLPLIIMVPEBT-UHFFFAOYSA-N 0.000 description 2
- ZNDDBSWYYMZOTH-UHFFFAOYSA-N N-[(4-chloro-3-cyano-2-fluorophenyl)methyl]butanamide Chemical compound ClC1=C(C(=C(CNC(CCC)=O)C=C1)F)C#N ZNDDBSWYYMZOTH-UHFFFAOYSA-N 0.000 description 2
- HIZTWPGNQPFOSO-UHFFFAOYSA-N N-[(4-chloro-3-cyanophenyl)methyl]-2,2-dimethylpropanamide Chemical compound ClC1=C(C=C(CNC(C(C)(C)C)=O)C=C1)C#N HIZTWPGNQPFOSO-UHFFFAOYSA-N 0.000 description 2
- VUFSOLWEPAULDW-UHFFFAOYSA-N N-[(4-chloro-3-cyanophenyl)methyl]-2-methoxy-2-methylpropanamide Chemical compound ClC1=C(C=C(CNC(C(C)(C)OC)=O)C=C1)C#N VUFSOLWEPAULDW-UHFFFAOYSA-N 0.000 description 2
- JONOLOWMNGHBED-UHFFFAOYSA-N N-[(4-chloro-3-cyanophenyl)methyl]-2-methylpropanamide Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C#N JONOLOWMNGHBED-UHFFFAOYSA-N 0.000 description 2
- CLGNWVXGDLVPNA-UHFFFAOYSA-N N-[(4-chloro-3-cyanophenyl)methyl]-3,3,3-trifluoro-2,2-dimethylpropanamide Chemical compound ClC1=C(C=C(CNC(C(C(F)(F)F)(C)C)=O)C=C1)C#N CLGNWVXGDLVPNA-UHFFFAOYSA-N 0.000 description 2
- GPRDDKOZNJFEFE-UHFFFAOYSA-N N-[(4-chloro-3-cyanophenyl)methyl]butanamide Chemical compound ClC1=C(C=C(CNC(CCC)=O)C=C1)C#N GPRDDKOZNJFEFE-UHFFFAOYSA-N 0.000 description 2
- LJWSZEBENIUPQL-UHFFFAOYSA-N N-[(4-chloro-3-cyanophenyl)methyl]cyclopropanecarboxamide Chemical compound ClC1=C(C=C(CNC(=O)C2CC2)C=C1)C#N LJWSZEBENIUPQL-UHFFFAOYSA-N 0.000 description 2
- DBOJGPBVXBQWCF-UHFFFAOYSA-N N-[(4-chloro-3-cyanophenyl)methyl]propanamide Chemical compound ClC1=C(C=C(C=C1)CNC(CC)=O)C#N DBOJGPBVXBQWCF-UHFFFAOYSA-N 0.000 description 2
- DDYGSYDNQBBQAA-UHFFFAOYSA-N N-[[3-cyano-4-(difluoromethoxy)phenyl]methyl]-2-methylpropanamide Chemical compound C(#N)C=1C=C(CNC(C(C)C)=O)C=CC=1OC(F)F DDYGSYDNQBBQAA-UHFFFAOYSA-N 0.000 description 2
- QQSPFJRFJNUMFR-UHFFFAOYSA-N N-[[3-cyano-4-(difluoromethyl)phenyl]methyl]-2-methylpropanamide Chemical compound C(#N)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)F QQSPFJRFJNUMFR-UHFFFAOYSA-N 0.000 description 2
- QMPPCNSRZSMYHY-UHFFFAOYSA-N N-[[3-cyano-4-(trifluoromethyl)phenyl]methyl]-2-methylpropanamide Chemical compound C(#N)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F QMPPCNSRZSMYHY-UHFFFAOYSA-N 0.000 description 2
- PFGVHBPOBPUDHF-UHFFFAOYSA-N N-[[3-cyano-4-(trifluoromethyl)phenyl]methyl]butanamide Chemical compound C(#N)C=1C=C(CNC(CCC)=O)C=CC=1C(F)(F)F PFGVHBPOBPUDHF-UHFFFAOYSA-N 0.000 description 2
- CKLMZYNOOHTCNZ-UHFFFAOYSA-N N-methoxy-N-methyl-5-(2,2,2-trifluoroethyl)pyridine-2-carboxamide Chemical compound CON(C(=O)C1=NC=C(C=C1)CC(F)(F)F)C CKLMZYNOOHTCNZ-UHFFFAOYSA-N 0.000 description 2
- WZCWYHJZNOCOAB-UHFFFAOYSA-N NCC=1C=C(C=CC=1)C1=NC(=CC(N1)=O)C1=NC=C(C=C1)Cl Chemical compound NCC=1C=C(C=CC=1)C1=NC(=CC(N1)=O)C1=NC=C(C=C1)Cl WZCWYHJZNOCOAB-UHFFFAOYSA-N 0.000 description 2
- NIXKMJRTHJPBJQ-UHFFFAOYSA-N O=C1C=C(N=C(N1)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)C1=NC=C(C=C1)C(F)(F)F Chemical compound O=C1C=C(N=C(N1)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)C1=NC=C(C=C1)C(F)(F)F NIXKMJRTHJPBJQ-UHFFFAOYSA-N 0.000 description 2
- XVQJMLMWAHEPAY-UHFFFAOYSA-N O=C1C=C(N=C(N1)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)C=1C=NC(=CC=1)C(F)(F)F Chemical compound O=C1C=C(N=C(N1)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)C=1C=NC(=CC=1)C(F)(F)F XVQJMLMWAHEPAY-UHFFFAOYSA-N 0.000 description 2
- BTMPHRMFJTVUNH-UHFFFAOYSA-N O=C1C=C(N=C(N1)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)C=1C=NC=C(C=1)C#CC Chemical compound O=C1C=C(N=C(N1)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)C=1C=NC=C(C=1)C#CC BTMPHRMFJTVUNH-UHFFFAOYSA-N 0.000 description 2
- LYBOVYRIUICRPS-UHFFFAOYSA-N O=C1C=C(N=C(N1)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)C=1SC=C(N=1)C(F)(F)F Chemical compound O=C1C=C(N=C(N1)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)C=1SC=C(N=1)C(F)(F)F LYBOVYRIUICRPS-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 208000005107 Premature Birth Diseases 0.000 description 2
- 206010036590 Premature baby Diseases 0.000 description 2
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 2
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 2
- VTHVRBJSLSRWDO-UHFFFAOYSA-N S1C(=NC2=C1C=CC=C2)C=1N=C(NC(C=1)=O)C=1C(=C(CNC(C(C)C)=O)C=CC=1F)F Chemical compound S1C(=NC2=C1C=CC=C2)C=1N=C(NC(C=1)=O)C=1C(=C(CNC(C(C)C)=O)C=CC=1F)F VTHVRBJSLSRWDO-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 2
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
- 239000000920 calcium hydroxide Substances 0.000 description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- DDDLJYBLWWBBSI-UHFFFAOYSA-N cyclopropanecarboxamide;hydrochloride Chemical compound Cl.NC(=O)C1CC1 DDDLJYBLWWBBSI-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- VRLDVERQJMEPIF-UHFFFAOYSA-N dbdmh Chemical compound CC1(C)N(Br)C(=O)N(Br)C1=O VRLDVERQJMEPIF-UHFFFAOYSA-N 0.000 description 2
- 239000012351 deprotecting agent Substances 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- MXFYYFVVIIWKFE-UHFFFAOYSA-N dicyclohexyl-[2-[2,6-di(propan-2-yloxy)phenyl]phenyl]phosphane Chemical compound CC(C)OC1=CC=CC(OC(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 MXFYYFVVIIWKFE-UHFFFAOYSA-N 0.000 description 2
- 229960004132 diethyl ether Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- KTQYAGCBPOFNPY-UHFFFAOYSA-N ethyl 2-fluoro-3-(4-methoxyphenyl)-3-oxopropanoate Chemical compound CCOC(=O)C(F)C(=O)C1=CC=C(OC)C=C1 KTQYAGCBPOFNPY-UHFFFAOYSA-N 0.000 description 2
- DTELMTOYSPFNNP-UHFFFAOYSA-N ethyl 2-fluoro-3-oxo-3-phenylpropanoate Chemical compound CCOC(=O)C(F)C(=O)C1=CC=CC=C1 DTELMTOYSPFNNP-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 125000004175 fluorobenzyl group Chemical group 0.000 description 2
- JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 235000014413 iron hydroxide Nutrition 0.000 description 2
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- 229910000000 metal hydroxide Inorganic materials 0.000 description 2
- 150000004692 metal hydroxides Chemical class 0.000 description 2
- 229950001413 metamfepramone Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- SKTCDJAMAYNROS-UHFFFAOYSA-N methoxycyclopentane Chemical compound COC1CCCC1 SKTCDJAMAYNROS-UHFFFAOYSA-N 0.000 description 2
- 229940095102 methyl benzoate Drugs 0.000 description 2
- 230000003228 microsomal effect Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- WUPYRQXDERVPIZ-UHFFFAOYSA-N n,n-diethyl-4-formylbenzenesulfonamide Chemical compound CCN(CC)S(=O)(=O)C1=CC=C(C=O)C=C1 WUPYRQXDERVPIZ-UHFFFAOYSA-N 0.000 description 2
- QYZFTMMPKCOTAN-UHFFFAOYSA-N n-[2-(2-hydroxyethylamino)ethyl]-2-[[1-[2-(2-hydroxyethylamino)ethylamino]-2-methyl-1-oxopropan-2-yl]diazenyl]-2-methylpropanamide Chemical compound OCCNCCNC(=O)C(C)(C)N=NC(C)(C)C(=O)NCCNCCO QYZFTMMPKCOTAN-UHFFFAOYSA-N 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- FXLOVSHXALFLKQ-UHFFFAOYSA-N p-tolualdehyde Chemical compound CC1=CC=C(C=O)C=C1 FXLOVSHXALFLKQ-UHFFFAOYSA-N 0.000 description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- FKRCODPIKNYEAC-UHFFFAOYSA-N propionic acid ethyl ester Natural products CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- YIBNHAJFJUQSRA-YNNPMVKQSA-N prostaglandin H2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O YIBNHAJFJUQSRA-YNNPMVKQSA-N 0.000 description 2
- 229940127293 prostanoid Drugs 0.000 description 2
- 150000003814 prostanoids Chemical class 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- VJKWLXJSHXRLBC-UHFFFAOYSA-N tert-butyl N-[[3-cyano-4-(difluoromethoxy)phenyl]methyl]carbamate Chemical compound C(C)(C)(C)OC(NCC1=CC(=C(C=C1)OC(F)F)C#N)=O VJKWLXJSHXRLBC-UHFFFAOYSA-N 0.000 description 2
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 2
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 2
- 235000019798 tripotassium phosphate Nutrition 0.000 description 2
- UKSZBOKPHAQOMP-SVLSSHOZSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 UKSZBOKPHAQOMP-SVLSSHOZSA-N 0.000 description 1
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- DOMQFIFVDIAOOT-ROUUACIJSA-N (2S,3R)-N-[4-(2,6-dimethoxyphenyl)-5-(5-methylpyridin-3-yl)-1,2,4-triazol-3-yl]-3-(5-methylpyrimidin-2-yl)butane-2-sulfonamide Chemical compound COC1=C(C(=CC=C1)OC)N1C(=NN=C1C=1C=NC=C(C=1)C)NS(=O)(=O)[C@@H](C)[C@H](C)C1=NC=C(C=N1)C DOMQFIFVDIAOOT-ROUUACIJSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- GDRGOJWXIJAVCR-UHFFFAOYSA-N (3-bromo-4-methylphenyl)methanamine Chemical compound CC1=CC=C(CN)C=C1Br GDRGOJWXIJAVCR-UHFFFAOYSA-N 0.000 description 1
- UNMJLQGKEDTEKJ-UHFFFAOYSA-N (3-ethyloxetan-3-yl)methanol Chemical compound CCC1(CO)COC1 UNMJLQGKEDTEKJ-UHFFFAOYSA-N 0.000 description 1
- NLQMSBJFLQPLIJ-UHFFFAOYSA-N (3-methyloxetan-3-yl)methanol Chemical compound OCC1(C)COC1 NLQMSBJFLQPLIJ-UHFFFAOYSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- DJCJOWDAAZEMCI-UHFFFAOYSA-N (6-methylpyridin-3-yl)methanol Chemical compound CC1=CC=C(CO)C=N1 DJCJOWDAAZEMCI-UHFFFAOYSA-N 0.000 description 1
- HAKVNWBUOCSHTR-UHFFFAOYSA-N (9,9-dimethylxanthen-1-yl)-diphenylphosphane Chemical compound C=12C(C)(C)C3=CC=CC=C3OC2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 HAKVNWBUOCSHTR-UHFFFAOYSA-N 0.000 description 1
- UKGJZDSUJSPAJL-YPUOHESYSA-N (e)-n-[(1r)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide Chemical compound CCCC1=NC(C(F)(F)F)=CC=C1\C=C\C(=O)N[C@H](C)C1=CC(F)=C(NS(C)(=O)=O)C(F)=C1 UKGJZDSUJSPAJL-YPUOHESYSA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 description 1
- YGTAZGSLCXNBQL-UHFFFAOYSA-N 1,2,4-thiadiazole Chemical compound C=1N=CSN=1 YGTAZGSLCXNBQL-UHFFFAOYSA-N 0.000 description 1
- JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-triazine Chemical compound C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- HOPKSBAEUKMTHH-UHFFFAOYSA-N 1-(2-methylpropyl)pyrazole-4-carbaldehyde Chemical compound CC(C)CN1C=C(C=O)C=N1 HOPKSBAEUKMTHH-UHFFFAOYSA-N 0.000 description 1
- UDPCIPDJGNJPBG-UHFFFAOYSA-N 1-(trifluoromethyl)cyclopropane-1-carbonyl chloride Chemical compound FC(F)(F)C1(C(Cl)=O)CC1 UDPCIPDJGNJPBG-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical group C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 1
- MMYKTRPLXXWLBC-UHFFFAOYSA-N 1-bromo-2-ethoxyethane Chemical compound CCOCCBr MMYKTRPLXXWLBC-UHFFFAOYSA-N 0.000 description 1
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 1
- YZWKKMVJZFACSU-UHFFFAOYSA-N 1-bromopentane Chemical compound CCCCCBr YZWKKMVJZFACSU-UHFFFAOYSA-N 0.000 description 1
- QYLFHLNFIHBCPR-UHFFFAOYSA-N 1-ethynylcyclohexan-1-ol Chemical compound C#CC1(O)CCCCC1 QYLFHLNFIHBCPR-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- JTOWCZGTZBCRNY-UHFFFAOYSA-N 1-propan-2-ylpyrazole-4-carbaldehyde Chemical compound CC(C)N1C=C(C=O)C=N1 JTOWCZGTZBCRNY-UHFFFAOYSA-N 0.000 description 1
- VGOOENCTKLBWEI-UHFFFAOYSA-N 1-propylpyrazole-4-carbaldehyde Chemical compound CCCN1C=C(C=O)C=N1 VGOOENCTKLBWEI-UHFFFAOYSA-N 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- KXRJDLZPCNTHJN-UHFFFAOYSA-N 1-tert-butylpyrazole-4-carbaldehyde Chemical compound CC(C)(C)N1C=C(C=O)C=N1 KXRJDLZPCNTHJN-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- SNTWKPAKVQFCCF-UHFFFAOYSA-N 2,3-dihydro-1h-triazole Chemical compound N1NC=CN1 SNTWKPAKVQFCCF-UHFFFAOYSA-N 0.000 description 1
- WCGPCBACLBHDCI-UHFFFAOYSA-N 2,4-difluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C(F)=C1 WCGPCBACLBHDCI-UHFFFAOYSA-N 0.000 description 1
- SYOANZBNGDEJFH-UHFFFAOYSA-N 2,5-dihydro-1h-triazole Chemical compound C1NNN=C1 SYOANZBNGDEJFH-UHFFFAOYSA-N 0.000 description 1
- HRBLSBRWIWIOGW-UHFFFAOYSA-N 2-(2,2,2-trifluoroethoxy)ethanol Chemical compound OCCOCC(F)(F)F HRBLSBRWIWIOGW-UHFFFAOYSA-N 0.000 description 1
- OAYXUHPQHDHDDZ-UHFFFAOYSA-N 2-(2-butoxyethoxy)ethanol Chemical compound CCCCOCCOCCO OAYXUHPQHDHDDZ-UHFFFAOYSA-N 0.000 description 1
- FAMRTHHQYMFCBD-UHFFFAOYSA-N 2-(4-bromo-2-fluorophenyl)-2-hydroxyacetic acid Chemical compound OC(=O)C(O)C1=CC=C(Br)C=C1F FAMRTHHQYMFCBD-UHFFFAOYSA-N 0.000 description 1
- SDTOCBWWASQPSN-UHFFFAOYSA-N 2-(trifluoromethyl)-1,3-thiazole-5-carbaldehyde Chemical compound FC(F)(F)C1=NC=C(C=O)S1 SDTOCBWWASQPSN-UHFFFAOYSA-N 0.000 description 1
- GAUDQBASERVUGM-UHFFFAOYSA-N 2-(trifluoromethyl)pyrimidine-5-carbaldehyde Chemical compound FC(F)(F)C1=NC=C(C=O)C=N1 GAUDQBASERVUGM-UHFFFAOYSA-N 0.000 description 1
- WFSMVVDJSNMRAR-UHFFFAOYSA-N 2-[2-(2-ethoxyethoxy)ethoxy]ethanol Chemical compound CCOCCOCCOCCO WFSMVVDJSNMRAR-UHFFFAOYSA-N 0.000 description 1
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 1
- VEWHOIWZDHMAAT-UHFFFAOYSA-N 2-butylpyrimidine-5-carbaldehyde Chemical compound CCCCC1=NC=C(C=O)C=N1 VEWHOIWZDHMAAT-UHFFFAOYSA-N 0.000 description 1
- KMQWNQKESAHDKD-UHFFFAOYSA-N 2-chloro-4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C(Cl)=C1 KMQWNQKESAHDKD-UHFFFAOYSA-N 0.000 description 1
- GZLDIGZOBXAKKD-UHFFFAOYSA-N 2-chloro-5-(2,2,2-trifluoroethyl)pyridine Chemical compound FC(F)(F)CC1=CC=C(Cl)N=C1 GZLDIGZOBXAKKD-UHFFFAOYSA-N 0.000 description 1
- UHLLSLUQSGFENQ-UHFFFAOYSA-N 2-chloro-6-fluoro-3-methylbenzonitrile Chemical compound CC1=CC=C(F)C(C#N)=C1Cl UHLLSLUQSGFENQ-UHFFFAOYSA-N 0.000 description 1
- UFRQDLJDTSUKCS-UHFFFAOYSA-N 2-chlorothiophene-3-carbaldehyde Chemical compound ClC=1SC=CC=1C=O UFRQDLJDTSUKCS-UHFFFAOYSA-N 0.000 description 1
- MESDALXDBSNYMH-UHFFFAOYSA-N 2-cyclopropylpyrimidine-5-carbaldehyde Chemical compound N1=CC(C=O)=CN=C1C1CC1 MESDALXDBSNYMH-UHFFFAOYSA-N 0.000 description 1
- DEACWPDDLIOZJV-UHFFFAOYSA-N 2-fluoro-4-(trifluoromethoxy)benzaldehyde Chemical compound FC1=CC(OC(F)(F)F)=CC=C1C=O DEACWPDDLIOZJV-UHFFFAOYSA-N 0.000 description 1
- ONRPXRPUBXXCCM-UHFFFAOYSA-N 2-fluoro-4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C(F)=C1 ONRPXRPUBXXCCM-UHFFFAOYSA-N 0.000 description 1
- UNWQNFJBBWXFBG-UHFFFAOYSA-N 2-fluoro-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C(F)=C1 UNWQNFJBBWXFBG-UHFFFAOYSA-N 0.000 description 1
- MVDRIMBGRZBWPE-UHFFFAOYSA-N 2-fluoro-4-methylbenzaldehyde Chemical compound CC1=CC=C(C=O)C(F)=C1 MVDRIMBGRZBWPE-UHFFFAOYSA-N 0.000 description 1
- DKIQXHIAEMGZGO-UHFFFAOYSA-N 2-fluoro-5-methoxybenzaldehyde Chemical compound COC1=CC=C(F)C(C=O)=C1 DKIQXHIAEMGZGO-UHFFFAOYSA-N 0.000 description 1
- ZWDVQMVZZYIAHO-UHFFFAOYSA-N 2-fluorobenzaldehyde Chemical compound FC1=CC=CC=C1C=O ZWDVQMVZZYIAHO-UHFFFAOYSA-N 0.000 description 1
- 125000004791 2-fluoroethoxy group Chemical group FCCO* 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- XTXZVLUCJBYWFC-UHFFFAOYSA-N 2-methoxy-1,3-thiazole-5-carbaldehyde Chemical compound COC1=NC=C(C=O)S1 XTXZVLUCJBYWFC-UHFFFAOYSA-N 0.000 description 1
- BKBZFJRHYSCZQA-UHFFFAOYSA-N 2-methoxy-2-methylpropanoic acid Chemical compound COC(C)(C)C(O)=O BKBZFJRHYSCZQA-UHFFFAOYSA-N 0.000 description 1
- 239000001431 2-methylbenzaldehyde Substances 0.000 description 1
- IDDXMCNSHNXTRS-UHFFFAOYSA-N 2-oxo-1h-pyridine-4-carbaldehyde Chemical compound OC1=CC(C=O)=CC=N1 IDDXMCNSHNXTRS-UHFFFAOYSA-N 0.000 description 1
- HCGFUIQPSOCUHI-UHFFFAOYSA-N 2-propan-2-yloxyethanol Chemical compound CC(C)OCCO HCGFUIQPSOCUHI-UHFFFAOYSA-N 0.000 description 1
- YEYKMVJDLWJFOA-UHFFFAOYSA-N 2-propoxyethanol Chemical compound CCCOCCO YEYKMVJDLWJFOA-UHFFFAOYSA-N 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- DJHUPNYIUPLHMG-UHFFFAOYSA-N 2-sulfanylidene-1h-pyrimidine-5-carbaldehyde Chemical compound O=CC=1C=NC(=S)NC=1 DJHUPNYIUPLHMG-UHFFFAOYSA-N 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- PPWNCLVNXGCGAF-UHFFFAOYSA-N 3,3-dimethylbut-1-yne Chemical compound CC(C)(C)C#C PPWNCLVNXGCGAF-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- KAGANPFKWIISOB-UHFFFAOYSA-N 3-(aminomethyl)-2,6-difluorobenzonitrile Chemical compound NCC1=CC=C(F)C(C#N)=C1F KAGANPFKWIISOB-UHFFFAOYSA-N 0.000 description 1
- KXGJFWARYFCCNT-UHFFFAOYSA-N 3-(aminomethyl)-2-chloro-6-fluorobenzonitrile Chemical compound NCC=1C(=C(C#N)C(=CC=1)F)Cl KXGJFWARYFCCNT-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- RNIDWJDZNNVFDY-UHFFFAOYSA-N 3-Acetylthiophene Chemical compound CC(=O)C=1C=CSC=1 RNIDWJDZNNVFDY-UHFFFAOYSA-N 0.000 description 1
- YGYGASJNJTYNOL-CQSZACIVSA-N 3-[(4r)-2,2-dimethyl-1,1-dioxothian-4-yl]-5-(4-fluorophenyl)-1h-indole-7-carboxamide Chemical compound C1CS(=O)(=O)C(C)(C)C[C@@H]1C1=CNC2=C(C(N)=O)C=C(C=3C=CC(F)=CC=3)C=C12 YGYGASJNJTYNOL-CQSZACIVSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
- AVIILPWTQMSBOW-UHFFFAOYSA-N 3-chloro-2-fluoro-6-(trifluoromethyl)benzonitrile Chemical compound FC1=C(Cl)C=CC(C(F)(F)F)=C1C#N AVIILPWTQMSBOW-UHFFFAOYSA-N 0.000 description 1
- YAOZCMANASAVFN-UHFFFAOYSA-N 3-chloro-2-fluorobenzaldehyde Chemical compound FC1=C(Cl)C=CC=C1C=O YAOZCMANASAVFN-UHFFFAOYSA-N 0.000 description 1
- XHMWPVBQGARKQM-UHFFFAOYSA-N 3-ethoxy-1-propanol Chemical compound CCOCCCO XHMWPVBQGARKQM-UHFFFAOYSA-N 0.000 description 1
- SOQCZBSZZLWDGU-UHFFFAOYSA-N 3-fluoro-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1F SOQCZBSZZLWDGU-UHFFFAOYSA-N 0.000 description 1
- UFPBMVRONDLOGK-UHFFFAOYSA-N 3-fluoro-4-methylbenzaldehyde Chemical compound CC1=CC=C(C=O)C=C1F UFPBMVRONDLOGK-UHFFFAOYSA-N 0.000 description 1
- PIKNVEVCWAAOMJ-UHFFFAOYSA-N 3-fluorobenzaldehyde Chemical compound FC1=CC=CC(C=O)=C1 PIKNVEVCWAAOMJ-UHFFFAOYSA-N 0.000 description 1
- NLRJUIXKEMCEOH-UHFFFAOYSA-N 3-fluoropropan-1-ol Chemical compound OCCCF NLRJUIXKEMCEOH-UHFFFAOYSA-N 0.000 description 1
- OXDSTEQMQRCOGK-UHFFFAOYSA-N 3-fluorothiophene-2-carbaldehyde Chemical compound FC=1C=CSC=1C=O OXDSTEQMQRCOGK-UHFFFAOYSA-N 0.000 description 1
- RBIGKSZIQCTIJF-UHFFFAOYSA-N 3-formylthiophene Chemical compound O=CC=1C=CSC=1 RBIGKSZIQCTIJF-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- JDFDHBSESGTDAL-UHFFFAOYSA-N 3-methoxypropan-1-ol Chemical compound COCCCO JDFDHBSESGTDAL-UHFFFAOYSA-N 0.000 description 1
- VZKSLWJLGAGPIU-UHFFFAOYSA-N 3-morpholin-4-ylpropan-1-ol Chemical compound OCCCN1CCOCC1 VZKSLWJLGAGPIU-UHFFFAOYSA-N 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- NBTQOWCTNYQOAF-UHFFFAOYSA-N 4-(2-ethoxyethoxy)-3-fluorobenzaldehyde Chemical compound CCOCCOC1=CC=C(C=O)C=C1F NBTQOWCTNYQOAF-UHFFFAOYSA-N 0.000 description 1
- IQCSLVHAFGNDGO-UHFFFAOYSA-N 4-(2-methoxyethoxy)benzaldehyde Chemical compound COCCOC1=CC=C(C=O)C=C1 IQCSLVHAFGNDGO-UHFFFAOYSA-N 0.000 description 1
- YYCQRWDSMUIVEY-UHFFFAOYSA-N 4-(difluoromethoxy)-2-fluorobenzaldehyde Chemical compound FC(F)OC1=CC=C(C=O)C(F)=C1 YYCQRWDSMUIVEY-UHFFFAOYSA-N 0.000 description 1
- ZWCXOJYJJINQGU-UHFFFAOYSA-N 4-(difluoromethoxy)benzaldehyde Chemical compound FC(F)OC1=CC=C(C=O)C=C1 ZWCXOJYJJINQGU-UHFFFAOYSA-N 0.000 description 1
- UMZKSQJPDSRGJG-UHFFFAOYSA-N 4-(difluoromethyl)benzaldehyde Chemical compound FC(F)C1=CC=C(C=O)C=C1 UMZKSQJPDSRGJG-UHFFFAOYSA-N 0.000 description 1
- XQNVDQZWOBPLQZ-UHFFFAOYSA-N 4-(trifluoromethoxy)benzaldehyde Chemical compound FC(F)(F)OC1=CC=C(C=O)C=C1 XQNVDQZWOBPLQZ-UHFFFAOYSA-N 0.000 description 1
- BEOBZEOPTQQELP-UHFFFAOYSA-N 4-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)C=C1 BEOBZEOPTQQELP-UHFFFAOYSA-N 0.000 description 1
- VJPPLCNBDLZIFG-ZDUSSCGKSA-N 4-[(3S)-3-(but-2-ynoylamino)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide Chemical compound C(C#CC)(=O)N[C@@H]1CN(CCC1)C1=C2C(=C(NC2=C(C=C1F)C(=O)N)C)C VJPPLCNBDLZIFG-ZDUSSCGKSA-N 0.000 description 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
- XYWIPYBIIRTJMM-IBGZPJMESA-N 4-[[(2S)-2-[4-[5-chloro-2-[4-(trifluoromethyl)triazol-1-yl]phenyl]-5-methoxy-2-oxopyridin-1-yl]butanoyl]amino]-2-fluorobenzamide Chemical compound CC[C@H](N1C=C(OC)C(=CC1=O)C1=C(C=CC(Cl)=C1)N1C=C(N=N1)C(F)(F)F)C(=O)NC1=CC(F)=C(C=C1)C(N)=O XYWIPYBIIRTJMM-IBGZPJMESA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- AZMDWRPTDCIFRD-UHFFFAOYSA-N 4-chloro-3-fluorobenzaldehyde Chemical compound FC1=CC(C=O)=CC=C1Cl AZMDWRPTDCIFRD-UHFFFAOYSA-N 0.000 description 1
- AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- CZUQVKFJAJAHGK-UHFFFAOYSA-N 4-cyclopropylbenzaldehyde Chemical compound C1=CC(C=O)=CC=C1C1CC1 CZUQVKFJAJAHGK-UHFFFAOYSA-N 0.000 description 1
- BGMHQBQFJYJLBP-UHFFFAOYSA-N 4-ethynylbenzaldehyde Chemical compound O=CC1=CC=C(C#C)C=C1 BGMHQBQFJYJLBP-UHFFFAOYSA-N 0.000 description 1
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 1
- NYMCQLLAIMUVSY-UHFFFAOYSA-N 4-methyl-1,3-thiazole-2-carbaldehyde Chemical compound CC1=CSC(C=O)=N1 NYMCQLLAIMUVSY-UHFFFAOYSA-N 0.000 description 1
- OXRWICUICBZVAE-UHFFFAOYSA-N 4-methylpent-1-yne Chemical compound CC(C)CC#C OXRWICUICBZVAE-UHFFFAOYSA-N 0.000 description 1
- QRVYABWJVXXOTN-UHFFFAOYSA-N 4-methylsulfanylbenzaldehyde Chemical compound CSC1=CC=C(C=O)C=C1 QRVYABWJVXXOTN-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- AEFXCBJLKRIRTG-UHFFFAOYSA-N 5-(2-cyclopropylethynyl)pyrazine-2-carbaldehyde Chemical compound C1(CC1)C#CC=1N=CC(=NC=1)C=O AEFXCBJLKRIRTG-UHFFFAOYSA-N 0.000 description 1
- IKZNZDYEQMJZHC-UHFFFAOYSA-N 5-(2-ethoxyethoxy)pyridine-2-carbaldehyde Chemical compound CCOCCOC1=CC=C(C=O)N=C1 IKZNZDYEQMJZHC-UHFFFAOYSA-N 0.000 description 1
- MMGRWXWEDSZDOI-UHFFFAOYSA-N 5-(3,3-dimethylbut-1-ynyl)pyrazine-2-carbaldehyde Chemical compound CC(C#CC=1N=CC(=NC=1)C=O)(C)C MMGRWXWEDSZDOI-UHFFFAOYSA-N 0.000 description 1
- HZEBRJCMGYVXSW-UHFFFAOYSA-N 5-(aminomethyl)-2-(difluoromethyl)benzonitrile Chemical compound NCC=1C=CC(=C(C#N)C=1)C(F)F HZEBRJCMGYVXSW-UHFFFAOYSA-N 0.000 description 1
- PFYLZCGPJPRDNQ-UHFFFAOYSA-N 5-(cyclopropylmethoxy)pyrazine-2-carbaldehyde Chemical compound O=CC1=CN=C(OCC2CC2)C=N1 PFYLZCGPJPRDNQ-UHFFFAOYSA-N 0.000 description 1
- WFMJTFFIAWTSRQ-UHFFFAOYSA-N 5-(difluoromethyl)pyridine-2-carbaldehyde Chemical compound FC(F)C1=CC=C(C=O)N=C1 WFMJTFFIAWTSRQ-UHFFFAOYSA-N 0.000 description 1
- DIFPFGFTRSMNNU-UHFFFAOYSA-N 5-(trifluoromethyl)thiophene-2-carbaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)S1 DIFPFGFTRSMNNU-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- DYDCPFNVIPHVKC-UHFFFAOYSA-N 5-bromo-1,3-thiazole-2-carbaldehyde Chemical compound BrC1=CN=C(C=O)S1 DYDCPFNVIPHVKC-UHFFFAOYSA-N 0.000 description 1
- NRSLKAXETGPAST-UHFFFAOYSA-N 5-bromo-2-(difluoromethoxy)benzonitrile Chemical compound FC(F)OC1=CC=C(Br)C=C1C#N NRSLKAXETGPAST-UHFFFAOYSA-N 0.000 description 1
- WDTUCEMLUHTMCB-UHFFFAOYSA-N 5-chloro-2-fluorobenzaldehyde Chemical compound FC1=CC=C(Cl)C=C1C=O WDTUCEMLUHTMCB-UHFFFAOYSA-N 0.000 description 1
- IACCXWQKIQUVFQ-UHFFFAOYSA-N 5-fluoropyridine-2-carbaldehyde Chemical compound FC1=CC=C(C=O)N=C1 IACCXWQKIQUVFQ-UHFFFAOYSA-N 0.000 description 1
- CTYUCLSCBVSTAA-UHFFFAOYSA-N 5-methoxypyridine-2-carbaldehyde Chemical compound COC1=CC=C(C=O)N=C1 CTYUCLSCBVSTAA-UHFFFAOYSA-N 0.000 description 1
- SARODJOLCPBJHK-UHFFFAOYSA-N 5-methylpyridine-2-carbaldehyde Chemical compound CC1=CC=C(C=O)N=C1 SARODJOLCPBJHK-UHFFFAOYSA-N 0.000 description 1
- JREMGXPAQPMEHI-UHFFFAOYSA-N 6-(2-methoxyethoxy)pyridine-3-carbaldehyde Chemical compound COCCOC1=CC=C(C=O)C=N1 JREMGXPAQPMEHI-UHFFFAOYSA-N 0.000 description 1
- FJXDVOAWWUURQN-UHFFFAOYSA-N 6-(3-morpholin-4-ylpropoxy)pyridine-3-carbaldehyde Chemical compound N1(CCOCC1)CCCOC1=CC=C(C=N1)C=O FJXDVOAWWUURQN-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- RHGWAWXNIVADMP-UHFFFAOYSA-N 6-(cyclopropylmethoxy)pyridazine-3-carbaldehyde Chemical compound O=CC1=NN=C(OCC2CC2)C=C1 RHGWAWXNIVADMP-UHFFFAOYSA-N 0.000 description 1
- UBMKXPLMFMGIMS-UHFFFAOYSA-N 6-(difluoromethyl)pyridine-3-carbaldehyde Chemical compound FC(F)C1=CC=C(C=O)C=N1 UBMKXPLMFMGIMS-UHFFFAOYSA-N 0.000 description 1
- DQKQAJDTTUGPQJ-UHFFFAOYSA-N 6-[2-(1-hydroxycyclohexyl)ethynyl]pyridine-3-carbaldehyde Chemical compound OC1(CCCCC1)C#CC1=CC=C(C=N1)C=O DQKQAJDTTUGPQJ-UHFFFAOYSA-N 0.000 description 1
- TYBPOSCCETYVBG-UHFFFAOYSA-N 6-[2-(2-methoxyethoxy)ethoxy]pyridine-3-carbaldehyde Chemical compound COCCOCCOC1=CC=C(C=N1)C=O TYBPOSCCETYVBG-UHFFFAOYSA-N 0.000 description 1
- QWFHFNGMCPMOCD-UHFFFAOYSA-N 6-bromopyridine-2-carbaldehyde Chemical compound BrC1=CC=CC(C=O)=N1 QWFHFNGMCPMOCD-UHFFFAOYSA-N 0.000 description 1
- CLQHTUGAHJVCGP-UHFFFAOYSA-N 6-butoxypyridazine-3-carbaldehyde Chemical compound C(CCC)OC1=CC=C(N=N1)C=O CLQHTUGAHJVCGP-UHFFFAOYSA-N 0.000 description 1
- ZZIYYBYHLBGXCD-UHFFFAOYSA-N 6-chloro-2-fluoro-3-methylbenzonitrile Chemical compound CC1=CC=C(Cl)C(C#N)=C1F ZZIYYBYHLBGXCD-UHFFFAOYSA-N 0.000 description 1
- JLVBSBMJQUMAMW-UHFFFAOYSA-N 6-methyl-2-pyridinemethanol Chemical compound CC1=CC=CC(CO)=N1 JLVBSBMJQUMAMW-UHFFFAOYSA-N 0.000 description 1
- HWDMDOSKSDLXEH-UHFFFAOYSA-N 6-phenylpyridine-3-carbaldehyde Chemical compound N1=CC(C=O)=CC=C1C1=CC=CC=C1 HWDMDOSKSDLXEH-UHFFFAOYSA-N 0.000 description 1
- BNNHZEKFKMAUEZ-UHFFFAOYSA-N 6-propan-2-yloxypyridine-3-carbaldehyde Chemical compound CC(C)OC1=CC=C(C=O)C=N1 BNNHZEKFKMAUEZ-UHFFFAOYSA-N 0.000 description 1
- MFIYHHBEGFWQNX-UHFFFAOYSA-N 6-propoxypyridine-3-carbaldehyde Chemical compound CCCOC1=CC=C(C=O)C=N1 MFIYHHBEGFWQNX-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- ZRPZPNYZFSJUPA-UHFFFAOYSA-N ARS-1620 Chemical compound Oc1cccc(F)c1-c1c(Cl)cc2c(ncnc2c1F)N1CCN(CC1)C(=O)C=C ZRPZPNYZFSJUPA-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- VZJCQVLBIGWUBH-UHFFFAOYSA-N C(#C)C=1C=C(C=NC=1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F Chemical compound C(#C)C=1C=C(C=NC=1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F VZJCQVLBIGWUBH-UHFFFAOYSA-N 0.000 description 1
- BAHPGXIAXMHIKH-UHFFFAOYSA-N C(C)(C)(C)N1N=CC(=C1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1Cl Chemical compound C(C)(C)(C)N1N=CC(=C1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1Cl BAHPGXIAXMHIKH-UHFFFAOYSA-N 0.000 description 1
- SFILKTFDOMKELS-UHFFFAOYSA-N C(C)(C)OCCOC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F Chemical compound C(C)(C)OCCOC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F SFILKTFDOMKELS-UHFFFAOYSA-N 0.000 description 1
- NQAHYLIDYWOLPR-UHFFFAOYSA-N C(C)(C)OCCOC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(CCC)=O)C=CC=1C(F)(F)F Chemical compound C(C)(C)OCCOC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(CCC)=O)C=CC=1C(F)(F)F NQAHYLIDYWOLPR-UHFFFAOYSA-N 0.000 description 1
- YLNKFRASAGOFHQ-UHFFFAOYSA-N C(C)OC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1F Chemical compound C(C)OC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1F YLNKFRASAGOFHQ-UHFFFAOYSA-N 0.000 description 1
- SHOLDVOWLAWAKF-UHFFFAOYSA-N C(C)OCCOC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(CCC)=O)C=CC=1C(F)(F)F Chemical compound C(C)OCCOC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(CCC)=O)C=CC=1C(F)(F)F SHOLDVOWLAWAKF-UHFFFAOYSA-N 0.000 description 1
- YVYUWYSDMOQGSJ-UHFFFAOYSA-N C(CC)OCCOC=1C=CC(=NC=1)C=O Chemical compound C(CC)OCCOC=1C=CC(=NC=1)C=O YVYUWYSDMOQGSJ-UHFFFAOYSA-N 0.000 description 1
- JMNNHMQPMFPECA-UHFFFAOYSA-N C(CCC)C1=NC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F Chemical compound C(CCC)C1=NC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F JMNNHMQPMFPECA-UHFFFAOYSA-N 0.000 description 1
- JHZGNHQTPIFMFQ-UHFFFAOYSA-N C(CCC)N1C(C=C(C=C1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1Cl)=O Chemical compound C(CCC)N1C(C=C(C=C1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1Cl)=O JHZGNHQTPIFMFQ-UHFFFAOYSA-N 0.000 description 1
- ONECZQAJOIPBIH-UHFFFAOYSA-N C(CCC)OCCOC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F Chemical compound C(CCC)OCCOC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F ONECZQAJOIPBIH-UHFFFAOYSA-N 0.000 description 1
- GIOBHSZEZSBWGX-UHFFFAOYSA-N C(CCC)OCCOC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1Cl Chemical compound C(CCC)OCCOC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1Cl GIOBHSZEZSBWGX-UHFFFAOYSA-N 0.000 description 1
- BLIPZZSBOBRRHN-UHFFFAOYSA-N C1(CC1)C#CC=1C=CC(=NC=1)C=1N=C(NC(C=1)=O)C=1C(=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)F Chemical compound C1(CC1)C#CC=1C=CC(=NC=1)C=1N=C(NC(C=1)=O)C=1C(=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)F BLIPZZSBOBRRHN-UHFFFAOYSA-N 0.000 description 1
- LDBWGHXYNVQSTM-UHFFFAOYSA-N C1(CC1)C#CC=1N=CC(=NC=1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F Chemical compound C1(CC1)C#CC=1N=CC(=NC=1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F LDBWGHXYNVQSTM-UHFFFAOYSA-N 0.000 description 1
- HQCIWQNGEKQSHU-UHFFFAOYSA-N C1(CC1)C#CC=1SC(=CN=1)C=1N=C(NC(C=1)=O)C=1C(=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)F Chemical compound C1(CC1)C#CC=1SC(=CN=1)C=1N=C(NC(C=1)=O)C=1C(=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)F HQCIWQNGEKQSHU-UHFFFAOYSA-N 0.000 description 1
- OAHNHDPCXVWVOF-UHFFFAOYSA-N C1(CC1)C1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F Chemical compound C1(CC1)C1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F OAHNHDPCXVWVOF-UHFFFAOYSA-N 0.000 description 1
- AOPXELZKCRVVGM-UHFFFAOYSA-N CC(C#CC1=NC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)(C)C Chemical compound CC(C#CC1=NC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)(C)C AOPXELZKCRVVGM-UHFFFAOYSA-N 0.000 description 1
- ZLGXYDFDXHDUNN-UHFFFAOYSA-N CC(C#CC=1N=CC(=NC=1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)(C)C Chemical compound CC(C#CC=1N=CC(=NC=1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)(C)C ZLGXYDFDXHDUNN-UHFFFAOYSA-N 0.000 description 1
- DXZJVHANIRFZRQ-UHFFFAOYSA-N CC(C)CNCC1=CC(=C(C=C1)C(F)(F)F)C2=NC(=CC(=O)N2)C3=CN=C(C=C3)C4CC4 Chemical compound CC(C)CNCC1=CC(=C(C=C1)C(F)(F)F)C2=NC(=CC(=O)N2)C3=CN=C(C=C3)C4CC4 DXZJVHANIRFZRQ-UHFFFAOYSA-N 0.000 description 1
- ZAUCYUHJOUJRDQ-UHFFFAOYSA-N CC(C)CNCC1=CC(=C(C=C1)Cl)C2=NC(=CC(=O)N2)C3=CN(N=C3)C(C)(C)C Chemical compound CC(C)CNCC1=CC(=C(C=C1)Cl)C2=NC(=CC(=O)N2)C3=CN(N=C3)C(C)(C)C ZAUCYUHJOUJRDQ-UHFFFAOYSA-N 0.000 description 1
- YTDWZSMRAJMBAX-UHFFFAOYSA-N CC(C)CNCC1=CC(=C(C=C1)Cl)C2=NC(=CC(=O)N2)C3=CN=C(C=C3)OCCCOC Chemical compound CC(C)CNCC1=CC(=C(C=C1)Cl)C2=NC(=CC(=O)N2)C3=CN=C(C=C3)OCCCOC YTDWZSMRAJMBAX-UHFFFAOYSA-N 0.000 description 1
- RESDSHOTROQXDH-UHFFFAOYSA-N CC(C)CNCC1=CC(=C(C=C1)Cl)C2=NC(=CC(=O)N2)C3=CN=C(C=C3)OCCOC Chemical compound CC(C)CNCC1=CC(=C(C=C1)Cl)C2=NC(=CC(=O)N2)C3=CN=C(C=C3)OCCOC RESDSHOTROQXDH-UHFFFAOYSA-N 0.000 description 1
- OARLEKNMVKPODY-UHFFFAOYSA-N CC(C)CNCC1=CC(=C(C=C1)OC(F)F)C2=NC(=CC(=O)N2)C3=CN=C(C=C3)C(F)(F)F Chemical compound CC(C)CNCC1=CC(=C(C=C1)OC(F)F)C2=NC(=CC(=O)N2)C3=CN=C(C=C3)C(F)(F)F OARLEKNMVKPODY-UHFFFAOYSA-N 0.000 description 1
- RWIKDUABGCNMND-UHFFFAOYSA-N CCCCCN1C=CC(=CC1=O)C2=CC(=O)NC(=N2)C3=C(C=CC(=C3)CNCC(C)C)Cl Chemical compound CCCCCN1C=CC(=CC1=O)C2=CC(=O)NC(=N2)C3=C(C=CC(=C3)CNCC(C)C)Cl RWIKDUABGCNMND-UHFFFAOYSA-N 0.000 description 1
- IDLLQUYQTWPQIK-UHFFFAOYSA-N CCCCOCCOC1=NC=C(C=C1)C2=CC(=O)NC(=N2)C3=C(C=CC(=C3)CNCC(C)C)Cl Chemical compound CCCCOCCOC1=NC=C(C=C1)C2=CC(=O)NC(=N2)C3=C(C=CC(=C3)CNCC(C)C)Cl IDLLQUYQTWPQIK-UHFFFAOYSA-N 0.000 description 1
- AQKIILQQBXSIIN-UHFFFAOYSA-N CCCOCCOC1=NC=C(C=C1)C2=CC(=O)NC(=N2)C3=C(C=CC(=C3)CNCC(C)C)Cl Chemical compound CCCOCCOC1=NC=C(C=C1)C2=CC(=O)NC(=N2)C3=C(C=CC(=C3)CNCC(C)C)Cl AQKIILQQBXSIIN-UHFFFAOYSA-N 0.000 description 1
- KPKGFCWUJZBJKN-UHFFFAOYSA-N CCOCCCOC1=NC=C(C=C1)C2=CC(=O)NC(=N2)C3=C(C=CC(=C3)CNCC(C)C)Cl Chemical compound CCOCCCOC1=NC=C(C=C1)C2=CC(=O)NC(=N2)C3=C(C=CC(=C3)CNCC(C)C)Cl KPKGFCWUJZBJKN-UHFFFAOYSA-N 0.000 description 1
- IKTVAVVPCSMFJC-UHFFFAOYSA-N CCOCCOC1=NC=C(C=C1)C2=CC(=O)NC(=N2)C3=C(C=CC(=C3)CNCC(C)C)Cl Chemical compound CCOCCOC1=NC=C(C=C1)C2=CC(=O)NC(=N2)C3=C(C=CC(=C3)CNCC(C)C)Cl IKTVAVVPCSMFJC-UHFFFAOYSA-N 0.000 description 1
- XLPFIVVDDUAXKZ-UHFFFAOYSA-N COC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C Chemical compound COC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C XLPFIVVDDUAXKZ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- XXCCEJYPCNTRQK-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)C#CC1(CCCCC1)O)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)C#CC1(CCCCC1)O)=O XXCCEJYPCNTRQK-UHFFFAOYSA-N 0.000 description 1
- MLEASCXQVPINNF-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)C1CC1)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)C1CC1)=O MLEASCXQVPINNF-UHFFFAOYSA-N 0.000 description 1
- MVSGRVFCODFUHY-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)CCC)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)CCC)=O MVSGRVFCODFUHY-UHFFFAOYSA-N 0.000 description 1
- IIDYGPAQHWWNFL-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC(F)(F)F)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC(F)(F)F)=O IIDYGPAQHWWNFL-UHFFFAOYSA-N 0.000 description 1
- GWAHNXBITBDEFS-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC(F)F)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC(F)F)=O GWAHNXBITBDEFS-UHFFFAOYSA-N 0.000 description 1
- CBDPUCIVLRSFME-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCC(F)(F)F)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCC(F)(F)F)=O CBDPUCIVLRSFME-UHFFFAOYSA-N 0.000 description 1
- BBYLKJUAIYKEOW-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOC(C)C)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOC(C)C)=O BBYLKJUAIYKEOW-UHFFFAOYSA-N 0.000 description 1
- VRAFGWFKOCVUCP-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=NC=1)C#CC(C)(C)C)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC(=NC=1)C#CC(C)(C)C)=O VRAFGWFKOCVUCP-UHFFFAOYSA-N 0.000 description 1
- LYACGJQXNHEPTP-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC=C(C=1)C(F)(F)F)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC=C(C=1)C(F)(F)F)=O LYACGJQXNHEPTP-UHFFFAOYSA-N 0.000 description 1
- JNCHXQZNPQODFO-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC=C(C=1)Cl)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1C=NC=C(C=1)Cl)=O JNCHXQZNPQODFO-UHFFFAOYSA-N 0.000 description 1
- ASOZVJVQOJSIJE-UHFFFAOYSA-N ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1SC=C(N=1)C)=O Chemical compound ClC1=C(C(=C(CNC(C(C)C)=O)C=C1)F)C=1NC(C=C(N=1)C=1SC=C(N=1)C)=O ASOZVJVQOJSIJE-UHFFFAOYSA-N 0.000 description 1
- KCUFXZHTLXQPID-UHFFFAOYSA-N ClC1=C(C(=C(CNC(CCC)=O)C=C1)F)C=1NC(C=C(N=1)C1=NC=C(C=C1)C(F)(F)F)=O Chemical compound ClC1=C(C(=C(CNC(CCC)=O)C=C1)F)C=1NC(C=C(N=1)C1=NC=C(C=C1)C(F)(F)F)=O KCUFXZHTLXQPID-UHFFFAOYSA-N 0.000 description 1
- OXDRVHXYFMIULJ-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C(F)(F)F)(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OC)=O Chemical compound ClC1=C(C=C(CNC(C(C(F)(F)F)(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OC)=O OXDRVHXYFMIULJ-UHFFFAOYSA-N 0.000 description 1
- XRGIQLZFKYSBCG-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)(C)C)=O)C=C1)C=1NC(C(=C(N=1)C1=C(C=C(C=C1)Cl)F)C#N)=O Chemical compound ClC1=C(C=C(CNC(C(C)(C)C)=O)C=C1)C=1NC(C(=C(N=1)C1=C(C=C(C=C1)Cl)F)C#N)=O XRGIQLZFKYSBCG-UHFFFAOYSA-N 0.000 description 1
- XPFDGILYQWIGMR-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)(C)C)=O)C=C1)C=1NC(C(=C(N=1)C1=CSC=C1)C#N)=O Chemical compound ClC1=C(C=C(CNC(C(C)(C)C)=O)C=C1)C=1NC(C(=C(N=1)C1=CSC=C1)C#N)=O XPFDGILYQWIGMR-UHFFFAOYSA-N 0.000 description 1
- BUKRPBCPCLOXCY-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)(C)OC)=O)C=C1)C=1NC(C=C(N=1)C1=CSC=C1)=O Chemical compound ClC1=C(C=C(CNC(C(C)(C)OC)=O)C=C1)C=1NC(C=C(N=1)C1=CSC=C1)=O BUKRPBCPCLOXCY-UHFFFAOYSA-N 0.000 description 1
- LDEHQEZAFLQZOD-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C(=C(N=1)C1=CC=C(C=C1)OC)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C(=C(N=1)C1=CC=C(C=C1)OC)F)=O LDEHQEZAFLQZOD-UHFFFAOYSA-N 0.000 description 1
- QBWGVCMBDXMKQU-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C(=C(N=1)C1=CC=CC=C1)C)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C(=C(N=1)C1=CC=CC=C1)C)=O QBWGVCMBDXMKQU-UHFFFAOYSA-N 0.000 description 1
- NHYVBDVJJNQIQR-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C(=C(N=1)C1=CC=CC=C1)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C(=C(N=1)C1=CC=CC=C1)F)=O NHYVBDVJJNQIQR-UHFFFAOYSA-N 0.000 description 1
- TWJXPRYDHCMMIR-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=C(C=C(C=C1)OCCOCC)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=C(C=C(C=C1)OCCOCC)F)=O TWJXPRYDHCMMIR-UHFFFAOYSA-N 0.000 description 1
- SNXHGIVSSXOHOU-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC(=C(C=C1)OCCOCC)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC(=C(C=C1)OCCOCC)F)=O SNXHGIVSSXOHOU-UHFFFAOYSA-N 0.000 description 1
- LFFBKWQSWFNBGM-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC=C(C=C1)C#N)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC=C(C=C1)C#N)=O LFFBKWQSWFNBGM-UHFFFAOYSA-N 0.000 description 1
- BHVGCBQMOIWZRM-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC=C(C=C1)C)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC=C(C=C1)C)=O BHVGCBQMOIWZRM-UHFFFAOYSA-N 0.000 description 1
- ZMSDXAFSCRCDED-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC=C(C=C1)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC=C(C=C1)F)=O ZMSDXAFSCRCDED-UHFFFAOYSA-N 0.000 description 1
- UEDVSZRLLNIPQX-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC=C(C=C1)SC)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC=C(C=C1)SC)=O UEDVSZRLLNIPQX-UHFFFAOYSA-N 0.000 description 1
- WCGZCKQYNRIGPK-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC=CC=C1)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=CC=CC=C1)=O WCGZCKQYNRIGPK-UHFFFAOYSA-N 0.000 description 1
- BNPFEGQWOSQNJN-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=NC(=CC=C1)OC)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C1=NC(=CC=C1)OC)=O BNPFEGQWOSQNJN-UHFFFAOYSA-N 0.000 description 1
- HJBRASRKBVXMDK-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OC)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OC)=O HJBRASRKBVXMDK-UHFFFAOYSA-N 0.000 description 1
- SBDPXERVQVZYPJ-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC(F)(F)F)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC(F)(F)F)=O SBDPXERVQVZYPJ-UHFFFAOYSA-N 0.000 description 1
- KTGQUSOLUCYJEO-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC1(COC1)CC)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC1(COC1)CC)=O KTGQUSOLUCYJEO-UHFFFAOYSA-N 0.000 description 1
- GPRFSWVIYDRYQY-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC=1C=NC(=CC=1)C)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC=1C=NC(=CC=1)C)=O GPRFSWVIYDRYQY-UHFFFAOYSA-N 0.000 description 1
- FZBVREBBHQXMAL-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCCOC)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCCOC)=O FZBVREBBHQXMAL-UHFFFAOYSA-N 0.000 description 1
- ZVNIVNQBBKEKHR-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCCOCC)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCCOCC)=O ZVNIVNQBBKEKHR-UHFFFAOYSA-N 0.000 description 1
- NDPVNVNIJOTVTA-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOC)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOC)=O NDPVNVNIJOTVTA-UHFFFAOYSA-N 0.000 description 1
- NQQUAYPQXZGMHX-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOCC)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOCC)=O NQQUAYPQXZGMHX-UHFFFAOYSA-N 0.000 description 1
- BZVCKFGZDBPPSJ-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOCCC)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOCCC)=O BZVCKFGZDBPPSJ-UHFFFAOYSA-N 0.000 description 1
- CCPYXURFWNNCJT-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOCCOC)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOCCOC)=O CCPYXURFWNNCJT-UHFFFAOYSA-N 0.000 description 1
- JMJBTIZNQZCQOB-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOCCOCCOCC)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOCCOCCOCC)=O JMJBTIZNQZCQOB-UHFFFAOYSA-N 0.000 description 1
- NQIOBXSFUGAJME-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=NC=1)OC)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=NC=1)OC)=O NQIOBXSFUGAJME-UHFFFAOYSA-N 0.000 description 1
- GVBDBTRDKYCGTG-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC=C(C=1)C#C)=O Chemical compound ClC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC=C(C=1)C#C)=O GVBDBTRDKYCGTG-UHFFFAOYSA-N 0.000 description 1
- YCNQEDKDOQBLEY-UHFFFAOYSA-N ClC1=C(C=C(CNC(CC)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC(F)(F)F)=O Chemical compound ClC1=C(C=C(CNC(CC)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC(F)(F)F)=O YCNQEDKDOQBLEY-UHFFFAOYSA-N 0.000 description 1
- KHQMOMXAMIYNLW-UHFFFAOYSA-N ClC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC(F)(F)F)=O)F Chemical compound ClC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCC(F)(F)F)=O)F KHQMOMXAMIYNLW-UHFFFAOYSA-N 0.000 description 1
- SPPONKAEFAUCDR-UHFFFAOYSA-N ClC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCC(F)(F)F)=O)F Chemical compound ClC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCC(F)(F)F)=O)F SPPONKAEFAUCDR-UHFFFAOYSA-N 0.000 description 1
- VAIVZPLDMSZPAB-UHFFFAOYSA-N ClC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOC(C)C)=O)F Chemical compound ClC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOC(C)C)=O)F VAIVZPLDMSZPAB-UHFFFAOYSA-N 0.000 description 1
- ZXMWDPUUYWCASI-UHFFFAOYSA-N ClC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOCC)=O)F Chemical compound ClC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOCC)=O)F ZXMWDPUUYWCASI-UHFFFAOYSA-N 0.000 description 1
- 101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- GKKZMYDNDDMXSE-UHFFFAOYSA-N Ethyl 3-oxo-3-phenylpropanoate Chemical compound CCOC(=O)CC(=O)C1=CC=CC=C1 GKKZMYDNDDMXSE-UHFFFAOYSA-N 0.000 description 1
- ZXYWBZZQLVVYPV-UHFFFAOYSA-N FC(COC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)F Chemical compound FC(COC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)F ZXYWBZZQLVVYPV-UHFFFAOYSA-N 0.000 description 1
- RQIVHKFHLQNROQ-UHFFFAOYSA-N FC(OC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)C(F)(F)F)=O)F Chemical compound FC(OC1=C(C=C(CNC(C(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)C(F)(F)F)=O)F RQIVHKFHLQNROQ-UHFFFAOYSA-N 0.000 description 1
- NFHIBJNQNMHDJD-UHFFFAOYSA-N FC(OC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C(=C(CNC(C(C)C)=O)C=CC=1F)F)F Chemical compound FC(OC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C(=C(CNC(C(C)C)=O)C=CC=1F)F)F NFHIBJNQNMHDJD-UHFFFAOYSA-N 0.000 description 1
- ADTVBBVXUVQMPK-UHFFFAOYSA-N FC(OC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)(C)C)=O)C=CC=1F)F Chemical compound FC(OC1=CC=C(C=N1)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)(C)C)=O)C=CC=1F)F ADTVBBVXUVQMPK-UHFFFAOYSA-N 0.000 description 1
- WTXZANHXHBZCJJ-UHFFFAOYSA-N FC1=C(C=C(CNC(C(C)(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)C(F)(F)F)=O Chemical compound FC1=C(C=C(CNC(C(C)(C)C)=O)C=C1)C=1NC(C=C(N=1)C=1C=NC(=CC=1)C(F)(F)F)=O WTXZANHXHBZCJJ-UHFFFAOYSA-N 0.000 description 1
- CTYVOUVULNIMEM-UHFFFAOYSA-N FC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C1=NC=C(C=C1)C#CC)=O)C(F)(F)F Chemical compound FC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C1=NC=C(C=C1)C#CC)=O)C(F)(F)F CTYVOUVULNIMEM-UHFFFAOYSA-N 0.000 description 1
- ZUZPJBLUNQVZMO-UHFFFAOYSA-N FC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C1=NC=C(C=C1)CNC(C(C)C)=O)=O)C(F)(F)F Chemical compound FC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C1=NC=C(C=C1)CNC(C(C)C)=O)=O)C(F)(F)F ZUZPJBLUNQVZMO-UHFFFAOYSA-N 0.000 description 1
- XNOBUUNHVRORJH-UHFFFAOYSA-N FC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)C(F)(F)F)=O)F Chemical compound FC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)C(F)(F)F)=O)F XNOBUUNHVRORJH-UHFFFAOYSA-N 0.000 description 1
- SGHUMSCZRQYBEY-UHFFFAOYSA-N FC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOC(C)C)=O)C(F)(F)F Chemical compound FC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOC(C)C)=O)C(F)(F)F SGHUMSCZRQYBEY-UHFFFAOYSA-N 0.000 description 1
- VDWFOLIBPCVNRV-UHFFFAOYSA-N FC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOCC(F)(F)F)=O)C(F)(F)F Chemical compound FC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOCC(F)(F)F)=O)C(F)(F)F VDWFOLIBPCVNRV-UHFFFAOYSA-N 0.000 description 1
- DNZKTYOOSUMITG-UHFFFAOYSA-N FC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOCCC)=O)C(F)(F)F Chemical compound FC1=C(CNC(C(C)C)=O)C=CC(=C1C=1NC(C=C(N=1)C=1C=NC(=CC=1)OCCOCCC)=O)C(F)(F)F DNZKTYOOSUMITG-UHFFFAOYSA-N 0.000 description 1
- GISRWBROCYNDME-PELMWDNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-PELMWDNLSA-N 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 101001135391 Homo sapiens Prostaglandin E synthase Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- FEYNFHSRETUBEM-UHFFFAOYSA-N N-[3-(1,1-difluoroethyl)phenyl]-1-(4-methoxyphenyl)-3-methyl-5-oxo-4H-pyrazole-4-carboxamide Chemical compound COc1ccc(cc1)N1N=C(C)C(C(=O)Nc2cccc(c2)C(C)(F)F)C1=O FEYNFHSRETUBEM-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- XWYVOJUMEJMBAU-UHFFFAOYSA-N O=C1C=C(N=C(N1)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)C1=NC=C(C=C1)CCC Chemical compound O=C1C=C(N=C(N1)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)C1=NC=C(C=C1)CCC XWYVOJUMEJMBAU-UHFFFAOYSA-N 0.000 description 1
- COOROCIOWCAVAF-UHFFFAOYSA-N O=C1C=C(N=C(N1)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)C=1C=NC(=CC=1)CCC Chemical compound O=C1C=C(N=C(N1)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)C=1C=NC(=CC=1)CCC COOROCIOWCAVAF-UHFFFAOYSA-N 0.000 description 1
- BSKIVHQJYAFQAM-UHFFFAOYSA-N O=C1C=C(N=C(N1)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)C=1C=NC(=CC=1)OCC1=NC=CC=C1 Chemical compound O=C1C=C(N=C(N1)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)C=1C=NC(=CC=1)OCC1=NC=CC=C1 BSKIVHQJYAFQAM-UHFFFAOYSA-N 0.000 description 1
- MZGAQOGJFZYNGM-UHFFFAOYSA-N O=C1C=C(N=C(N1)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)C=1C=NC(=CC=1)OCCC(F)(F)F Chemical compound O=C1C=C(N=C(N1)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)C=1C=NC(=CC=1)OCCC(F)(F)F MZGAQOGJFZYNGM-UHFFFAOYSA-N 0.000 description 1
- MLHJKECQXQQLRM-UHFFFAOYSA-N O=C1C=C(N=C(N1)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)C=1C=NC(=CC=1)OCCOCC(F)(F)F Chemical compound O=C1C=C(N=C(N1)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)C=1C=NC(=CC=1)OCCOCC(F)(F)F MLHJKECQXQQLRM-UHFFFAOYSA-N 0.000 description 1
- VGMHRYUMDAQXGY-UHFFFAOYSA-N O=C1C=C(N=C(N1)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)C=1C=NC=C(C=1)C(F)(F)F Chemical compound O=C1C=C(N=C(N1)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F)C=1C=NC=C(C=1)C(F)(F)F VGMHRYUMDAQXGY-UHFFFAOYSA-N 0.000 description 1
- OZIBQZRDPLITPE-UHFFFAOYSA-N O=C1C=C(N=C(N1)C=1C=C(CNC(CCC)=O)C=CC=1C(F)(F)F)C1=NC=C(C=C1)C(F)(F)F Chemical compound O=C1C=C(N=C(N1)C=1C=C(CNC(CCC)=O)C=CC=1C(F)(F)F)C1=NC=C(C=C1)C(F)(F)F OZIBQZRDPLITPE-UHFFFAOYSA-N 0.000 description 1
- MMVLWGVHHMKNJX-UHFFFAOYSA-N O=C1C=C(N=C(N1)C=1C=C(CNC(CCC)=O)C=CC=1C(F)(F)F)C=1C=NC(=CC=1)OCC1CCOCC1 Chemical compound O=C1C=C(N=C(N1)C=1C=C(CNC(CCC)=O)C=CC=1C(F)(F)F)C=1C=NC(=CC=1)OCC1CCOCC1 MMVLWGVHHMKNJX-UHFFFAOYSA-N 0.000 description 1
- PGLJKESBXLPCJP-UHFFFAOYSA-N O=C1C=C(N=C(N1)C=1C=C(CNC(CCC)=O)C=CC=1C(F)(F)F)C=1C=NC(=CC=1)OCCOCCC Chemical compound O=C1C=C(N=C(N1)C=1C=C(CNC(CCC)=O)C=CC=1C(F)(F)F)C=1C=NC(=CC=1)OCCOCCC PGLJKESBXLPCJP-UHFFFAOYSA-N 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 229910002666 PdCl2 Inorganic materials 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 102000008866 Prostaglandin E receptors Human genes 0.000 description 1
- 108010088540 Prostaglandin E receptors Proteins 0.000 description 1
- 102000004226 Prostaglandin-E Synthases Human genes 0.000 description 1
- 108090000748 Prostaglandin-E Synthases Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- DILIRNRNZGJFJT-UHFFFAOYSA-N S1C(=NC2=C1C=CC=C2)C=1N=C(NC(C=1)=O)C=1C(=C(CNC(C(C)C)=O)C=CC=1Cl)F Chemical compound S1C(=NC2=C1C=CC=C2)C=1N=C(NC(C=1)=O)C=1C(=C(CNC(C(C)C)=O)C=CC=1Cl)F DILIRNRNZGJFJT-UHFFFAOYSA-N 0.000 description 1
- IJTMFDLFLLCMJG-UHFFFAOYSA-N S1C(=NC2=C1C=CC=C2)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F Chemical compound S1C(=NC2=C1C=CC=C2)C=1N=C(NC(C=1)=O)C=1C=C(CNC(C(C)C)=O)C=CC=1C(F)(F)F IJTMFDLFLLCMJG-UHFFFAOYSA-N 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000004760 Tenosynovitis Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- PHTKKLUKRXYIRA-UHFFFAOYSA-N [5-(2-cyclopropylethynyl)pyrazin-2-yl]methanol Chemical compound C1(CC1)C#CC=1N=CC(=NC=1)CO PHTKKLUKRXYIRA-UHFFFAOYSA-N 0.000 description 1
- QYMGFTBROPDHFR-UHFFFAOYSA-N [5-(3,3-dimethylbut-1-ynyl)pyrazin-2-yl]methanol Chemical compound CC(C#CC=1N=CC(=NC=1)CO)(C)C QYMGFTBROPDHFR-UHFFFAOYSA-N 0.000 description 1
- DBGUUPDUZXSAJF-UHFFFAOYSA-N [Cu+].[I+] Chemical compound [Cu+].[I+] DBGUUPDUZXSAJF-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000005035 acylthio group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229910000318 alkali metal phosphate Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000002521 alkyl halide group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 125000000707 boryl group Chemical group B* 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- DGLFSNZWRYADFC-UHFFFAOYSA-N chembl2334586 Chemical compound C1CCC2=CN=C(N)N=C2C2=C1NC1=CC=C(C#CC(C)(O)C)C=C12 DGLFSNZWRYADFC-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- SFJMFSWCBVEHBA-UHFFFAOYSA-M copper(i)-thiophene-2-carboxylate Chemical compound [Cu+].[O-]C(=O)C1=CC=CS1 SFJMFSWCBVEHBA-UHFFFAOYSA-M 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 125000001651 cyanato group Chemical group [*]OC#N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- KFGVRWGDTLZAAO-UHFFFAOYSA-N cyclopenta-1,3-diene dicyclohexyl(cyclopenta-1,3-dien-1-yl)phosphane iron(2+) Chemical compound [Fe++].c1cc[cH-]c1.C1CCC(CC1)P(C1CCCCC1)c1ccc[cH-]1 KFGVRWGDTLZAAO-UHFFFAOYSA-N 0.000 description 1
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
- AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 description 1
- GUDMZGLFZNLYEY-UHFFFAOYSA-N cyclopropylmethanol Chemical compound OCC1CC1 GUDMZGLFZNLYEY-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 201000009274 endometriosis of uterus Diseases 0.000 description 1
- 230000001856 erectile effect Effects 0.000 description 1
- NJBWORPRIRNTLH-UHFFFAOYSA-N ethyl 2-(benzenesulfonyl)acetate Chemical compound CCOC(=O)CS(=O)(=O)C1=CC=CC=C1 NJBWORPRIRNTLH-UHFFFAOYSA-N 0.000 description 1
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 1
- RAWGHPXIJSCHFZ-UHFFFAOYSA-N ethyl 2-methyl-3-oxo-3-phenylpropanoate Chemical compound CCOC(=O)C(C)C(=O)C1=CC=CC=C1 RAWGHPXIJSCHFZ-UHFFFAOYSA-N 0.000 description 1
- ASYASKBLHYSMEG-UHFFFAOYSA-N ethyl 3-cyclohexyl-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)C1CCCCC1 ASYASKBLHYSMEG-UHFFFAOYSA-N 0.000 description 1
- MUDKQMLLCRJCEY-UHFFFAOYSA-N ethyl 3-cyclopentyl-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)C1CCCC1 MUDKQMLLCRJCEY-UHFFFAOYSA-N 0.000 description 1
- VKSDKUXHVLZDHO-UHFFFAOYSA-N ethyl 3-oxo-3-thiophen-2-ylpropanoate Chemical compound CCOC(=O)CC(=O)C1=CC=CS1 VKSDKUXHVLZDHO-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- MHYCRLGKOZWVEF-UHFFFAOYSA-N ethyl acetate;hydrate Chemical compound O.CCOC(C)=O MHYCRLGKOZWVEF-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- CNUDBTRUORMMPA-UHFFFAOYSA-N formylthiophene Chemical compound O=CC1=CC=CS1 CNUDBTRUORMMPA-UHFFFAOYSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 102000047789 human PTGES Human genes 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- 125000005638 hydrazono group Chemical group 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001261 isocyanato group Chemical group *N=C=O 0.000 description 1
- 125000002462 isocyano group Chemical group *[N+]#[C-] 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001810 isothiocyanato group Chemical group *N=C=S 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- FEIOASZZURHTHB-UHFFFAOYSA-N methyl 4-formylbenzoate Chemical compound COC(=O)C1=CC=C(C=O)C=C1 FEIOASZZURHTHB-UHFFFAOYSA-N 0.000 description 1
- HAPIXNBOBZHNCA-UHFFFAOYSA-N methyl 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate Chemical compound COC(=O)C1=CC=C(C)C(B2OC(C)(C)C(C)(C)O2)=C1 HAPIXNBOBZHNCA-UHFFFAOYSA-N 0.000 description 1
- CVVMLRFXZPKILB-UHFFFAOYSA-N methyl 5-chloropyrazine-2-carboxylate Chemical compound COC(=O)C1=CN=C(Cl)C=N1 CVVMLRFXZPKILB-UHFFFAOYSA-N 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000011707 mineral Chemical class 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- FMASTMURQSHELY-UHFFFAOYSA-N n-(4-fluoro-2-methylphenyl)-3-methyl-n-[(2-methyl-1h-indol-4-yl)methyl]pyridine-4-carboxamide Chemical compound C1=CC=C2NC(C)=CC2=C1CN(C=1C(=CC(F)=CC=1)C)C(=O)C1=CC=NC=C1C FMASTMURQSHELY-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- NNKPHNTWNILINE-UHFFFAOYSA-N n-cyclopropyl-3-fluoro-4-methyl-5-[3-[[1-[2-[2-(methylamino)ethoxy]phenyl]cyclopropyl]amino]-2-oxopyrazin-1-yl]benzamide Chemical compound CNCCOC1=CC=CC=C1C1(NC=2C(N(C=3C(=C(F)C=C(C=3)C(=O)NC3CC3)C)C=CN=2)=O)CC1 NNKPHNTWNILINE-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000003431 oxalo group Chemical group 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 125000005479 oxodihydropyridyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- SEVSMVUOKAMPDO-UHFFFAOYSA-N para-Acetoxybenzaldehyde Natural products CC(=O)OC1=CC=C(C=O)C=C1 SEVSMVUOKAMPDO-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- OWTCGJRBQMOICX-UHFFFAOYSA-M phenacyl(triphenyl)phosphanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1C(=O)C[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 OWTCGJRBQMOICX-UHFFFAOYSA-M 0.000 description 1
- NIXKBAZVOQAHGC-UHFFFAOYSA-N phenylmethanesulfonic acid Chemical class OS(=O)(=O)CC1=CC=CC=C1 NIXKBAZVOQAHGC-UHFFFAOYSA-N 0.000 description 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- LZMJNVRJMFMYQS-UHFFFAOYSA-N poseltinib Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(OC=C2)C2=N1 LZMJNVRJMFMYQS-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 229940080818 propionamide Drugs 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- SHNUBALDGXWUJI-UHFFFAOYSA-N pyridin-2-ylmethanol Chemical compound OCC1=CC=CC=N1 SHNUBALDGXWUJI-UHFFFAOYSA-N 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- FREJAOSUHFGDBW-UHFFFAOYSA-N pyrimidine-5-carbaldehyde Chemical compound O=CC1=CN=CN=C1 FREJAOSUHFGDBW-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 239000012363 selectfluor Substances 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000000213 sulfino group Chemical group [H]OS(*)=O 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- UTYXJYFJPBYDKY-UHFFFAOYSA-N tetrapotassium;iron(2+);hexacyanide;trihydrate Chemical compound O.O.O.[K+].[K+].[K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] UTYXJYFJPBYDKY-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000005300 thiocarboxy group Chemical group C(=S)(O)* 0.000 description 1
- 125000000858 thiocyanato group Chemical group *SC#N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 125000000464 thioxo group Chemical group S=* 0.000 description 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 150000003918 triazines Chemical class 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- PBIMIGNDTBRRPI-UHFFFAOYSA-N trifluoro borate Chemical compound FOB(OF)OF PBIMIGNDTBRRPI-UHFFFAOYSA-N 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000003652 trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
R1は水素原子、ハロゲン原子、アルキル基、アルカノイル基、シアノ基、又はカルボキシル基を示す。本明細書において、ハロゲン原子の用語には、フッ素原子、塩素原子、臭素原子、及びヨウ素原子が包含される。ハロゲン原子としては、フッ素原子又は塩素原子が好ましい。
R6はアルキル基(該アルキル基はヒドロキシ基、ハロゲン原子又はアルコキシ基で置換されていてもよい)、又はアルコキシ基を示す。好ましくはR6は直鎖状、分枝鎖状又は環状C1-6アルキル基であり、該分枝鎖C1-6アルキル基はC1-6アルコキシ基で置換されていてもよい。R6として、好ましくはエチル基、プロピル基、イソプロピル基又は1-メチル-1-メトキシエチル基、シクロプロピル基、t-ブチル基などを用いることができ、特に好ましくはエチル基、プロピル基又はイソプロピル基を用いることができる。
下記式(2)
下記式(3)
下記式(4)
本反応における溶媒については、慣用のものであればよいが、水、N,N-ジメチルアセトアミド、メタノール、エタノール、1-プロパノール、2-プロパノール、1-ブタノール、1-ペンタノールなどが好ましい。
式(2)(式中、R3、R4、R5、R6およびXは前記の意味を有する)で示されるアミジン誘導体と、
下記式(5)
反応時間、反応温度などについては、慣用のものであればよいが、反応温度については、25°〜120°が好ましく、60°〜80°が特に好ましい。また、反応時間については、2時間〜48時間が好ましく、10時間〜24時間が特に好ましい。
また、本反応中、式(3)で示されるエステルは、上記の式(3)-1で示されるエステルであってもよい。
下記式(1)
下記式(7)
脱保護反応における反応時間、反応温度などについては、慣用のものであればよいが、反応温度については、0°〜50°が好ましく、10°〜30°が特に好ましい。また、反応時間については、1時間〜48時間が好ましく、3時間〜24時間が特に好ましい。
アミド化反応における反応時間、反応温度などについては、慣用のものであればよいが、反応温度については、-10°〜60°が好ましく、0°〜30°が特に好ましい。また、反応時間については、1時間〜48時間が好ましく、3時間〜24時間が特に好ましい。
下記式(3)-1
下記式(4)
本反応におけるリガンドとしては、XPhos、SPhos、RuPhosなどが挙げられる。
本反応における溶媒については、慣用のものであればよいが、1,4-ジオキサン/水、CPME/水、トルエン/水、THF/水、i-PrOH/水、EtOH/水、MeOH、THF、CPME、DME、1,4-ジオキサンなどが好ましい。
N-{4-クロロ-3-[4-(4-クロロ-2-フルオロフェニル)-5-シアノ-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}-2,2-ジメチルプロピオンアミド;
N-[4-クロロ-3-(5-シアノ-6-オキソ-4-チオフェン-3-イル-1,6-ジヒドロピリミジン-2-イル)ベンジル]-2,2-ジメチルプロピオンアミド;
N-[4-クロロ-3-(5-シアノ-6-オキソ-4-チオフェン-3-イル-1,6-ジヒドロピリミジン-2-イル)ベンジル]イソブチルアミド;
N-[4-クロロ-3-(6-オキソ-4-チオフェン-3-イル-1,6-ジヒドロピリミジン-2-イル)ベンジル]イソブチルアミド;
N-{4-クロロ-3-[4-(4-クロロ-2-フルオロフェニル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド;
N-{4-クロロ-3-[4-(4-クロロフェニル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド;
N-{4-クロロ-3-[4-(5-クロロピリジン-2-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド;
N-[4-クロロ-3-(6-オキソ-4-フェニル-1,6-ジヒドロピリミジン-2-イル)ベンジル]イソブチルアミド;
N-{4-クロロ-3-[6-オキソ-4-(6-トリフルオロメチルピリジン-3-イル)-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド;
N-[4-クロロ-3-(6-オキソ-4-チオフェン-3-イル-1,6-ジヒドロピリミジン-2-イル)ベンジル]-2-メトキシ-2-メチルプロピオンアミド;
N-{4-クロロ-3-[6-オキソ-4-(5-トリフルオロメチルピリジン-2-イル)-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド;
N-{4-クロロ-3-[4-(5-クロロピリジン-2-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}-2-メトキシ-2-メチルプロピオンアミド;
N-{4-クロロ-3-[4-(3-クロロ-2-フルオロフェニル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド;
N-{4-クロロ-3-[4-(2-クロロ-4-フルオロフェニル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド;
N-{4-クロロ-3-[4-(4-ジフルオロメトキシ-2-フルオロフェニル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド;
N-{4-クロロ-3-[4-(2-フルオロ-4-トリフルオロメトキシフェニル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド;
N-{4-クロロ-3-[4-(2-フルオロ-4-メトキシフェニル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド;
N-{4-クロロ-3-[4-(4-メトキシフェニル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド;
N-{4-クロロ-3-[4-(4-ジフルオロメトキシフェニル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド;
N-{4-クロロ-3-[6-オキソ-4-(4-トリフルオロメチルフェニル)-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド;
N-[4-クロロ-3-(4-シクロペンチル-6-オキソ-1,6-ジヒドロピリミジン-2-イル)ベンジル]イソブチルアミド;
N-{4-クロロ-3-[6-オキソ-4-(4-トリフルオロメトキシフェニル)-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド;
N-{4-クロロ-3-[4-(2,4-ジフルオロフェニル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド;
N-{4-クロロ-3-[4-(2-クロロチオフェン-3-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド;
N-[4-クロロ-3-(4-シクロヘキシル-6-オキソ-1,6-ジヒドロピリミジン-2-イル)ベンジル]イソブチルアミド;
N-{4-クロロ-3-[4-(2-フルオロ-5-メトキシフェニル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド;
N-{4-クロロ-3-[4-(5-クロロ-2-フルオロフェニル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド;
N-{4-クロロ-3-[6-オキソ-4-(6-トリフルオロメチルピリジン-2-イル)-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド;
N-{4-クロロ-3-[4-(2-フルオロフェニル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド;
N-[4-クロロ-3-(6-オキソ-4-チオフェン-2-イル-1,6-ジヒドロピリミジン-2-イル)ベンジル]イソブチルアミド;及び
N-[4-クロロ-3-(5-メチル-6-オキソ-4-フェニル-1,6-ジヒドロピリミジン-2-イル)ベンジル]イソブチルアミド
N-{4-クロロ-3-[4-(6-メトキシピリジン-3-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド
N-{4-クロロ-3-[4-(6-エトキシピリジン-3-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド
N-{4-クロロ-3-[4-(3-フルオロ-4-メチルフェニル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド
N-(4-クロロ-3-{4-[4-(2-メトキシエトキシ)フェニル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-{4-クロロ-3-[4-(5-メチルピリジン-2-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド
N-(4-クロロ-3-{6-オキソ-4-[6-(トリフルオロメチル)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)シクロプロパンカルボキサミド
N-(4-クロロ-3-{6-オキソ-4-[5-(トリフルオロメチル)チオフェン-2-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-(4-クロロ-3-{6-オキソ-4-[2-(トリフルオロメチル)チアゾール-5-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-{4-クロロ-3-[4-(2-フルオロ-4-メチルフェニル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド
N-(4-クロロ-3-{4-[6-(ジフルオロメトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-(4-クロロ-3-{4-[4-(2-エトキシエトキシ)-3-フルオロフェニル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-(4-クロロ-3-{4-[4-(2-エトキシエトキシ)-2-フルオロフェニル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-{4-クロロ-3-[4-(6-イソプロポキシピリジン-3-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド
N-(4-クロロ-3-{6-オキソ-4-[6-(2,2,2-トリフルオロエトキシ)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-{3-[4-(1-tert-ブチル-1H-ピラゾール-4-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-4-クロロベンジル}イソブチルアミド
N-{4-クロロ-3-[4-(1-イソブチル-1H-ピラゾール-4-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド
N-{4-クロロ-3-[4-(2-メトキシチアゾール-5-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド
N-(4-クロロ-3-{6-オキソ-4-[6-(トリフルオロメチル)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)-3,3,3-トリフルオロ-2,2-ジメチルプロピオンアミド
N-{4-クロロ-3-[4-(6-メトキシピリジン-3-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}-3,3,3-トリフルオロ-2,2-ジメチルプロピオンアミド
N-(4-フルオロ-3-{6-オキソ-4-[6-(トリフルオロメチル)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)-2,2-ジメチルプロピオンアミド
N-(3-{4-[6-(ジフルオロメトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-フルオロベンジル)-2,2-ジメチルプロピオンアミド
N-(4-ジフルオロメトキシ-3-{6-オキソ-4-[6-(トリフルオロメチル)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-(4-クロロ-3-{4-[6-(2-エトキシエトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-(4-クロロ-3-{4-[6-(3-メトキシプロポキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-(4-クロロ-3-{4-[6-(2-メトキシエトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-{4-クロロ-3-[4-(3-フルオロフェニル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド
N-[4-クロロ-3-(5-フルオロ-6-オキソ-4-フェニル-1,6-ジヒドロピリミジン-2-イル)ベンジル]イソブチルアミド
N-{4-クロロ-3-[5-フルオロ-4-(4-メトキシフェニル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド
N-{4-クロロ-3-[5-フルオロ-6-オキソ-4-(チオフェン-2-イル)-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド
N-{4-クロロ-3-[5-フルオロ-6-オキソ-4-(チオフェン-3-イル)-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド
N-{3-[4-(ベンゾ[b]チオフェン-7-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-4-クロロ-ベンジル}イソブチルアミド
N-{4-クロロ-3-[4-(4-シアノフェニル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド
N-(4-クロロ-3-{4-[4-(メチルスルファニル)フェニル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-{4-クロロ-3-[6-オキソ-4-(p-トルイル)-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド
N-(4-クロロ-3-{4-[4-(ジエチルスルファモイル)フェニル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-(4-クロロ-3-{6-オキソ-4-[4-(ピペリジン-1-スルホニル)フェニル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-(3-{6-オキソ-4-[6-(トリフルオロメチル)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-{3-[4-(6-メトキシピリジン-3-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]- 4-(トリフルオロメチル)ベンジル}イソブチルアミド
N-(3-{4-[6-(ジフルオロメトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-{3-[4-(6-エトキシピリジン-3-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]- 4-(トリフルオロメチル)ベンジル}イソブチルアミド
N-(4-メチル-3-{6-オキソ-4-[6-(トリフルオロメチル)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-(3-{4-[6-(ジフルオロメトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-メチルベンジル)イソブチルアミド
N-{3-[4-(6-エトキシピリジン-3-イル)- 6-オキソ-1,6-ジヒドロピリミジン-2-イル]- 4-メチルベンジル}イソブチルアミド
N-[4-(ジフルオロメチル)-3-{6-オキソ-4-[6-(トリフルオロメチル)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル]イソブチルアミド
N-(3-{4-[6-(ジフルオロメトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-(ジフルオロメチル)ベンジル)イソブチルアミド
N-(4-クロロ-3-{6-オキソ-4-[2-(トリフルオロメチル)ピリジン-4-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-{4-クロロ-3-[4-(3-フルオロ-4-メトキシフェニル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド
4-{2-[2-クロロ-5-(イソブチリルアミノメチル)フェニル]-6-オキソ-1,6-ジヒドロピリミジン-4-イル}-N,N-ジメチルベンズアミド
N-{4-クロロ-3-[4-(4-フルオロフェニル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド
N-{4-クロロ-3-[4-(6-メトキシピリジン-2-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド
N-(4-フルオロ-3-{6-オキソ-4-[6-(トリフルオロメチル)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-{4-クロロ-3-[4-(6-シクロプロピルピリジン-3-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド
N-{3-[4-(6-エトキシピリジン-3-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-4-フルオロベンジル}イソブチルアミド
N-[4-クロロ-3-(2’-メトキシ-6-オキソ-1,6-ジヒドロ[4,5’]ビピリミジニル-2-イル)ベンジル]イソブチルアミド
N-(3-{4-[6-(ジフルオロメトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-フルオロベンジル)イソブチルアミド
N-(4-クロロ-2-フルオロ-3-{6-オキソ-4-[6-(トリフルオロメチル)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-(4-クロロ-3-{4-[6-(ジフルオロメトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-2-フルオロベンジル)イソブチルアミド
4-{2-[2-クロロ-5-(イソブチリルアミノメチル)フェニル]-6-オキソ-1,6-ジヒドロピリミジン-4-イル}安息香酸メチル
N-(3-{4-[6-(ジフルオロメトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-フルオロベンジル)-1-(トリフルオロメチル)シクロプロパン-1-カルボキサミド
N-(2,4-ジフルオロ-3-{6-オキソ-4-[6-(トリフルオロメチル)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-(4-クロロ-3-{6-オキソ-4-[6-(2-プロポキシエトキシ)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-(3-{4-[6-(2-ブトキシエトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-クロロベンジル)イソブチルアミド
N-{4-クロロ-3-[6-オキソ-2 '-(トリフルオロメチル)-1,6-ジヒドロ[4,5’]-ビピリミジン-2-イル]ベンジル}イソブチルアミド
N-(4-クロロ-3-{4-[6-(3-エトキシプロポキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-(4-クロロ-3-{4-[6-(シクロプロピルメトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-[3-(4-{6-[2-(2-ブトキシエトキシ)エトキシ]ピリジン-3-イル}-6-オキソ-1,6-ジヒドロピリミジン-2-イル)-4-クロロベンジル]イソブチルアミド
N-(4-クロロ-3-{6-オキソ-4-[6-(ピリジン-2-イルメトキシ)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-(4-クロロ-3-{4-[6-(6-メチルピリジン-3-イルメトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-{4-クロロ-3-[6-オキソ-4-(2-オキソ-1-ペンチル-1,2-ジヒドロピリジン-4-イル)-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド
N-{3-[4-(1-ブチル-2-オキソ-1,2-ジヒドロピリジン-4-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-4-クロロベンジル}イソブチルアミド
N-(4-クロロ-3-{4-[6-(ジフルオロメトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}ベンジル)プロピオンアミド
N-(4-クロロ-3-{4-[6-(シクロプロピルメトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}ベンジル)プロピオンアミド
N-(4-クロロ-3-{4-[6-(ジフルオロメトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}ベンジル)ブチルアミド
N-(4-クロロ-3-{6-オキソ-4-[6-(2-プロポキシエトキシ)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)ブチルアミド
N-{4-クロロ-3-[4-(5-フルオロピリジン-3-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド
N-(4-クロロ-3-{6-オキソ-4-[6-(2,2,2-トリフルオロエトキシ)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)プロピオンアミド
N-(4-クロロ-3-{4-[5-(ジフルオロメトキシ)ピリジン-2-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}ベンジル)ブチルアミド
N-{3-[4-(5-クロロピリジン-3-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-4-(トリフルオロメチル)ベンジル}イソブチルアミド
N-{3-[4-(5-フルオロピリジン-3-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-4-(トリフルオロメチル)ベンジル}イソブチルアミド
N-(4-クロロ-3-{4-[5-(ジフルオロメトキシ)ピリジン-2-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}ベンジル)プロピオンアミド
N-{3-[4-(5-メトキシピリジン-3-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-4-(トリフルオロメチル)ベンジル}イソブチルアミド
N-(4-クロロ-3-{6-オキソ-4-[6-プロポキシピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)プロピオンアミド
N-(4-クロロ-3-{4-[6-(2,2-ジフルオロエトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}ベンジル)プロピオンアミド
N-{4-クロロ-3-[4-(5-メチルピリジン-3-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド
N-{3-[4-(5-メチルピリジン-3-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-4-(トリフルオロメチル)ベンジル}イソブチルアミド
N-{4-クロロ-2-フルオロ-3-[4-(5-メチルピリジン-3-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド
N-{4-クロロ-3-[4-(5-メトキシピリジン-2-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド
N-{4-クロロ-3-[4-(1-イソプロピル-1H-ピラゾール-4-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド
N-{4-クロロ-3-[6-オキソ-4-(1-プロピル-1H-ピラゾール-4-イル)-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド
N-(4-ジフルオロメトキシ-3-{4-[6-(ジフルオロメトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-[4-クロロ-3-(4-{6-[2-(2-メトキシエトキシ)エトキシ]ピリジン-3-イル}-6-オキソ-1,6-ジヒドロピリミジン-2-イル)ベンジル]イソブチルアミド
N-(4-クロロ-3-{4-[6-(6-メチルピリジン-2-イルメトキシ)ピリジン-3-イル]- 6-オキソ-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-(4-クロロ-3-{6-オキソ-4-[6-(2-プロポキシエトキシ)ピリジン-3-イル]- 1,6-ジヒドロピリミジン-2-イル}ベンジル)プロピオンアミド
N-(4-クロロ-3-{4-[6-(2-エトキシエトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}ベンジル)ブチルアミド
N-(4-クロロ-3-{4-[6-(2-フルオロエトキシ)ピリジン-3-イル]- 6-オキソ-1,6-ジヒドロピリミジン-2-イル}ベンジル)ブチルアミド
N-(4-クロロ-3-{4-[6-(3-フルオロプロポキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}ベンジル)プロピオンアミド
N-(3-{4-[6-(2-エトキシエトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-(3-{6-オキソ-4-[6-(2-プロポキシエトキシ)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-{3-[4-(6-シクロプロピルピリジン-3-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-4-(トリフルオロメチル)ベンジル}イソブチルアミド
N-(3-{4-[6-(2-ブトキシエトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-[4-クロロ-3-(6-オキソ-4-ピリジン-3-イル-1,6-ジヒドロピリミジン-2-イル)ベンジル]イソブチルアミド
N-{3-[4-(6-メトキシピリジン-3-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-4-メチルベンジル}イソブチルアミド
N-(4-クロロ-3-{6-オキソ-4-[2-(トリフルオロメチル)ピリジン-4-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-[4-(ジフルオロメチル)-3-{6-オキソ-4-[6-(トリフルオロメチル)ピリジン-3-イル]- 1,6-ジヒドロピリミジン-2-イル}ベンジル]イソブチルアミド
N-(3-{4-[2-(シクロプロピルメトキシ)ピリジン-4-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-(3-{4-[6-(シクロプロピルメトキシ)ピリダジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
4-(2-{2-クロロ-5-[(3,3,3-トリフルオロ-2,2-ジメチルプロピオニルアミノ)メチル]フェニル}-6-オキソ-1,6-ジヒドロピリミジン-4-イル)-N,N-ジメチルベンズアミド
N-(3-{4-[6-(ジフルオロメトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-2,4-ジフルオロベンジル)イソブチルアミド
N-[3-(2'-メトキシ-6-オキソ-1,6-ジヒドロ-[4,5'-ビピリミジン]-2-イル)-4-(トリフルオロメチル)ベンジル]イソブチルアミド
N-{4-クロロ-3-[4-(5-クロロピリジン-3-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド
N-{4-クロロ-3-[4-(6-シクロプロピルピリジン-3-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-2-フルオロベンジル}イソブチルアミド
N-[4-クロロ-3-(2'-シクロプロピル-6-オキソ-1,6-ジヒドロ-[4,5'-ビピリミジン]-2-イル)ベンジル]イソブチルアミド
N-(4-クロロ-3-{4-[6-(シクロプロピルメトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-2-フルオロベンジル)イソブチルアミド
N-(3-{4-[6-(シクロプロピルメトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-(4-クロロ-2-フルオロ-3-{6-オキソ-4-[6-(2-プロポキシエトキシ)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-{4-クロロ-3-[4-(6-エトキシピリジン-3-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-2-フルオロベンジル}イソブチルアミド
N-(4-クロロ-2-フルオロ-3-{6-オキソ-4-[5-(トリフルオロメチル)ピリジン-2-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-(3-{4-[6-(2-エトキシエトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-2,4-ジフルオロベンジル)イソブチルアミド
N-(3-{4-[6-(シクロプロピルメトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-2,4-ジフルオロベンジル)イソブチルアミド
N-(2-クロロ-3-{4-[6-(ジフルオロメトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-フルオロベンジル)イソブチルアミド
N-(2-クロロ-3-{4-[6-(シクロプロピルメトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-フルオロベンジル)イソブチルアミド
N-(4-クロロ-2-フルオロ-3-{6-オキソ-4-[6-(2,2,2-トリフルオロエトキシ)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-{4-クロロ-3-[4-(5-クロロピリジン-3-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-2-フルオロベンジル}イソブチルアミド
N-(2-フルオロ-3-{6-オキソ-4-[6-(トリフルオロメチル)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-(2-クロロ-4-フルオロ-3-{6-オキソ-4-[6-(2,2,2-トリフルオロエトキシ)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-{4-クロロ-3-[4-(5-クロロピリジン-2-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-2-フルオロベンジル}イソブチルアミド
N-(2-クロロ-4-フルオロ-3-{6-オキソ-4-[5-(トリフルオロメチル)ピリジン-2-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-(3-{4-[6-(ジフルオロメトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-2-フルオロ-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-(4-クロロ-2-フルオロ-3-{6-オキソ-4-[5-(2-プロポキシエトキシ)ピリジン-2-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-(3-{4-[6-(2-エトキシエトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-2-フルオロ-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-(4-クロロ-3-{4-[6-(2,2-ジフルオロエトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-2-フルオロベンジル)イソブチルアミド
N-(2-クロロ-3-{4-[6-(2,2-ジフルオロエトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-フルオロベンジル)イソブチルアミド
N-(4-クロロ-3-{4-[5-(ジフルオロメトキシ)ピリジン-2-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-2-フルオロベンジル)イソブチルアミド
N-(4-クロロ-3-{4-[5-(2-エトキシエトキシ)ピリジン-2-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-2-フルオロベンジル)イソブチルアミド
N-{3-[4-(5-クロロピリジン-3-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-4-フルオロベンジル}イソブチルアミド
N-(2-フルオロ-3-{6-オキソ-4-[5-(トリフルオロメチル)ピリジン-2-イル]-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-(4-クロロ-3-{4-[5-(シクロプロピルメトキシ)ピリジン-2-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-2-フルオロベンジル)イソブチルアミド
N-{4-クロロ-2-フルオロ-3-[4-(5-フルオロピリジン-3-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド
N-(2-クロロ-3-{4-[6-(2-エトキシエトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-フルオロベンジル)イソブチルアミド
N-(2-クロロ-3-{4-[5-(シクロプロピルメトキシ)ピリジン-2-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-フルオロベンジル)イソブチルアミド
N-(2-クロロ-4-フルオロ-3-{6-オキソ-4-[6-(3,3,3-トリフルオロプロポキシ)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-(3-{6-オキソ-4-[6-(テトラヒドロピラン-4-イルメトキシ)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-(4-クロロ-3-{6-オキソ-4-[6-(テトラヒドロピラン-4-イルメトキシ)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)ブチルアミド
N-{4-クロロ-2-フルオロ-3-[6-オキソ-4-(4-トリフルオロメチルチアゾール-2-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-{4-クロロ-3-[4-(5-エチニルピリジン-3-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド
N-(4-クロロ-3-{6-オキソ-4-[5-(1-プロピニル)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-(3-{4-[6-(3-メチルオキセタン-3-イルメトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-{3-[4-(5-エチニルピリジン-3-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-4-(トリフルオロメチル)ベンジル}イソブチルアミド
N-(4-クロロ-3-{4-[6-(3-メチルオキセタン-3-イルメトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イルベンジル)イソブチルアミド
N-(3-{6-オキソ-4-[5-(1-プロピニル)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-(4-クロロ-3-{6-オキソ-4-[5-(トリフルオロメチル)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-(3-{4-[6-(3-エトキシプロポキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-(4-クロロ-3-{4-[6-(2,2-ジフルオロエトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-(3-{4-[6-(2,2-ジフルオロエトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-(3-{6-オキソ-4-[6-(2,2,2-トリフルオロエトキシ)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-(3-{6-オキソ-4-[6-(3,3,3-トリフルオロプロポキシ)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-(3-{4-[6-(3-フルオロプロポキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-(3-{4-[2-(ジフルオロメトキシ)ピリジン-4-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-(3-{6-オキソ-4-[5-(トリフルオロメチル)ピリジン-2-イル]-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-{3-[4-(5-クロロピリジン-2-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-4-(トリフルオロメチル)ベンジル}イソブチルアミド
N-(3-{6-オキソ-4-[5-(2-プロポキシエトキシ)ピリジン-2-イル]-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-(3-{4-[5-(ジフルオロメトキシ)ピリジン-2-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-(4-クロロ-3-{4-[5-(シクロプロピルメトキシ)ピリジン-2-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-(3-{4-[5-(シクロプロピルメトキシ)ピリジン-2-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-(4-クロロ-2-フルオロ-3-{6-オキソ-4-[6-(トリフルオロメチル)ピリジン-3-イル]- 1,6-ジヒドロピリミジン-2-イル}ベンジル)ブチルアミド
N-(4-クロロ-3-{4-[6-(ジフルオロメトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-2-フルオロベンジル)ブチルアミド
N-[3-(2'-シクロプロピルメトキシ-6-オキソ-1,6-ジヒドロ-[4,5'-ビピリミジン]-2-イル)-4-(トリフルオロメチル)ベンジル]イソブチルアミド
N-{3-[4-(6-ブトキシピリダジン-3-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル] -4-(トリフルオロメチル)ベンジル}イソブチルアミド
N-{4-クロロ-3-[6-オキソ-2'-(トリフルオロメチル)-1,6-ジヒドロ-[4,5'-ビピリミジン]-2-イル]ベンジル}イソブチルアミド
N-{4-クロロ-2-フルオロ-3-[4-(5-フルオロピリジン-2-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド
N-{2-フルオロ-3-[4-(6-メトキシピリジン-3-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-4-(トリフルオロメチル)ベンジル}イソブチルアミド
N-(4-クロロ-3-{4-[6-(シクロプロピルエチニル)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-2-フルオロベンジル)イソブチルアミド
N-{2-クロロ-3-[4-(5-クロロピリジン-2-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-4-フルオロベンジル}イソブチルアミド
N-{4-クロロ-3-[4-(4-シアノフェニル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-2-フルオロベンジル}イソブチルアミド
N-{4-クロロ-2-フルオロ-3-[6-オキソ-4-(6-フェニルピリジン-3-イル)-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド
N-(2,4-ジフルオロ-3-{6-オキソ-4-[5-(トリフルオロメチル)ピリジン-2-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-{3-[4-(5-クロロピリジン-3-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-2,4-ジフルオロベンジル)イソブチルアミド
N-(4-クロロ-3-{4-[6-(ジフルオロメチル)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-2-フルオロベンジル)イソブチルアミド
N-(2-クロロ-3-{4-[6-(シクロプロピルエチニル)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-フルオロベンジル)イソブチルアミド
N-(4-クロロ-3-{4-[5-(ジフルオロメチル)ピリジン-2-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-2-フルオロベンジル)イソブチルアミド
N-(4-クロロ-2-フルオロ-3-{6-オキソ-4-[6-(トリフルオロメチル)ピリジン-2-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-(2-クロロ-4-フルオロ-3-{6-オキソ-4-[4-(トリフルオロメチル)チアゾール-2-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-(4-クロロ-3-{4-[2-(シクロプロピルエチニル)チアゾール-5-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-2-フルオロベンジル)イソブチルアミド
N-(2-クロロ-3-{4-[5-(シクロプロピルエチニル)ピリジン-2-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-フルオロベンジル)イソブチルアミド
N-(4-クロロ-3-{4-[6-(3-エチルオキセタン-3-イルメトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-(3-{4-[6-(3-エチルオキセタン-3-イルメトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-{4-クロロ-2-フルオロ-3-[4-(4-メチルチアゾール-2-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド
N-(4-クロロ-2-フルオロ-3-{6-オキソ-4-[4-(1-プロピニル)チアゾール-2-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-(4-クロロ-3-{4-[5-(シクロプロピルエチニル)チアゾール-2-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-2-フルオロベンジル)イソブチルアミド
N-(4-クロロ-3-{4-[4-(シクロプロピルエチニル)チアゾール-2-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-2-フルオロベンジル)イソブチルアミド
N-(3-{4-[5-(シクロプロピルエチニル)チアゾール-2-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-(3-{4-[6-(シクロプロピルエチニル)ピリジン-2-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-(3-{4-[5-(シクロプロピルエチニル)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-(3-{4-[6-(3-モルホリン-4-イルプロポキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-(3-{6-オキソ-4-[5-(トリフルオロメチル)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-(4-クロロ-2-フルオロ-3-{6-オキソ-4-[5-(トリフルオロメチル)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-[3-(2'-ブチル-6-オキソ-1,6-ジヒドロ-[4,5'-ビピリミジン]-2-イル)-4-(トリフルオロメチル)ベンジル]イソブチルアミド
N-(3-{6-オキソ-4-[5-(トリフルオロメチル)ピリジン-2-イル]-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)ブチルアミド
N-(4-クロロ-2-フルオロ-3-{6-オキソ-4-[5-(トリフルオロメチル)ピリジン-2-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)ブチルアミド
N-{4-クロロ-2-フルオロ-3-[6-オキソ-4-(6-プロピルピリジン-3-イル)-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド
N-{3-[6-オキソ-4-(6-プロピルピリジン-3-イル)-1,6-ジヒドロピリミジン-2-イル]-4-(トリフルオロメチル)ベンジル}イソブチルアミド
N-{3-[2'-(3,3-ジメチル-1-ブチニル)-6-オキソ-1,6-ジヒドロ-[4,5'-ビピリミジン]-2-イル]-4-(トリフルオロメチル)ベンジル}イソブチルアミド
N-(4-クロロ-3-{4-[5-(シクロプロピルエチニル)ピリジン-2-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-2-フルオロベンジル)イソブチルアミド
N-(4-クロロ-2-フルオロ-3-{6-オキソ-4-[6-(1-プロピニル)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-(2,4-ジフルオロ-3-{6-オキソ-4-[6-(2-プロポキシエトキシ)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-{4-クロロ-2-フルオロ-3-[4-(6-メトキシピリジン-2-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]ベンジル}イソブチルアミド
N-{2-フルオロ-3-[4-(5-フルオロピリジン-3-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-4-(トリフルオロメチル)ベンジル}イソブチルアミド
N-[4-クロロ-2-フルオロ-3-(4-{6-[(1-ヒドロキシシクロヘキシル)エチニル]ピリジン-3-イル}-6-オキソ-1,6-ジヒドロピリミジン-2-イル)ベンジル]イソブチルアミド
N-(4-クロロ-2-フルオロ-3-{6-オキソ-4-[5-(1-プロピニル)ピリジン-2-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-{3-[4-(6-エトキシピリジン-3-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-2-フルオロ-4-(トリフルオロメチル)ベンジル}イソブチルアミド
N-{3-[4-(ベンゾチアゾール-2-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-4-クロロ-2-フルオロベンジル}イソブチルアミド
N-(3-{4-[6-(2-イソプロポキシエトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-(2,4-ジフルオロ-3-{4-[6-(2-イソプロポキシエトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-(2-クロロ-4-フルオロ-3-{4-[6-(2-イソプロポキシエトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-(3-{6-オキソ-4-[6-(テトラヒドロピラン-4-イルメトキシ)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)ブチルアミド
N-(3-{4-[6-(2-イソプロポキシエトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)ブチルアミド
N-(3-{4-[6-(2-エトキシエトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)ブチルアミド
N-(3-{6-オキソ-4-[6-(2-プロポキシエトキシ)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)ブチルアミド
N-{3-[4-(ベンゾチアゾール-2-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-2,4-ジフルオロベンジル}イソブチルアミド
N-{3-[4-(ベンゾチアゾール-2-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-4-(トリフルオロメチル)ベンジル}イソブチルアミド
N-(2-クロロ-4-フルオロ-3-{6-オキソ-4-[6-(2-プロポキシエトキシ)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-(3-{6-オキソ-4-[4-(トリフルオロメチル)チアゾール-2-イル]-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-[3-(6-オキソ-4-{6-[2-(2,2,2-トリフルオロエトキシ)エトキシ]ピリジン-3-イル}-1,6-ジヒドロピリミジン-2-イル)-4-(トリフルオロメチル)ベンジル]イソブチルアミド
N-[4-クロロ-2-フルオロ-3-(6-オキソ-4-{6-[2-(2,2,2-トリフルオロエトキシ)エトキシ]ピリジン-3-イル}-1,6-ジヒドロピリミジン-2-イル)ベンジル]イソブチルアミド
N-[2,4-ジフルオロ-3-(6-オキソ-4-{6-[2-(2,2,2-トリフルオロエトキシ)エトキシ]ピリジン-3-イル}-1,6-ジヒドロピリミジン-2-イル)ベンジル]イソブチルアミド
N-[2-クロロ-4-フルオロ-3-(6-オキソ-4-{6-[2-(2,2,2-トリフルオロエトキシ)エトキシ]ピリジン-3-イル}-1,6-ジヒドロピリミジン-2-イル)ベンジル]イソブチルアミド
N-(3-{4-[5-(シクロプロピルエチニル)ピリジン-2-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)ブチルアミド
N-(4-クロロ-3-{4-[5-(シクロプロピルエチニル)ピリジン-2-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-2-フルオロベンジル)ブチルアミド
N-(3-{4-[5-(3,3-ジメチル-1-ブチニル)ピラジン-2-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-(3-{4-[5-(シクロプロピルエチニル)ピラジン-2-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-{3-[2'-(4-メチル-1-ペンチニル)-6-オキソ-1,6-ジヒドロ-[4,5'-ビピリミジン]-2-イル]-4-(トリフルオロメチル)ベンジル}イソブチルアミド
N-{3-[6-オキソ-4-(5-プロピルピリジン-2-イル)-1,6-ジヒドロピリミジン-2-イル]-4-(トリフルオロメチル)ベンジル}イソブチルアミド
N-{4-クロロ-3-[2'-(シクロプロピルメトキシ)-6-オキソ-1,6-ジヒドロ-[4,5'-ビピリミジン]-2-イル]-2-フルオロベンジル}イソブチルアミド
N-{3-[2'-(シクロプロピルメトキシ)-6-オキソ-1,6-ジヒドロ-[4,5'-ビピリミジン]-2-イル]-4-(トリフルオロメチル)ベンジル}ブチルアミド
N-{4-クロロ-3-[2'-(シクロプロピルメトキシ)-6-オキソ-1,6-ジヒドロ-[4,5'-ビピリミジン]-2-イル]-2-フルオロベンジル}ブチルアミド
N-(3-{4-[5-(シクロプロピルメトキシ)ピラジン-2-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-(4-クロロ-2-フルオロ-3-{6-オキソ-4-[2-(1-プロピニル)チアゾール-5-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-(2-クロロ-3-{4-[2-(シクロプロピルエチニル)チアゾール-5-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-フルオロベンジル)イソブチルアミド
N-(3-{4-[5-(シクロプロピルエチニル)ピリジン-2-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-2,4-ジフルオロベンジル)イソブチルアミド
N-(3-{4-[6-(シクロプロピルエチニル)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-2,4-ジフルオロベンジル)イソブチルアミド
N-(2-フルオロ-3-{4-[5-(イソブチリルアミノメチル)ピリジン-2-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-(2-フルオロ-3-{6-オキソ-4-[5-(1-プロピニル)ピリジン-2-イル]-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル}イソブチルアミド
N-(3-{4-[6-(シクロプロピルエチニル)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-(2-フルオロ-3-{6-オキソ-4-[6-(2-プロポキシエトキシ)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-(2-フルオロ-3-{4-[6-(2-イソプロポキシエトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-(3-{4-[2-(シクロプロピルエチニル)チアゾール-5-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-2-フルオロ-4-(トリフルオロメチル)ベンジル)イソブチルアミド
N-[2-フルオロ-3-(6-オキソ-4-{6-[2-(2,2,2-トリフルオロエトキシ)エトキシ]ピリジン-3-イル}-1,6-ジヒドロピリミジン-2-イル)-4-(トリフルオロメチル)ベンジル]イソブチルアミド
N-(4-クロロ-2-フルオロ-3-{6-オキソ-4-[5-(2,2,2-トリフルオロエチル)ピリジン-2-イル]-1,6-ジヒドロピリミジン-2-イル}ベンジル)イソブチルアミド
N-(3-{4-[5-(シクロプロピルエチニル)ピリジン-2-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル}-2-フルオロ-4-(トリフルオロメチル)ベンジル)イソブチルアミド
などを挙げることができるが、これらに限定されることはない。
1H-NMR(CDCl3,δ):1.24(9H,s),4.43(2H,d,J=5.9Hz),6.11(1H,brs),7.4-7.6(3H,m)
MS(m/z):250(M+)。
1H-NMR(CDCl3,δ):1.19(6H,d,J=6.8Hz),2.3-2.5(1H,m),4.43(2H,d,J=6.4Hz),5.96(1H,brs),7.4-7.6(3H,m)
MS(m/z):236(M+)。
1H-NMR(CDCl3,δ):1.41(6H,s),3.29(3H,s),4.43(2H,d,J=6.4Hz),7.18(1H,brs),7.4-7.7(3H,m)
MS(m/z):266(M+)。
1H-NMR(DMSO-d6,δ):1.41(9H,m),4.24(2H,d,J=6.4Hz),7.17(1H,brs),7.4-7.5(4H,m),8.0-8.1(2H,m),8.19(1H,brs),8.48(1H,d,J=8.8Hz),8.78(1H,d,J=2.0Hz)
MS(m/z):412(M+)
N-(3-カルバミミドイル-4-クロロベンジル)-2,2-ジメチルプロパン酸アミド塩酸塩807mgへ炭酸カリウム611mg、水15mLを加え10分間撹拌した。シアノ酢酸エチル0.47 mL、4-クロロ-2-フルオロベンズアルデヒド350mgを加え、マイクロ波をかけ40分間100℃にした。反応後酢酸エチルで抽出し溶媒を留去した。シリカゲルカラムクロマトグラフィーを行い表題化合物48mgを得た。
1H-NMR(DMSO-d6,δ):1.12(9H,s),4.28(2H,d,J=5.8Hz),7.3-7.8(6H,m),8.0-8.2(1H,m)
MS(m/z):472(M+)。
チオフェン-3-カルバルデヒドを用い、実施例1と同様の操作を行って表題化合物を得た。
1H-NMR(DMSO-d6,δ):1.13(9H,s),4.30(2H,d,J=5.8Hz),7.3-7.9(5H,m),8.0-8.2(1H,m),8.5-8.6(1H,m),13.78(1H,brs)
MS(m/z):426(M+)。
チオフェン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロベンジル)イソブチルアミド塩酸塩を用い、実施例1と同様の操作を行って表題化合物を得た。
1H-NMR(DMSO-d6,δ):1.03(6H,d,J=6.8Hz),2.3-2.5(1H,m),4.31(2H,d,J=5.9Hz),7.3-7.9(5H,m),8.3-8.4(1H,m),8.5-8.6(1H,m)
MS(m/z):412(M+)。
N-(3-カルバミミドイル-4-クロロベンジル)イソブチルアミド塩酸塩1.039gへ炭酸カリウム990mg、水15mLを加え10分間撹拌した。フェニルスルホニル酢酸エチル1.634g、チオフェン-3-カルバルデヒド0.31mLを加え、マイクロ波をかけ40分間100℃にした。反応後酢酸エチルで抽出し溶媒を留去した。シリカゲルカラムクロマトグラフィーで精製して表題化合物89mgを得た。
1H-NMR(DMSO-d6,δ):1.03(6H,d,J=6.8Hz),2.3-2.5(1H,m),4.31(2H,d,J=5.9Hz),6.84(1H,s),7.3-7.8(5H,m),8.2-8.4(2H,m),12.45(1H,brs)
MS(m/z):387(M+)。
4-クロロ-2-フルオロベンズアルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(DMSO-d6,δ):1.03(6H,d,J=6.8Hz),2.3-2.5(1H,m),4.30(2H,d,J=5.9Hz),6.78(1H,s),7.3-7.7(5H,m),7.9-8.1(1H,m),8.2-8.4(1H,m),12.95(1H,brs)
MS(m/z):433(M+)。
4-クロロベンズアルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(DMSO-d6,δ):1.03(6H,d,J=6.8Hz),2.3-2.5(1H,m),4.31(2H,d,J=5.8Hz),6.98(1H,s),7.3-7.6(5H,m),8.0-8.4(3H,m),12.89(1H,brs)
MS(m/z):415(M+)。
5-クロロピリジン-2-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(DMSO-d6,δ):1.04(6H,d,J=6.8Hz),2.3-2.5(1H,m),4.32(2H,d,J=5.9Hz),7.21(1H,s),7.4-7.7(3H,m),8.0-8.4(3H,m),8.78(1H,d,J=1.9Hz),13.04(1H,brs)
MS(m/z):416(M+)。
ベンズアルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(DMSO-d6,δ):1.03(6H,d,J=6.8Hz),2.3-2.5(1H,m),4.31(2H,d,J=5.9Hz),6.94(1H,s),7.3-7.6(6H,m),8.0-8.2(2H,m),8.3-8.4(1H,m),12.85(1H,brs)
MS(m/z):381(M+)。
6-トリフルオロメチルピリジン-3-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(DMSO-d6,δ):1.03(6H,d,J=6.8Hz),2.3-2.5(1H,m),4.32(2H,d,J=6.4Hz),7.25(1H,s),7.4-7.7(3H,m),8.03(1H,d,J=8.3Hz),8.2-8.4(1H,m),8.69(1H,dd,J=1.4Hz,8.3Hz),9.40(1H,s),13.13(1H,brs)
MS(m/z):450(M+)。
4-クロロ-3-フルオロベンズアルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(DMSO-d6,δ):1.04(6H,d,J=6.8Hz),2.3-2.5(1H,m),4.31(2H,d,J=6.3Hz),7.08(1H,s),7.3-7.8(4H,m),7.97(1H,dd,J=1.4Hz,8.3Hz),8.09(1H,dd,J=1.9Hz,9.3Hz),8.2-8.4(1H,m),12.90(1H,brs)
MS(m/z):433(M+)。
チオフェン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロベンジル)-2-メトキシ-2-メチルプロピオンアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(DMSO-d6,δ):1.27(6H,s),3.16(3H,s),4.32(2H,d,J=6.3Hz),6.83(1H,s),7.3-7.8(5H,m),8.2-8.5(2H,m),12.75(1H,brs)
MS(m/z):417(M+)。
5-トリフルオロメチルピリジン-2-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(DMSO-d6,δ):1.04(6H,d,J=7.3Hz),2.3-2.5(1H,m),4.32(2H,d,J=5.8Hz),7.31(1H,s),7.4-7.7(3H,m),8.2-8.5(3H,m),9.12(1H,d,J=0.9Hz),13.14(1H,brs)
MS(m/z):450(M+)。
5-クロロピリジン-2-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロベンジル)-2-メトキシ-2-メチルプロピオンアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(DMSO-d6,δ):1.28(6H,s),3.17(3H,s),4.33(2H,d,J=5.8Hz),7.21(1H,s),7.4-7.7(3H,m),8.0-8.5(3H,m),8.78(1H,d,J=1.9Hz),13.06(1H,brs)
MS(m/z):446(M+)。
3-クロロ-2-フルオロベンズアルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(DMSO-d6,δ):1.03(6H,d,J=7.2Hz),2.43(1H,sept,J=6.8Hz),4.30(2H,d,J=6.4Hz),6.78(1H,brs),7.35(1H,t,J=7.2Hz),7.42(1H,dd,J=2.0Hz,8.0Hz),7.5-7.6(2H,m),7.7-7.8(1H,m)7.91(1H,t,J=6.8Hz),8.33(1H,t,J=6.0Hz),13.08(1H,s)
MS(m/z):433(M+)。
2-クロロ-4-フルオロベンズアルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(DMSO-d6,δ):1.02(6H,d,J=6.8Hz),2.3-2.5(1H,m),4.29(2H,d,J=5.6Hz),6.62(1H,brs),7.3-7.5(2H,m),7.51(1H,d,J=2.0Hz),7.5-7.6(2H,m),7.72(1H,dd,J=6.0Hz,8.8Hz),8.2-8.3(1H,m),13.03(1H,brs)
MS(m/z):433(M+)。
4-ジフルオロメトキシ-2-フルオロベンズアルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(DMSO-d6,δ):1.03(6H,d,J=6.8Hz),2.3-2.6(1H,m),4.30(2H,d,J=5.6Hz),6.74(1H,brs),7.16(1H,dd,J=2.8Hz,8.8Hz),7.29(1H,dd,J=2.4Hz,12.8Hz),7.40(1H,t,J=73.2Hz),7.41(1H,dd,J=2.4Hz,8.4Hz)7.5-7.6(2H,m),8.07(1H,t,J=8.8Hz),8.33(1H,t,J=6.0Hz),13.01(1H,brs)
MS(m/z):465(M+)。
2-フルオロ-4-トリフルオロメトキシベンズアルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(DMSO-d6,δ):1.03(6H,d,J=6.8Hz),2.3-2.6(1H,m),4.30(2H,d,J=6.0Hz),6.79(1H,brs),7.37(1H,d,J=8.8Hz),7.41(1H,dd,J=2.0Hz,8.4Hz),7.5-7.6(3H,m),8.12(1H,t,J=8.8Hz),8.33(1H,t,J=6.0Hz)13.04(1H,brs)
MS(m/z):483(M+)。
2-フルオロ-4-メトキシベンズアルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(DMSO-d6,δ):1.03(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),3.84(3H,s),4.31(2H,d,J=6.0Hz),6.68(1H,brs),6.90(1H,dd,J=2.4Hz,8.8Hz),6.98(1H,dd,J=2.4Hz,13.6Hz),7.41(1H,dd,J=2.0Hz,8.4Hz),7.5-7.6(2H,m),8.00(1H,t,J=8.8Hz),8.33(1H,t,J=6.4Hz),12.89(1H,brs)
MS(m/z):429(M+)。
4-メトキシベンズアルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(DMSO-d6,δ):1.03(6H,d,J=6.8Hz),2.4-2.6(1H,m),3.82(3H,s),4.31(2H,d,J=6.0Hz),6.84(1H,brs),7.0-7.1(2H,m),7.41(1H,dd,J=2.0Hz,8.4Hz),7.5-7.6(2H,m),8.04(2H,d,J=8.8Hz),8.34(1H,t,J=6.0Hz),12.75(1H,brs)
MS(m/z):411(M+)。
4-ジフルオロメトキシベンズアルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(DMSO-d6,δ):1.03(6H,d,J=6.8Hz),2.3-2.5(1H,m),4.31(2H,d,J=5.6Hz),6.95(1H,brs),7.27(2H,d,J=8.8Hz),7.34(1H,t,J=73.6Hz),7.42(1H,d,J=8.4Hz),7.5-7.6(2H,m),8.14(2H,d,J=8.4Hz),8.3-8.4(1H,m),12.90(1H,brs)
MS(m/z):447(M+)。
4-トリフルオロメチルベンズアルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(DMSO-d6,δ):1.03(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),4.31(2H,d,J=5.6Hz),7.08(1H,brs),7.42(1H,dd,J=2.0Hz,8.4Hz),7.5-7.6(2H,m),7.84(2H,d,J=8.0Hz),8.2-8.4(3H,m),13.04(1H,brs)
MS(m/z):449(M+)。
3-フルオロチオフェン-2-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(DMSO-d6,δ):1.04(6H,d,J=7.2Hz),2.3-2.6(1H,m),4.31(2H,d,J=6.0Hz),6.61(1H,brs),7.18(1H,d,J=5.6Hz),7.42(1H,d,J=8.4Hz),7.49(1H,s),7.57(1H,d,J=8.0Hz),7.81(1H,t,J=5.6Hz),8.34(1H,t,J=6.0Hz),12.91(1H,brs)
MS(m/z):405(M+)。
窒素雰囲気下、N-(3-カルバミミドイル-4-クロロベンジル)イソブチルアミド塩酸塩580mgをエタノール8mLに溶解し、3-シクロペンチル-3-オキソプロパン酸エチル405mgを加えた。氷冷下でナトリウムエトキシドの20%エタノール溶液1.5mLをゆっくりと滴加し、一夜加熱還流を行なった。エタノールを減圧下除去し、残渣を酢酸エチルに溶解し、2N-塩酸、水、飽和食塩水で順次洗浄した。溶媒を減圧下除去した後、得られた残渣をシリカゲルカラムクロマトグラフィーで精製し、減圧下乾燥して表題化合物88mgを得た。
1H-NMR(DMSO-d6,δ):1.03(6H,d,J=6.8Hz),1.5-2.0(8H,m),2.42(1H,sept,J=6.8Hz),2.8-3.0(1H,m),4.29(2H,d,J=5.6Hz),6.19(1H,brs),7.38(1H,dd,J=2.0Hz,8.4Hz),7.41(1H,d,J=1.6Hz),7.53(1H,d,J=8.4Hz),8.3-8.4(1H,m),12.62(1H,brs)
MS(m/z):373(M+)。
4-トリフルオロメトキシベンズアルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(DMSO-d6,δ):1.03(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),4.31(2H,d,J=6.4Hz),7.01(1H,brs),7.4-7.6(5H,m),8.21(2H,d,J=8.8Hz),8.34(1H,t,J=6.4Hz),12.96(1H,brs)
MS(m/z):465(M+)
2,4-ジフルオロベンズアルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(DMSO-d6,δ):1.03(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),4.30(2H,d,J=6.0Hz),6.73(1H,brs),7.2-7.3(1H,m),7.4-7.6(4H,m),8.07(1H,ddd,J=2.4Hz,6.8Hz,8.8Hz),8.32 (1H,t,J=6.4Hz),12.96(1H,brs)
MS(m/z):417(M+)
2-クロロチオフェン-3-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(DMSO-d6,δ): 1.03(6H,d,J=6.8Hz),2.42(1H,sept,J=6.8Hz),4.30(2H,d,J=5.6Hz), 6.83(1H,brs),7.41(1H,dd,J=2.0Hz,8.0Hz),7.45(1H,d,J=6.0Hz),7.5-7.6(3H,m),8.3-8.4(1H,m),12.96(1H,brs)
MS(m/z):422(M+)
3-シクロヘキシル-3-オキソプロパン酸エチルを用い、実施例23と同様の操作を行って表題化合物を得た。
1H-NMR(DMSO-d6,δ): 1.03(6H,d,J=6.8Hz),1.2-1.4(5H,m),1.7-1.9(5H,m),2.3-2.6(2H,m), 4.29(2H,d,J=5.6Hz),6.13(1H,brs),7.4-7.5(2H,m),7.52(1H,d,J=8.0Hz),8.3-8.4(1H,m),12.63(1H,brs)
MS(m/z):387(M+)
2-フルオロ-5-メトキシベンズアルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(DMSO-d6,δ):1.03(6H,d,J=6.8Hz),2.3-2.6(1H,m),3.77(3H,s),4.31(2H,d,J=6.0Hz),6.76(1H,brs),7.0-7.1(1H,m),7.2-7.3(1H,m),7.41(1H,dd,J=2.0Hz,8.4Hz),7.4-7.5(1H,m),7.5-7.6(2H,m),8.33(1H,t,J=6.0Hz),13.00(1H,brs)
MS(m/z):429(M+)
5-クロロ-2-フルオロベンズアルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(DMSO-d6,δ):1.04(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),4.31(2H,d,J=6.0Hz),6.79(1H,brs),7.4-7.6(5H,m),7.98(1H,dd,J=2.8Hz,6.8Hz),8.34(1H,t,J=6.4Hz),13.06(1H,brs)
MS(m/z):433(M+)
6-トリフルオロメチルピリジン-2-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(DMSO-d6,δ):1.03(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),4.31(2H,d,J=6.4Hz),7.18(1H,brs),7.41(1H,dd,J=1.9Hz,8.3Hz),7.5-7.6(2H,m),8.03(1H,dd,J=0.8Hz,8.0Hz),8.25(1H,t,J=8.0Hz),8.34(1H,t,J=6.4Hz),8.49(1H,d,J=8.0Hz),13.13(1H,brs)
MS(m/z):450(M+)
2-フルオロベンズアルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(DMSO-d6,δ):1.03(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),4.30(2H,d,J=6.0Hz),6.75(1H,brs),7.3-7.4(3H,m),7.5-7.6(3H,m),8.00(1H,dt,J=2.0Hz,8.0Hz),8.33(1H,t,J=6.0Hz),12.98(1H,brs)
MS(m/z):399(M+)
2-(3-アミノメチルフェニル)-6-(5-クロロピリジン-2-イル)-3H-ピリミジン-4-オン92mgのN,N-ジメチルホルムアミド4mL溶液に、ジイソプロピルエチルアミン178μLを加えた。氷冷下,塩化イソブチリル46μLを滴加し,室温で一夜撹拌した。反応液に酢酸エチルを加え、水で2回洗浄して有機層を減圧下濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィーで精製して表題化合物10mgを得た。
1H-NMR(DMSO-d6,δ):1.07(6H,d,J=6.8Hz),2.4-2.6(1H,m),4.37(2H,d,J=5.6Hz),7.19(1H,brs),7.4-7.6(2H,m),8.0-8.3(4H,m),8.47(1H,d,J=8.4Hz),8.7-8.8(1H,m),12.94(1H,brs)
MS(m/z):382(M+)
チオフェン-2-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(DMSO-d6,δ):1.04(6H,d,J=7.2Hz),2.43(1H,sept,J=6.8Hz),4.31(2H,d,J=5.6Hz),6.86(1H,brs),7.1-7.2(1H,m),7.42(1H,dd,J=2.0Hz,8.4Hz),7.50(1H,d,J=2.0Hz),7.57(1H,d,J=8.4Hz),7.77(1H,dd,J=0.8Hz,4.8Hz),7.92(1H,d,J=3.2Hz),8.34(1H,t,J=5.6Hz),12.82(1H,brs)
MS(m/z):387(M+)
2-メチル-3-オキソ-3-フェニルプロパン酸エチルを用い、実施例23と同様の操作を行って表題化合物を得た。
1H-NMR(DMSO-d6,δ):1.02(6H,d,J=6.8Hz),2.07(3H,s),2.3-2.6(1H,m),4.28(2H,d,J=6.0Hz),7.18(1H,brs),7.3-7.6(7H,m),8.3-8.4(1H,m),12.38(1H,brs)
MS(m/z):395(M+)
1H-NMR(CDCl3,δ):0.7-1.1(4H,m),1.3-1.5(1H,m),4.44(2H,d,J=5.8Hz),6.16(1H,brs),7.4-7.5(2H,m), 7.58(1H,brs)
MS(m/z):234(M+)。
MS(m/z):212(M+)。
1H-NMR(CDCl3,δ):1.44(6H,s),4.48(2H,d,J=6.4Hz),6.33(1H,brs),7.43(1H,dd,J=1.9Hz,8.3Hz),7.48(1H,d,J=8.3Hz),7.54(1H,d,J=2.5Hz)
MS(m/z):304(M+)。
1H-NMR(CDCl3,δ):1.23(9H,s),4.42(2H,d,J=6.4Hz),6.10(1H,brs),7.18(1H,t,J=8.6Hz),8.4-8.6(2H,m)
MS(m/z):234(M+)。
1H-NMR(CDCl3,δ):1.41(2H,brs),3.92(2H,s),6.63(1H,t,J=71.8Hz),7.2-7.4(1H,m),7.58(1H,dd,J=1.9Hz,8.3Hz),7.68(1H,d,J=1.9Hz)
MS(m/z):197(M+-1) 。
1H-NMR(CDCl3,δ):1.19(6H,d,J=6.8Hz),2.42(1H,sept,J=6.8Hz),4.44(2H,d,J=6.3Hz),5.97(1H,brs),6.63(1H,t,J=71.6Hz),7.2-7.4(1H,m),7.53(1H,dd,J=2.4Hz,8.8Hz),7.57(1H,d,J=2.0Hz)
MS(m/z):268(M+)。
1H-NMR(CDCl3,δ):2.0-2.2(2H,m),3.36(3H,s),3.55(2H,t,J=6.4Hz),4.50(2H,t,J=6.6Hz),6.83(1H,d,J=8.8Hz),8.06(1H,dd,J=2.5Hz,8.8Hz),8.62(1H,d,J=1.9Hz),9.95(1H,s)
MS(m/z):196(M++1) 。
1H-NMR(d6-DMSO,δ):7.4-7.5(1H,m),7.7-7.8(1H,m),7.8-7.9(3H,m),7.9-8.0(2H,m),8.6-8.7(1H,m),10.06(1H,s)
MS(m/z):207(M+)。
1H-NMR(d6-DMSO,δ):1.26(3H,t,J=7.2Hz),4.2-4.3(2H,m),5.86(1H,d,J=48.8Hz),7.4-7.5(2H,m),7.6-7.7(1H,m), 8.0-8.1(2H,m)
MS(m/z):210(M+)。
1H-NMR(CDCl3,δ):1.27(3H,t,J=7.2Hz),3.89(3H,s),4.2-4.3(2H,m),5.81(1H,d,J=48.8Hz),6.9-7.0(2H,m),8.0-8.1(2H,m)
MS(m/z):240(M+)。
1H-NMR(d6-DMSO,δ):1.16(3H,t,J=6.8Hz),4.22(2H,q,J=6.8Hz),6.53(1H,d,J=46.8Hz),7.35(1H,dd,J=4.8Hz),8.1-8.2(1H,m),8.22(1H,dd,J=0.8Hz,4.8Hz)
MS(m/z): 216(M+)。
1H-NMR(CDCl3,δ):1.26(3H,t,J=7.2Hz),3.89(2H,s),4.21(2H,q,J=7.2Hz),7.3-7.4(1H,m),7.56(1H,dd,J=1.6Hz,5.6Hz),8.11(1H,dd,J=1.6Hz,2.8Hz)
MS(m/z): 198(M+)。
1H-NMR(CDCl3,δ):1.28(3H,t,J=6.8Hz),4.2-4.4(2H,m),5.65(1H,d,J=49.2Hz),7.36(1H,dd,J=2.8Hz,4.8Hz),7.65(1H,dd,J=0.8Hz,6.4Hz),8.40(1H,quin,J=1.6Hz)
MS(m/z): 216(M+)。
1H-NMR(d6-DMSO,δ):1.05(6H,t,J=7.2Hz),3.21(4H,q,J=7.2Hz)),7.9-8.0(2H,m),8.0-8.1(2H,m), 10.11(1H,s)
MS(m/z):241(M+)。
1H-NMR(d6-DMSO,δ):1.4-1.5(2H,m),1.65(4H,quin,J=5.6Hz),3.04(4H,t,J=5.6Hz),7.93(2H,dd,J=2.0Hz,6.8Hz),8.04(2H,dd,J=2.0Hz,6.4Hz),10.12(1H,s)
MS(m/z):253(M+)。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=7.6Hz),2.45(1H,sept,J=6.8Hz),4.38(2H,d,J=6.0Hz), 7.76(1H,d,J=8.8Hz),7.9-8.0(2H,m),8.40(1H,t,J=6.0Hz)
MS(m/z):270(M+)。
参考例31:N-(3-ブロモ-4-メチルベンジル)イソブチルアミド
1H-NMR(d6-DMSO,δ):1.02(6H,d,J=6.8Hz),2.2-2.5(4H,m),4.20(2H,d,J=6.0Hz),7.14(1H,dd,J=2.0Hz,7.6Hz),7.29(1H,d,J=7.6Hz),7.42(1H,d,J=1.2Hz),8.23(1H,t,J=5.2Hz)
MS(m/z):269(M+-1) 。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),2.3-2.6(4H,m),4.24(2H,d,J=5.6Hz),7.4-7.5(2H,m),7.58(1H,s),8.30(1H,t,J=6.0Hz)
MS(m/z):216(M+)。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.44(1H,sept,J=6.8Hz),4.34(2H,d,J=5.6Hz), 7.23(1H,t,J=54Hz),7.69(1H,d,J=8.0Hz),7.78(1H,d,J=8.0Hz),7.85(1H,s),8.36(1H,t,J=5.6Hz)
MS(m/z):252(M+)。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=7.2Hz),2.42(1H,sept,J=6.8Hz),4.26(2H,d,J=5.6Hz),7.49(1H,t,J=8.8Hz),7.6-7.7(1H,m),7.7-7.8(1H,m),8.30(1H,t,J=5.6Hz)
MS(m/z):220(M+)。
1H-NMR(d6-DMSO,δ):4.74(2H,d,J=1.2Hz),7.66(1H,dd,J=1.2Hz,8.8Hz),7.95(1H,t,J=8.8Hz)
MS(m/z):249(M++1) 。
得られた化合物をテトラヒドロフラン24mL、水1mLに溶解し、氷冷下でトリフェニルホスフィン2.97gを加え、室温で一晩撹拌した。1N-塩酸を加え、ジエチルエーテルで洗浄した。水層へ1N-水酸化ナトリウムを加えアルカリ性にした。ジクロロメタンで抽出した後、硫酸マグネシウムで乾燥させ、得られた有機層をそのまま次の反応に用いた。
1H-NMR(d6-DMSO,δ):1.02(6H,d,J=6.8Hz),2.41(1H,sept,J=6.8Hz),4.29(2H,d,J=5.6Hz),7.5-7.7(2H,m),8.33(1H,t,J=5.6Hz)
MS(m/z):254(M+)。
1H-NMR(d6-DMSO,δ):1.2-1.4(4H,m),4.29(2H,d,J=6.0Hz),7.49(1H,t,J=8.8Hz),7.5-7.7(1H,m),7.7-7.8(1H,m),8.41(1H,t,J=5.6Hz)
MS(m/z):286(M+)。
1H-NMR(d6-DMSO,δ):1.02(6H,d,J=6.8Hz),2.41(1H,sept,J=6.8Hz),4.28(2H,d,J=6.0Hz),7.3-7.5(1H,m),7.6-7.8(1H,m),8.32(1H,t,J=5.6Hz)
MS(m/z):238(M+)。
1H-NMR(CDCl3,δ):0.93(3H,t,J=7.3Hz),1.5-1.8(2H,m),3.49(2H,t,J=6.8Hz),3.7-3.9(2H,m),4.5-4.7(2H,m),6.90(1H,d,J=8.3Hz),8.06(1H,dd,J=2.5Hz,8.8Hz),8.61(1H,d,J=1.9Hz),9.95(1H,s)
MS(m/z):210(M++1) 。
6-メトキシピリジン-3-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),3.92(3H,s),4.31(2H,d,J=5.8Hz),6.91(1H,d,J=8.3Hz),6.96(1H,brs),7.3-7.6(3H,m),8.2-8.4(2H,m),8.89(1H,d,J=2.0Hz),12.79(1H,brs)
MS(m/z):412(M+)。
6-エトキシピリジン-3-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),1.34(3H,t,J=6.8Hz),2.43(1H,sept,J=6.8Hz),4.31(2H,d,J=5.8Hz),4.37(2H,q,J=7.0Hz),6.88(1H,d,J=8.8Hz),6.95(1H,brs),7.3-7.6(3H,m),8.2-8.4(2H,m),8.87(1H,d,J=2.4Hz),12.81(1H,brs)
MS(m/z):426(M+)。
3-フルオロ-4-メチルベンズアルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.29(3H,d,J=1.0Hz),2.44(1H,sept,J=6.8Hz),4.32(2H,d,J=6.4Hz),6.98(1H,brs),7.3-7.9(6H,m),8.2-8.4(1H,m),12.91(1H,brs)
MS(m/z):413(M+)。
4-(2-メトキシエトキシ)ベンズアルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),3.32(3H,s),3.6-3.8(2H,m),4.1-4.2(2H,m),4.31(2H,d,J=6.3Hz),6.84(1H,brs),7.03(2H,d,J=9.3Hz),7.41(1H,dd,J=1.9Hz,8.3Hz),7.53(1H,d,J=2.0Hz),7.56(1H,d,J=8.3Hz),8.03(2H,d,J=8.8Hz),8.2-8.4(1H,m),12.77(1H,brs)
MS(m/z):455(M+)。
5-メチルピリジン-2-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.37(3H,s),2.3-2.5(1H,m),4.32(2H,d,J=5.9Hz),7.20(1H,brs),7.42(1H,dd,J=1.9Hz,8.3Hz),7.5-7.6(2H,m),7.76(1H,dd,J=2.4Hz,8.3Hz),8.14(1H,d,J=8.3Hz),8.3-8.4(1H,m),8.57(1H,d,J=2.4Hz)
MS(m/z):396(M+)。
6-(トリフルオロメチル)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロベンジル)シクロプロパンカルボキサミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.6-0.8(4H,m),1.5-1.7(1H,m),4.35(2H,d,J=6.4Hz),7.25(1H,brs),7.4-7.7(3H,m),8.03(1H,d,J=8.3Hz),8.5-8.8(2H,m),9.41(1H,s),13.13(1H,brs)
MS(m/z):448(M+)。
4-(ジフルオロメチル)ベンズアルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.44(1H,sept,J=6.8Hz),4.32(2H,d,J=6.4Hz),7.03(1H,brs),7.10(1H,t,J=56.0Hz),7.42(1H,dd,J=2.4Hz,8.3Hz),7.56(1H,d,J=2.0Hz),7.58(1H,d,J=8.3Hz),7.68(2H,d,J=8.3Hz),8.21(2H,d,J=8.3Hz),8.3-8.4(1H,m),12.96(1H,brs)
MS(m/z):431(M+)。
5-(トリフルオロメチル)チオフェン-2-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.44(1H,sept,J=6.8Hz),4.31(2H,d,J=6.3Hz),7.12(1H,brs),7.43(1H,dd,J=2.4Hz,8.3Hz),7.52(1H,d,J=2.0Hz),7.58(1H,d,J=8.3Hz),7.68(1H,dd,J=1.2Hz,4.2Hz),8.04(1H,dd,J=1.5Hz,3.9Hz),8.3-8.4(1H,m),13.01(1H,brs)
MS(m/z):455(M+)。
2-(トリフルオロメチル)チアゾール-5-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),4.31(2H,d,J=5.9Hz),7.24(1H,brs),7.44(1H,dd,J=1.9Hz,8.4Hz),7.52(1H,d,J=1.9Hz),7.58(1H,d,J=8.3Hz),8.2-8.4(1H,m),8.91(1Hs),13.15(1H,brs)
MS(m/z):456(M+)。
2-フルオロ-4-メチルベンズアルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),2.37(3H,s),2.3-2.5(1H,m),4.31(2H,d,J=5.9Hz),6.74(1H,brs),7.14(1H,d,J=7.8Hz),7.19(1H,d,J=12.7Hz),7.41(1H,dd,J=2.4Hz,8.3Hz),7.54(1H,d,J=1.9Hz),7.57(1H,d,J=8.3Hz),7.92(1H,t,J=8.1Hz),8.2-8.4(1H,m),12.93(1H,brs)
MS(m/z):413(M+)。
6-(ジフルオロメトキシ)ピリジン-3-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),4.31(2H,d,J=5.8Hz),7.08(1H,brs),7.20(1H,d,J=8.8Hz),7.42(1H,dd,J=1.9Hz,8.3Hz),7.5-7.6(2H,m),7.77(1H,t,J=73.0Hz),8.2-8.4(1H,m),8.53(1H,dd,J=2.5Hz,8.3Hz),8.95(1H,d,J=2.0Hz),12.97(1H,brs)
MS(m/z):448(M+)。
4-(2-エトキシエトキシ)-3-フルオロベンズアルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),1.13(3H,t,J=7.1Hz),2.44(1H,sept,J=6.8Hz),3.52(2H,q,J=7.0Hz),3.7-3.8(2H,m),4.2-4.3(2H,m),4.32(2H,d,J=6.4Hz),6.94(1H,brs),7.27(1H,t,J=8.8Hz),7.42(1H,dd,J=2.0Hz,8.3Hz),7.54(1H,d,J=2.0Hz),7.57(1H,d,J=8.3Hz),7.8-8.0(2H,m),8.2-8.4(1H,m),12.80(1H,brs)
MS(m/z):487(M+)。
4-(2-エトキシエトキシ)-2-フルオロベンズアルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),1.13(3H,t,J=7.1Hz),2.43(1H,sept,J=6.8Hz),3.50(2H,q,J=7.0Hz),3.6-3.8(2H,m),4.1-4.3(2H,m),4.31(2H,d,J=5.9Hz),6.70(1H,brs),6.91(1H,dd,J=2.5Hz,8.8Hz),6.99(1H,dd,J=2.4Hz,14.2Hz),7.41(1H,dd,J=2.0Hz,8.3Hz),7.54(1H,d,J=2.4Hz),7.56(1H,d,J=8.3Hz), 8.00(1H,t,J=9.3Hz),8.2-8.4(1H,m),12.84(1H,brs)
MS(m/z):487(M+)。
6-イソプロポキシピリジン-3-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),1.31(6H,d,J=5.9Hz),2.43(1H,sept,J=6.8Hz),4.31(2H,d,J=5.8Hz),5.32(1H,quin,J=6.4Hz),6.83(1H,d,J=8.3Hz),6.94(1H,brs),7.41(1H,dd,J=1.9Hz,8.3Hz),7.55(1H,d,J=1.9Hz),7.57(1H,d,J=8.3Hz),8.30(1H,dd,J=2.5Hz,8.8Hz),8.34(1H,d,J=6.3Hz),8.86(1H,d,J=2.5Hz),12.84(1H,brs)
MS(m/z):440(M+)。
6-(2,2,2-トリフルオロエトキシ)ピリジン-3-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),4.31(2H,d,J=6.3Hz),5.07(2H,q,J=9.1Hz),7.02(1H,brs),7.09(1H,d,J=8.8Hz),7.42(1H,dd,J=2.5Hz,8.3Hz),7.5-7.6(2H,m), 8.2-8.4(1H,m),8.44(1H,dd,J=2.4Hz,8.3Hz),8.91(1H,d,J=2.5Hz),12.91(1H,brs)
MS(m/z):480(M+)。
1-tert-ブチル-1H-ピラゾール-4-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),1.54(9H,s),2.43(1H,sept,J=6.8Hz),4.30(2H,d,J=5.8Hz),6.66(1H,brs),7.39(1H,dd,J=2.0Hz,8.3Hz),7.47(1H,d,J=2.0Hz),7.54(1H,d,J=8.3Hz),8.01(1H,s),8.3-8.4(2H,m),12.44(1H,brs)
MS(m/z):427(M+)。
1-イソブチル-1H-ピラゾール-4-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.84(6H,d,J=6.8Hz),1.03(6H,d,J=6.8Hz),2.12(1H,sept,J=6.8Hz),2.43(1H,sept,J=6.8Hz),3.93(2H,d,J=7.3Hz),4.30(2H,d,J=5.9Hz),6.62(1H,brs),7.39(1H,dd,J=1.9Hz,8.3Hz),7.48(1H,d,J=2.0Hz),7.54(1H,d,J=8.3Hz),8.02(1H,s),8.28(1H,s),8.3-8.4(1H,m),12.61(1H,brs)
MS(m/z):427(M+)。
2-メトキシチアゾール-5-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),4.06(3H,s),4.30(2H,d,J=5.9Hz),6.83(1H,brs),7.41(1H,dd,J=2.0Hz,8.3Hz),7.47(1H,d,J=1.9Hz),7.57(1H,d,J=8.3Hz),8.05(1H,s),8.3-8.4(1H,m),12.85(1H,brs)
MS(m/z):418(M+)。
6-(トリフルオロメチル)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロベンジル)-3,3,3-トリフルオロ-2,2-ジメチルプロピオンアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.38(6H,s),4.37(2H,d,J=5.9Hz),7.25(1H,s),7.41(1H,dd,J=1.9Hz,8.3Hz),7.57(1H,d,J=1.9Hz),7.60(1H,d,J=8.3Hz),8.03(1H,d,J=8.3Hz),8.5-8.7(1H,m),8.69(1H,dd,J=1.9Hz,8.3Hz),9.41(1H,d,J=1.5Hz),13.11(1H,brs)
MS(m/z):518(M+)。
6-メトキシピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロベンジル)-3,3,3-トリフルオロ-2,2-ジメチルプロピオンアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.38(6H,s),3.92(3H,s),4.37(2H,d,J=5.9Hz),6.91(1H,d,J=8.8Hz),6.96(1H,brs),7.40(1H,dd,J=2.0Hz,8.3Hz),7.5-7.6(1H,m),7.58(1H,d,J=8.3Hz),8.34(1H,dd,J=2.0Hz,8.8Hz),8.5-8.7(1H,m),8.89(1H,d,J=1.9Hz),12.87(1H,brs)
MS(m/z):480(M+)。
6-(ジフルオロメトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロベンジル)-3,3,3-トリフルオロ-2,2-ジメチルプロピオンアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.38(6H,s),4.37(2H,d,J=6.4Hz),7.08(1H,brs),7.20(1H,d,J=8.8Hz),7.40(1H,dd,J=1.9Hz,8.3Hz),7.5-7.7(2H,m),7.77(1H,t,J=72.5Hz),8.54(1H,dd,J=2.5Hz,8.8Hz),8.5-8.7(1H,m),8.95(1H,d,J=2.0Hz),12.95(1H,brs)
MS(m/z):516(M+)。
6-(トリフルオロメチル)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-フルオロベンジル)-2,2-ジメチルプロピオンアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.14(9H,s),4.32(2H,d,J=6.3Hz),7.23(1H,s),7.3-7.5(2H,m),7.6-7.8(1H,m),8.04(1H,d,J=8.3Hz),8.1-8.2(1H,m),8.71(1H,dd,J=1.4Hz,7.8Hz),9.43(1H,d,J=1.5Hz),12.95(1H,brs)
MS(m/z):448(M+)。
6-(ジフルオロメトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-フルオロベンジル)-2,2-ジメチルプロピオンアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.14(9H,s),4.32(2H,d,J=5.9Hz),7.08(1H,brs),7.22(1H,d,J=9.3Hz),7.3-7.5(2H,m),7.72(1H,d,J=5.3Hz),7.79(1H,t,J=72.6Hz),8.1-8.3(1H,m),8.57(1H,dd,J=2.4Hz,8.8Hz),8.99(1H,d,J=2.5Hz),12.85(1H,brs)
MS(m/z):446(M+)。
6-(トリフルオロメチル)ピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(ジフルオロメトキシ)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),4.32(2H,d,J=6.3Hz),7.20(1H,t,J=73.5Hz),7.21(1H,brs),7.30(1H,d,J=8.3Hz),7.49(1H,dd,J=2.5Hz,8.8Hz),7.66(1H,d,J=1.9Hz),8.03(1H,d,J=8.3Hz),8.2-8.4(1H,m),8.70(1H,dd,J=1.9Hz,8.3Hz),9.40(1H,d,J=1.4Hz),12.92(1H,brs)
MS(m/z):482(M+)。
6-(2-エトキシエトキシ)ピリジン-3-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),1.12(3H,t,J=7.1Hz),2.43(1H,sept,J=6.8Hz),3.49(2H,q,J=7.0Hz),3.6-3.8(2H,m),4.31(2H,d,J=5.8Hz),4.4-4.5(2H,m),6.93(1H,d,J=8.7Hz),6.96(1H,brs),7.41(1H,dd,J=1.9Hz,8.3Hz),7.55(1H,d,J=1.9Hz),7.57(1H,d,J=8.3Hz),8.2-8.4(2H,m),8.87(1H,d,J=2.4Hz),12.86(1H,brs)
MS(m/z):470(M+)。
6-(3-メトキシプロポキシ)ピリジン-3-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),1.97(2H,quin,J=6.5Hz),2.43(1H,sept,J=6.8Hz),3.24(3H,s),3.47(2H,q,J=6.4Hz),4.31(2H,d,J=5.8Hz),4.37(2H,t,J=6.6Hz),6.89(1H,d,J=8.7Hz),6.95(1H,brs),7.41(1H,dd,J=2.4Hz,8.3Hz),7.55(1H,d,J=2.4Hz),7.57(1H,d,J=8.3Hz),8.2-8.4(2H,m),8.87(1H,d,J=2.4Hz),12.81(1H,brs)
MS(m/z):470(M+)。
6-(2-メトキシエトキシ)ピリジン-3-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),3.30(3H,s),3.6-3.8(2H,m),4.31(2H,d,J=6.3Hz),4.4-4.5(2H,m),6.92(1H,d,J=8.3Hz),6.96(1H,brs),7.41(1H,dd,J=2.4Hz,8.3Hz),7.55(1H,d,J=1.9Hz),7.57(1H,d,J=8.3Hz),8.2-8.4(2H,m),8.87(1H,d,J=2.4Hz),12.85(1H,brs)
MS(m/z):456(M+)。
3-フルオロベンズアルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=7.2Hz),2.43(1H,sept,J=6.8Hz),4.32(2H,d,J=6.0Hz),7.03(1H,s),7.3-7.4(1H,m),7.4-7.5(1H,m),7.5-7.6(3H,m),7.88(1H,d,J=10.0Hz),7.94(1H,d,J=8.0Hz),8.3-8.4(1H,m),12.96(1H,s)
MS(m/z):399(M+)。
4-(ピリジン-2-イルエチニル)ベンズアルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.44(1H,sept,J=6.8Hz),4.32(2H,d,J=6.0Hz),7.03(1H,s),7.4-7.5(2H,m),7.5-7.6(2H,m),7.6-7.8(3H,m),7.87(1H,ddd,J=1.6Hz,7.6Hz,7.6Hz),8.17(2H,d,J=8.0Hz),8.35(1H,t,J=6.0Hz),8.6-8.7(1H,m),12.96(1H,s)
MS(m/z):482(M+)。
2-フルオロ-3-オキソ-3-フェニルプロパン酸エチルを用い、実施例23と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),4.30(2H,d,J=6.0Hz),7.42(1H,dd,J=2.0Hz,8.4Hz),7.5-7.6(5H,m),7.9-8.0(2H,m),8.34(1H,t,J=6.0Hz),13.47(1H,s)
MS(m/z):399(M+)。
2-フルオロ-3-(4-メトキシフェニル)-3-オキソプロパン酸エチルを用い、実施例23と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),2.3-2.6(1H,m),3.83(3H,s),4.30(2H,d,J=5.6Hz),7.0-7.1(2H,m),7.41(1H,dd,J=2.4Hz,8.4Hz),7.5-7.6(2H,m),7.95(2H,d,J=8.8Hz),8.33(1H,t,J=6.0Hz),13.35(1H,s)
MS(m/z):429(M+)。
2-フルオロ-3-オキソ-3-(チオフェン-2-イル)プロパン酸エチルを用い、実施例23と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),4.31(2H,d,J=6.4Hz),7.28(1H,dd,J=4.0Hz,4.8Hz),7.43(1H,dd,J=2.0Hz,8.4Hz),7.51(1H,d,J=2.0Hz),7.57(1H,d,J=8.4Hz),7.83(1H,d,J=4.0Hz),7.91(1H,dd,J=0.8Hz,4.8Hz),8.34(1H,t,J=6.0Hz),13.38(1H,s)
MS(m/z):405(M+)。
2-フルオロ-3-オキソ-3-(チオフェン-3-イル)プロパン酸エチルを用い、実施例23と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),4.30(2H,d,J=5.6Hz),7.41(1H,dd,J=2.4Hz,8.4Hz),7.53(1H,d,J=2.0Hz),7.57(1H,d,J=8.4Hz),7.65(1H,d,J=4.8Hz),7.72(1H,dd,J=2.8Hz,4.8Hz),8.25(1H,d,J=2.0Hz),8.34(1H,t,J=6.0Hz),13.36(1H,s)
MS(m/z):405(M+)。
ベンゾ[b]チオフェン-7-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),2.46(1H,sept,J=6.8Hz),4.35(2H,d,J=6.4Hz),7.11(1H,s),7.45(1H,dd,J=2.0Hz,8.4Hz),7.5-7.6(2H,m),7.60(1H,d,J=8.4Hz),7.65(1H,d,J=2.0Hz),7.74(1H,d,J=5.6Hz),8.0-8.1(2H,m),8.36(1H,t,J=6.0Hz),13.03(1H,s)
MS(m/z):437(M+)。
4-シアノベンズアルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),4.31(2H,d,J=6.0Hz),7.11(1H,s),7.4-7.5(1H,m),7.5-7.6(2H,m),7.95(2H,d,J=8.0Hz),8.30(2H,d,J=8.4Hz),8.34(1H,t,J=6.0Hz),13.05(1H,s)
MS(m/z):406(M+)。
4-(メチルスルファニル)ベンズアルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),2.52(3H,s),4.31(2H,d,J=6.0Hz),6.91(1H,s),7.34(2H,d,J=8.8Hz),7.42(1H,dd,J=2.0Hz,8.4Hz),7.5-7.6(2H,m),8.02(2H,d,J=8.4Hz),8.34(1H,t,J=6.0Hz),12.84(1H,s)
MS(m/z):427(M+)。
4-メチルベンズアルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),2.36(3H,s),2.3-2.6(1H,m),4.31(2H,d,J=6.0Hz),6.88(1H,s),7.29(2H,d,J=8.0Hz),7.41(1H,dd,J=2.0Hz,8.4Hz),7.5-7.6(2H,m),7.97(2H,d,J=8.4Hz), 8.34(1H,t,J=6.0Hz),12.83(1H,s)
MS(m/z):395(M+)。
N,N-ジエチル-4-ホルミルベンゼンスルホンアミドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.0-1.1(12H,m),2.3-2.6(1H,m),3.19(4H,q,J=7.2Hz),4.31(2H,d,J=6.4Hz),7.07(1H,s),7.42(1H,dd,J=2.4Hz,8.4Hz),7.5-7.6(2H,m),7.88(2H,d,J=8.0Hz),8.27(2H,d,J=8.8Hz),8.34(1H,t,J=6.0Hz),13.02(1H,s)
MS(m/z):516(M+)。
4-(ピペリジン-1-イルスルホニル)ベンズアルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=7.2Hz),1.3-1.4(2H,m),1.5-1.6(4H,m),2.3-2.6(1H,m),2.9-3.0(4H,m),4.31(2H,d,J=5.6Hz),7.09(1H,s),7.43(1H,dd,J=2.8Hz,8.4Hz),7.5-7.6(2H,m),7.81(2H,d,J=8.8Hz),8.3-8.4(3H,m),13.05(1H,s)
MS(m/z):529(M++1) 。
4-シクロプロピルベンズアルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.7-0.8(2H,m),1.0-1.1(8H,m),1.9-2.0(1H,m),2.43(1H,sept,J=6.8Hz),4.31(2H,d,J=5.6Hz),6.87(1H,s),7.17(2H,d,J=8.4Hz),7.41(1H,dd,J=2.0Hz,8.4Hz),7.5-7.6(2H,m),7.95(2H,d,J=8.4Hz),8.33(1H,t,J=6.0Hz),12.80(1H,s)
MS(m/z):421(M+)。
6-(トリフルオロメチル)ピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),2.4-2.6(1H,m),4.40(2H,d,J=6.0Hz),7.26(1H,s),7.6-7.7(2H,m),7.90(1H,d,J=8.4Hz),8.03(1H,d,J=8.0Hz),8.40(1H,t,J=6.0Hz),8.66(1H,d,J=8.0Hz),9.39(1H,s),13.23(1H,s)
MS(m/z):484(M+)。
6-メトキシピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),2.4-2.6(1H,m),3.91(3H,s),4.40(2H,d,J=6.0Hz),6.91(1H,d,J=8.8Hz),6.98(1H,s),7.5-7.6(2H,m),7.88(1H,d,J=8.4Hz),8.31(1H,dd,J=2.0Hz,8.4Hz),8.39(1H,t,J=6.0Hz),8.87(1H,s),12.97(1H,s)
MS(m/z):446(M+)。
6-(ジフルオロメトキシ)ピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),2.4-2.6(1H,m),4.40(2H,d,J=6.0Hz),7.10(1H,s),7.20(1H,d,J=8.8Hz),7.61(2H,dd,J=4.4Hz,12.8Hz),7.77(1H,t,J=72.4Hz),7.89(1H,d,J=8.4Hz),8.39(1H,t,J=6.0Hz),8.51(1H,d,J=8.4Hz),8.93(1H,s),13.09(1H,s)
MS(m/z):482(M+)。
6-エトキシピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=7.2Hz),1.33(3H,t,J=7.6Hz),2.4-2.6(1H,m),4.3-4.4(4H,m),6.88(1H,d,J=8.8Hz),6.97(1H,s),7.6-7.7(2H,m),7.88(1H,d,J=7.6Hz),8.30(1H,dd,J=2.4Hz,8.8Hz),8.39(1H,t,J=6.0Hz),8.85(1H,d,J=2.4Hz),12.93(1H,s)
MS(m/z): 460(M+)。
6-(トリフルオロメチル)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-メチルベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),2.3-2.6(4H,m),4.29(2H,d,J=6.0Hz),7.19(1H,s),7.32(2H,s),7.44(1H,s),8.03(1H,d,J=8.4Hz),8.24(1H,t,J=6.0Hz),8.70(1H,dd,J=1.2Hz,8.4Hz),9.41(1H,s),12.90(1H,s)
MS(m/z):430(M+)。
6-(ジフルオロメトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-メチルベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),2.3-2.6(4H,m),4.29(2H,d,J=5.6Hz),7.02(1H,s),7.20(1H,d,J=8.8Hz),7.31(2H,s),7.43(1H,s),7.77(1H,t,J=72.8Hz),8.24(1H,t,J=5.6Hz),8.55(1H,dd,J=2.4Hz,8.8Hz),8.95(1H,d,J=2.0Hz),12.77(1H,s)
MS(m/z):428(M+)。
6-エトキシピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-メチルベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),1.34(3H,t,J=6.8Hz),2.3-2.6(4H,m),4.28(2H,d,J=6.0Hz),4.37(2H,q,J=6.8Hz),6.87(1H,s),6.89(1H,s),7.30(2H,s),7.42(1H,s),8.24(1H,t,J=6.0Hz),8.33(1H,dd,J=2.4Hz,8.8Hz),8.87(1H,d,J=2.4Hz)12.64(1H,s)
MS(m/z):406(M+)。
6-(トリフルオロメチル)ピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(ジフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),2.4-2.6(1H,m),4.39(2H,d,J=6.0Hz),7.26(1H,s),7.4-7.7(2H,m),7.80(1H,d,J=8.0Hz),8.05(1H,d,J=8.4Hz),8.34(1H,t,J=5.6Hz),8.72(1H,d,J=7.2Hz),9.44(1H,s),13.17(1H,s)
MS(m/z):466(M+)。
6-(ジフルオロメトキシ)ピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(ジフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),2.45(1H,sept,J=6.8Hz),4.38(2H,d,J=6.0Hz),7.09(1H,s),7.22(2H,d,J=8.0Hz),7.4-8.0(4H,m),8.33(1H,t,J=6.0Hz),8.58(1H,d,J=8.4Hz),8.99(1H,s),13.04(1H,s)
MS(m/z):464(M+)。
2-(トリフルオロメチル)ピリジン-4-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),4.32(2H,d,J=6.0Hz),7.36(1H,s),7.44(1H,dd,J=2.0Hz,8.4Hz),7.5-7.6(2H,m),8.3-8.4(2H,m),8.45(1H,s),8.91(1H,d,J=5.6Hz),13.19(1H,s)
MS(m/z):450(M+)。
2-(ジフルオロメトキシ)ピリジン-4-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=7.6Hz),2.44(1H,sept,J=6.8Hz),4.32(2H,d,J=6.0Hz),7.22(1H,s),7.43(1H,dd,J=1.2Hz,8.4Hz),7.58(2H,d,J=8.8Hz),7.68(1H,s),7.75(1H,t,J=72.8Hz),7.90(1H,d,J=5.6Hz),8.34(1H,t,J=6.0Hz),8.39(1H,d,J=5.2Hz),13.14(1H,s)
MS(m/z):448(M+)。
3-フルオロ-4-メトキシベンズアルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=7.2Hz),2.43(1H,sept,J=6.8Hz),3.91(3H,s),4.31(2H,d,J=6.0Hz),6.93(1H,s),7.26(1H,t,J=8.8Hz),7.42(1H,dd,J=2.0Hz,8.0Hz),7.54(1H,d,J=1.6Hz),7.57(1H,d,J=8.0Hz),7.9-8.0(2H,m),8.34(1H,t,J=6.0Hz),12.84(1H,s)
MS(m/z):429(M+)。
4-ホルミル-N,N-ジメチルベンズアミドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),2.92(3H,s),3.00(3H,s),4.32(2H,d,J=5.6Hz),6.99(1H,s),7.42(1H,dd,J=1.6Hz,8.0Hz),7.49(2H,d,J=8.4Hz),7.55(1H,d,J=1.6Hz),7.57(1H,d,J=8.4Hz),8.13(2H,d,J=8.4Hz),8.34(1H,t,J=5.6Hz),12.95(1H,s)
MS(m/z):452(M+)。
4-フルオロベンズアルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),4.31(2H,d,J=6.0Hz),6.95(1H,s),7.2-7.4(2H,m),7.42(1H,dd,J=2.0Hz,8.0Hz),7.54(1H,d,J=1.6Hz),7.57(1H,d,J=8.4Hz),8.1-8.2(2H,m),8.34(1H,t,J=6.0Hz),12.91(1H,s)
MS(m/z):399(M+)。
6-メトキシピリジン-2-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=7.2Hz),2.44(1H,sept,J=6.8Hz),3.98(3H,s),4.32(2H,d,J=6.4Hz),6.9-7.0(1H,m),7.24(1H,s),7.42(1H,dd,J=2.0Hz,8.4Hz),7.55(1H,d,J=2.0Hz),7.58(1H,d,J=8.0Hz),7.8-7.9(2H,m),8.34(1H,t,J=6.4Hz),12.96(1H,s)
MS(m/z):412(M+)。
6-(トリフルオロメチル)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.44(1H,sept,J=6.8Hz),4.32(2H,d,J=5.6Hz),7.23(1H,s),7.3-7.4(1H,m),7.4-7.5(1H,m),7.74(1H,d,J=5.6Hz),8.04(1H,d,J=8.0Hz),8.34(1H,t,J=6.0Hz),8.72(1H,dd,J=1.2Hz,8.4Hz),9.44(1H,d,J=1.6Hz),12.97(1H,s)
MS(m/z):434(M+)。
6-シクロプロピルピリジン-3-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.9-1.1(4H,m),1.03(6H,d,J=6.8Hz),2.1-2.2(1H,m),2.43(1H,sept,J=6.8Hz),4.31(2H,d,J=6.0Hz),6.99(1H,s),7.39(1H,d,J=8.4Hz),7.43(1H,d,J=2.0Hz),7.55(1H,d,J=1.2Hz),7.57(1H,d,J=8.4Hz),8.25(1H,dd,J=2.0Hz,8.4Hz),8.33(1H,t,J=6.0Hz),9.06(1H,d,J=1.6Hz),12.91(1H,s)
MS(m/z):422(M+)。
6-エトキシピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=7.6Hz),1.34(3H,t,J=7.2Hz),2.44(1H,sept,J=6.8Hz),4.32(2H,d,J=6.0Hz),4.38(2H,q,J=7.2Hz),6.89(1H,d,J=8.8Hz),6.94(1H,s),7.3-7.4(1H,m),7.4-7.5(1H,m),7.73(1H,d,J=5.6Hz),8.3-8.4(2H,m),8.92(1H,d,J=2.0Hz),12.72(1H,s)
MS(m/z):410(M+)。
2-メトキシピリミジン-5-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),3.99(3H,s),4.31(2H,d,J=6.0Hz),7.07(1H,s),7.42(1H,dd,J=1.6Hz,8.0Hz),7.5-7.6(2H,m),8.33(1H,t,J=6.0Hz),9.22(2H,s),12.98(1H,s)
MS(m/z):413(M+)。
6-(ジフルオロメトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),4.32(2H,d,J=6.0Hz),7.07(1H,s),7.22(1H,d,J=9.6Hz),7.3-7.4(1H,m),7.4-7.5(1H,m),7.74(1H,d,J=5.6Hz),7.78(1H,t,J=72.0Hz),8.34(1H,t,J=6.0Hz),8.57(1H,dd,J=2.4Hz,8.8Hz),8.99(1H,d,J=2.4Hz),12.84(1H,s)
MS(m/z):433(M++1) 。
6-(トリフルオロメチル)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.45(1H,sept,J=6.8Hz),4.33(2H,d,J=6.0Hz),7.30(1H,s),7.4-7.6(2H,m),8.02(1H,d,J=8.4Hz),8.36(1H,t,J=5.6Hz),8.67(1H,d,J=8.4Hz),9.39(1H,s),13.37(1H,s)
MS(m/z):468(M+)。
6-(ジフルオロメトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.45(1H,sept,J=6.8Hz),4.32(2H,d,J=6.0Hz),7.13(1H,s),7.19(1H,d,J=8.4Hz),7.4-7.6(2H,m),7.77(1H,t,J=72.4Hz),8.36(1H,t,J=6.0Hz),8.51(1H,dd,J=2.0Hz,8.8Hz),8.93(1H,s),13.22(1H,s)
MS(m/z):466(M+)。
6-(トリフルオロメチル)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-フルオロベンジル)-1-(トリフルオロメチル)シクロプロパン-1-カルボキサミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.2-1.4(4H,m),4.35(2H,d,J=5.6Hz),7.23(1H,s),7.3-7.4(1H,m),7.4-7.5(1H,m),7.75(1H,d,J=5.6Hz),8.04(1H,d,J=8.0Hz),8.46(1H,t,J=6.0Hz),8.72(1H,d,J=8.4Hz),9.44(1H,s),12.99(1H,s)
MS(m/z):500(M+)。
4-ホルミル安息香酸メチルを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),3.88(3H,s),4.31(2H,d,J=6.4Hz),7.06(1H,s),7.42(1H,dd,J=2.0Hz,8.4Hz),7.55(1H,d,J=2.0Hz),7.58(1H,d,J=8.4Hz),8.04(2H,d,J=8.4Hz),8.20(2H,d,J=8.4Hz),8.34(1H,t,J=6.0Hz),13.00(1H,s)
MS(m/z):439(M+)。
6-(ジフルオロメトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-フルオロベンジル)-1-(トリフルオロメチル)シクロプロパン-1-カルボキサミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.2-1.4(4H,m),4.35(2H,d,J=6.0Hz),7.08(1H,s),7.22(1H,d,J=8.8Hz),7.3-7.4(1H,m),7.4-7.5(1H,m),7.75(1H,d,J=6.4Hz),7.78(1H,t,J=72.0Hz),8.46(1H,t,J=6.0Hz),8.58(1H,dd,J=2.4Hz,8.8Hz),9.00(1H,d,J=2.4Hz),12.84(1H,s)
MS(m/z):498(M+)。
6-(トリフルオロメチル)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-2,4-ジフルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.45(1H,sept,J=6.8Hz),4.32(2H,d,J=6.0Hz),7.2-7.4(2H,m),7.4-7.6(1H,m),8.03(1H,d,J=8.4Hz),8.33(1H,t,J=6.0Hz),8.67(1H,d,J=8.4Hz),9.39(1H,s),13.37(1H,s)
MS(m/z):452(M+)。
6-(2-プロポキシエトキシ)ピリジン-3-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.85(3H,t,J=7.3Hz),1.03(6H,d,J=6.8Hz),1.4-1.6(2H,m),2.43(1H,sept,J=6.8Hz),3.40(2H,t,J=6.6Hz),3.6-3.8(2H,m),4.31(2H,d,J=5.8Hz),4.4-4.5(2H,m),6.92(1H,d,J=8.8Hz),6.96(1H,brs),7.41(1H,dd,J=1.9Hz,8.3Hz),7.5-7.7(2H,m),8.2-8.4(2H,m),8.87(1H,d,J=2.4Hz),12.84(1H,brs)
MS(m/z):484(M+)。
6-(2-ブトキシエトキシ)ピリジン-3-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.85(3H,t,J=7.3Hz),1.03(6H,d,J=6.8Hz),1.2-1.4(2H,m),1.4-1.6(2H,m),2.43(1H,sept,J=6.8Hz),3.44(2H,t,J=6.6Hz),3.6-3.8(2H,m),4.31(2H,d,J=5.8Hz),4.4-4.5(2H,m),6.92(1H,d,J=8.8Hz),6.96(1H,brs),7.41(1H,dd,J=1.9Hz,8.3Hz),7.5-7.7(2H,m),8.2-8.4(2H,m),8.87(1H,d,J=2.0Hz),12.87(1H,brs)
MS(m/z):498(M+)。
2-(トリフルオロメチル)ピリミジン-5-カルボキシアルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),4.32(2H,d,J=6.0Hz),7.34(1H,s),7.44(1H,dd,J=2.0Hz,8.0Hz),7.5-7.6(2H,m),8.34(1H,t,J=6.0Hz),9.26(2H,s),13.21(1H,s)
MS(m/z):451(M+)。
1H-NMR(CDCl3,δ):1.1-1.3(3H,m),2.0-2.2(2H,m),3.4-3.7(4H,m),4.5-4.7(2H,m),6.83(1H,d,J=8.3Hz),8.06(1H,dd,J=2.4Hz,8.8Hz),8.62(1H,d,J=1.4Hz),9.95(1H,s)
MS(m/z):209(M+) 。
1H-NMR(CDCl3,δ):0.3-0.7(4H,m),1.2-1.4(1H,m),4.24(2H,d,J=7.3Hz),6.86(1H,d,J=8.3Hz),8.06(1H,dd,J=2.5Hz,8.8Hz),8.60(1H,d,J=2.5Hz),9.95(1H,s)。
参考例49:6-[2-(2-ブトキシエトキシ)エトキシ]ピリジン-3-カルバルデヒド
1H-NMR(CDCl3,δ):0.91(3H,t,J=7.3Hz),1.3-1.7(4H,m),3.4-4.0(8H,m),4.5-4.7(2H,m),6.88(1H,d,J=8.8Hz),8.06(1H,dd,J=2.0Hz,8.3Hz),8.60(1H,d,J=2.4Hz),9.95(1H,s)
MS(m/z):267(M+) 。
1H-NMR(CDCl3,δ):5.61(2H,s),6.98(1H,d,J=8.3Hz),7.2-7.3(1H,m),7.45(1H,d,J=7.8Hz),7.71(1H,dt,J=2.0Hz,7.8Hz),8.11(1H,dd,J=2.4Hz,8.8Hz),8.6-8.7(2H,m),9.97(1H,s)
MS(m/z):214(M+) 。
1H-NMR(CDCl3,δ):2.57(3H,s),5.47(2H,s),6.88(1H,d,J=8.8Hz),7.18(1H,d,J=8.3Hz),7.69(1H,dd,J=2.5Hz,7.9Hz),8.09(1H,dd,J=2.4Hz,8.3Hz),8.5-8.7(2H,m),9.97(1H,s)
MS(m/z):228(M+) 。
1H-NMR(CDCl3,δ):0.91(3H,t,J=7.3Hz),1.2-1.5(4H,m),1.6-1.9(2H,m),3.95(2H,t,J=7.8Hz),6.56(1H,dd,J=1.5Hz,6.8Hz),6.99(1H,d,J=2.0Hz),7.37(1H,d,J=6.8Hz),9.88(1H,d,J=0.9Hz)
MS(m/z):193(M+) 。
1H-NMR(CDCl3,δ):0.97(3H,t,J=7.3Hz),1.3-1.5(2H,m),1.6-1.9(2H,m),3.96(2H,t,J=7.3Hz),6.56(1H,dd,J=2.0Hz,7.3Hz),7.00(1H,d,J=1.5Hz),7.38(1H,d,J=7.3Hz),9.87(1H,s)
MS(m/z):179(M+) 。
1H-NMR(CDCl3,δ):1.19(3H,t,J=7.3Hz),2.29(2H,q,J=7.3Hz),4.44(2H,d,J=5.8Hz),5.95(1H,brs),7.4-7.6(2H,m),7.57(1H,s)
MS(m/z):222(M+)。
1H-NMR(CDCl3,δ):0.96(3H,t,J=7.3Hz),1.6-1.8(2H,m),2.23(2H,t,J=7.8Hz),4.44(2H,d,J=5.8Hz),5.95(1H,brs),7.4-7.6(2H,m),7.57(1H,s)
MS(m/z):236(M+)。
1H-NMR(CDCl3,δ):1.21(3H,t,J=7.3Hz),3.52(2H,q,J=6.8Hz),3.5-4.0(10H,m),4.5-4.7(2H,m),6.88(1H,d,J=8.8Hz),8.06(1H,dd,J=2.5Hz,8.8Hz),8.60(1H,d,J=1.9Hz),9.95(1H,s)
MS(m/z):283(M+) 。
1H-NMR(CDCl3,δ):2.59(3H,s),5.57(2H,s),6.97(1H,d,J=8.8Hz),7.10(1H,d,J=7.8Hz),7.23(1H,d,J=7.3Hz),7.59(1H,t,J=7.9Hz),8.10(1H,dd,J=2.4Hz,8.8Hz),8.63(1H,d,J=2.4Hz),9.96(1H,s)
MS(m/z):228(M+) 。
1H-NMR(CDCl3,δ):1.1-1.3(2H,m),4.4-4.7(3H,m),4.70(1H,t,J=5.4Hz),6.84(1H,d,J=8.8Hz),8.08(1H,dd,J=2.5Hz,8.8Hz),8.62(1H,d,J=2.0Hz),9.96(1H,s)
MS(m/z):183(M+) 。
得られた化合物をテトラヒドロフラン75mL、水3mLに溶解し、氷冷下でトリフェニルホスフィン9.62gを加え、室温で一晩撹拌した。1N-塩酸を加え、ジエチルエーテルで洗浄した。1N-水酸化ナトリウム水溶液を加え、ジクロロメタンで抽出した後、硫酸マグネシウムで乾燥させ、得られた有機層をそのまま次の反応に用いた。
1H-NMR(CDCl3,δ):1.17(6H,d,J=6.8Hz),2.40(1H,sept,J=6.8Hz),4.50(2H,d,J=6.4Hz),5.98(1H,s),7.13(1H,t,J=8.8Hz),7.6-7.7(1H,m)
MS(m/z):254(M+)。
1H-NMR(d6-DMSO,δ):7.38(1H,s),7.87(1H,d,J=8.4Hz),8.04(1H,d,J=8.4Hz),8.10(1H,t,J=7.6Hz),8.65(1H,d,J=7.6Hz),9.38(1H,s),13.44(1H,brs)
MS(m/z):437(M+)。
1H-NMR(d6-DMSO,δ):7.2-7.3(2H,m),7.77(1H,t,J=72.8Hz),7.86(1H,d,J=8.8Hz),8.09(1H,t,J=8.0Hz),8.50(1H,dd,J=2.4Hz,8.8Hz),8.92(1H,d,J=2.0Hz),13.30(1H,brs)
MS(m/z):435(M+)。
1H-NMR(d6-DMSO,δ):1.12(3H,t,J=6.8Hz),3.49(2H,q,J=6.8Hz),3.71(2H,t,J=5.2Hz),4.43(2H,t,J=5.2Hz),6.94(1H,d,J=8.8Hz),7.06(1H,s),7.85(1H,d,J=8.0Hz),8.08(1H,t,J=8.0Hz),8.30(1H,d,J=7.2Hz),8.84(1H,s),13.20(1H,brs)
MS(m/z):457(M+)。
1H-NMR(d6-DMSO,δ):7.41(1H,s),7.88(1H,d,J=8.8Hz),8.11(1H,t,J=8.4Hz),8.34-8.40(2H,m),9.13(1H,s),13.45(1H,brs)
MS(m/z):437(M+)。
1H-NMR(CDCl3,δ):1.3-1.8(4H,m),2.0-2.2(1H,m),3.3-3.6(2H,m).3.9-4.1(2H,m),4.27(2H,d,J=6.9Hz),6.83(1H,d,J=8.3Hz),8.07(1H,dd,J=2.4Hz,8.8Hz),8.61(1H,d,J=2.5Hz),9.96(1H,s)
MS(m/z):221(M+)。
1H-NMR(CDCl3,δ):2.11(3H,s),8.12(1H,s),8.83(1H,s),8.94(1H,s),10.08(1H,s)
MS(m/z):145(M+)。
1H-NMR(CDCl3,δ):1.44(3H,s),4.4-4.8(6H,m),6.87(1H,d,J=8.8Hz),8.10(1H,dd,J=2.5Hz,8.8Hz),8.63(1H,d,J=2.0Hz),9.97(1H,s)
MS(m/z):207(M+)。
1H-NMR(CDCl3,δ):0.98(3H,t,J=7.6Hz),1.42(2H,sext,J=7.6Hz),1.85(2H,quin,J=7.6Hz),4.26(2H,t,J=7.6Hz),6.96(1H,d,J=9.2Hz),7.74(1H,d,J=9.6Hz),9.74(1H,d,J=1.2Hz)
MS(m/z):180(M+)。
1H-NMR(CDCl3,δ):0.94(3H,t,J=7.6Hz),1.67(2H,sext,J=7.6Hz),2.19(2H,t,J=7.6Hz),4.46(2H,t,J=6.4Hz),7.29(1H,dd,J=1.2Hz,8.4Hz),7.61(1H,t,J=8.4Hz)
MS(m/z):254(M+)。
1H-NMR(d6-DMSO,δ):3.92(3H,s),6.92(1H,d,J=8.8Hz),7.07(1H,s),7.85(1H,d,J=8.4Hz),8.08(1H,t,J=8.4Hz),8.30(1H,dd,J=2.4Hz,8.8Hz),8.86(1H,d,J=2.0Hz),13.17(1H,brs)
MS(m/z):399(M+)。
1H-NMR(CDCl3,δ):0.9-1.0(4H,m),1.5-1.6(1H,m),7.48(1H,d,J=7.6Hz),8.08(1H,dd,J=2.0Hz,8.0Hz),8.97(1H,d,J=2.0Hz),10.07(1H,s)
MS(m/z):171(M+)。
1H-NMR(CDCl3,δ):0.9-1.1(4H,m),1.5-1.6(1H,m),8.32(1H,s),9.98(1H,s)
MS(m/z):177(M+)。
1H-NMR(CDCl3,δ):0.8-1.0(4H,m),1.4-1.6(1H,m),7.79(1H,dd,J=2.0Hz,8.0Hz),7.87(1H,d,J=8.0Hz),8.72(1H,d,J=2.0Hz),10.05(1H,s)
MS(m/z):171(M+)。
1H-NMR(CDCl3,δ):0.96(3H,t,J=7.3Hz),1.87(2H,q,J=7.3Hz),4.4-4.7(6H,m),6.89(1H,d,J=8.3Hz),8.09(1H,dd,J=2.5Hz,8.8Hz),8.63(1H,d,J=2.5Hz),9.97(1H,s)
MS(m/z):221(M+)。
1H-NMR(CDCl3,δ):2.10(3H,s),7.69(1H,d,J=1.0Hz),9.96(1H,d,J=1.5Hz)
MS(m/z):151(M+)。
1H-NMR(CDCl3,δ):0.8-1.1(4H,m),1.4-1.6(1H,m),7.99(1H,s),9.90(1H,s)
MS(m/z):177(M+)。
1H-NMR(CDCl3,δ):0.8-1.0(4H,m),1.4-1.6(1H,m),7.67(1H,d,J=1.5Hz),9.95(1H,d,J=1.0Hz)
MS(m/z):177(M+)。
1H-NMR(CDCl3,δ):0.8-1.1(4H,m),1.4-1.7(1H,m),7.56(1H,dd,J=1.4Hz,7.8Hz),7.7-7.9(2H,m),10.05(1H,s)
MS(m/z):171(M+)。
1H-NMR(CDCl3,δ):0.8-1.0(4H,m),1.4-1.6(1H,m),8.10(1H,t,J=1.7Hz),8.79(1H,d,J=2.4Hz),8.92(1H,d,J=1.9Hz),10.08(1H,s)
MS(m/z):171(M+)。
1H-NMR(CDCl3,δ):0.98(3H,t,J=7.2Hz),1.72(2H,quin,J=7.6Hz),2.26(2H,t,J=7.2Hz),4.53(2H,d,J=5.6Hz),6.06(1H,s),7.4-7.8(3H,m)
MS(m/z):270(M+)。
1H-NMR(CDCl3,δ):2.0(2H,sext,J=6.8Hz),2.4-2.6(6H,m),3.73(4H,t,J=4.8Hz),4.47(2H,t,J=6.4Hz),6.83(1H,d,J=8.8Hz),8.06(1H,dd,J=2.4Hz,8.8Hz),8.62(1H,d,J=2.4Hz),9.95(1H,s)
MS(m/z):250(M+)。
1H-NMR(CDCl3,δ):2.14(3H,s),7.51(1H,d,J=8.4Hz),8.10(1H,dd,J=2.0Hz,8.4Hz),8.99(1H,d,J=1.6Hz),10.09(1H,s)
MS(m/z):145(M+)。
1H-NMR(d6-DMSO,δ):7.31(1H,s),7.87(1H,d,J=8.8Hz),8.10(1H,t,J=8.4Hz),8.2-8.3(1H,m),8.72(1H,d,J=2.4Hz),9.11(1H,s),13.37(1H,brs)
MS(m/z):387(M+)。
1H-NMR(CDCl3,δ):1.2-1.4(1H,m),1.5-1.8(7H,m),2.0-2.1(2H,m),2.29(1H,s),7.58(1H,d,J=8.0Hz),8.13(1H,dd,J=1.6Hz,8.0Hz),9.03(1H,d,J=1.6Hz),10.11(1H,s)
MS(m/z):229(M+)。
1H-NMR(CDCl3,δ):2.13(3H,s),7.8-7.9(2H,m),8.75(1H,d,J=1.2Hz),10.06(1H,s)
MS(m/z):145(M+)。
1H-NMR(d6-DMSO,δ):1.33(3H,t,J=6.8Hz),4.37(2H,q,J=6.8Hz),6.89(1H,d,J=8.8Hz),7.05(1H,s),7.85(1H,d,J=8.8Hz),8.08(1H,t,J=7.6Hz),8.29(1H,dd,J=1.6Hz,8.8Hz),8.83(1H,s),13.19(1H,brs)
MS(m/z):413(M+)。
6-(3-エトキシプロポキシ)ピリジン-3-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),1.10(3H,t,J=6.8Hz),1.96(2H,quint,J=6.3Hz),2.43(1H,sept,J=6.8Hz),3.42(2H,q,J=6.8Hz),3.50(2H,t,J=5.9Hz),4.31(2H,d,J=6.3Hz),4.37(2H,t,J=6.4Hz),6.89(1H,d,J=8.8Hz),6.95(1H,brs),7.41(1H,dd,J=1.9Hz,8.3Hz),7.5-7.6(2H,m),8.2-8.4(2H,m),8.87(1H,d,J=2.4Hz),12.80(1H,brs)
MS(m/z):484(M+)。
6-(シクロプロピルメトキシ)ピリジン-3-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.3-0.4(2H,m),0.5-0.6(2H,m),1.03(6H,d,J=6.8Hz),1.1-1.4(1H,m),2.43(1H,sept,J=6.8Hz),4.16(2H,d,J=6.8Hz),4.31(2H,d,J=5.8Hz),6.8-7.0(2H,m),7.41(1H,dd,J=1.9Hz,8.3Hz),7.5-7.6(2H,m),8.2-8.4(2H,m),8.85(1H,d,J=1.9Hz),12.86(1H,brs)
MS(m/z):452(M+)。
6-[2-(2-ブトキシエトキシ)エトキシ]ピリジン-3-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.85(3H,t,J=7.3Hz),1.03(6H,d,J=6.8Hz),1.2-1.5(4H,m),2.43(1H,sept,J=7.8Hz),3.36(2H,t,J=6.4Hz),3.4-3.6(4H,m),3.7-3.8(2H,m),4.31(2H,d,J=5.8Hz),4.4-4.5(2H,m),6.92(1H,d,J=8.8Hz),6.96(1H,brs),7.41(1H,dd,J=1.9Hz,8.3Hz),7.5-7.6(2H,m),8.2-8.4(2H,m),8.87(1H,d,J=2.4Hz),12.77(1H,brs)
MS(m/z):542(M+)。
6-(ピリジン-2-イルメトキシ)ピリジン-3-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),4.31(2H,d,J=5.8Hz),5.49(2H,d,J=6.8Hz),6.97(1H,brs),7.05(1H,d,J=8.8Hz),7.3-7.4(1H,m),7.41(1H,dd,J=1.9Hz,8.3Hz),7.46(1H,d,J=7.8Hz),7.5-7.6(2H,m),7.81(1H,dt,J=1.5Hz,7.3Hz),8.33(1H,t,J=5.8Hz),8.39(1H,dd,J=2.4Hz,8.8Hz),8.5-8.6(1H,m),8.87(1H,d,J=2.4Hz),12.87(1H,brs)
MS(m/z):489(M+)。
6-(ピリジン-2-イルメトキシ)ピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.45(1H,sept,J=6.8Hz),4.40(2H,d,J=5.8Hz),5.49(2H,s),6.98(1H,brs),7.04(1H,d,J=8.8Hz),7.2-7.4(1H,m),7.46(1H,d,J=7.8Hz),7.5-7.7(2H,m),7.80(1H,dt,J=1.5Hz,7.9Hz),7.88(1H,d,J=7.9Hz),8.3-8.6(3H,m),8.8-8.9(1H,m),12.95(1H,brs)
MS(m/z):523(M+)。
6-(6-メチルピリジン-3-イルメトキシ)ピリジン-3-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),2.46(3H,s),4.31(2H,d,J=5.8Hz),5.42(2H,s),6.9-7.1(2H,m),7.26(1H,d,J=1.3Hz),7.42(1H,dd,J=2.0Hz,8.3Hz),7.5-7.6(2H,m),7.77(1H,dd,J=2.4Hz,7.8Hz),8.2-8.4(2H,m),8.55(1H,d,J=2.0Hz),8.90(1H,d,J=2.5Hz)
MS(m/z):503(M+)。
2-オキソ-1-ペンチル-1,2-ジヒドロピリジン-4-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.86(3H,t,J=7.3Hz),1.03(6H,d,J=6.8Hz),1.1-1.4(4H,m),1.5-1.7(2H,m),2.43(1H,sept,J=6.8Hz),3.89(2H,t,J=6.9Hz),4.31(2H,d,J=5.8Hz),6.80(1H,dd,J=1.9Hz,6.8Hz),7.01(1H,brs),7.06(1H,d,J=1.5Hz),7.42(1H,dd,J=2.0Hz,8.3Hz),7.53(1H,d,J=2.0Hz),7.57(1H,d,J=8.3Hz),7.77(1H,d,J=7.3Hz),8.34(1H,t,J=6.1Hz),13.04(1H,brs)
MS(m/z):468(M+)。
1-ブチル-2-オキソ-1,2-ジヒドロピリジン-4-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.90(3H,t,J=7.3Hz),1.03(6H,d,J=6.8Hz),1.2-1.4(2H,m),1.5-1.7(2H,m),2.43(1H,sept,J=6.8Hz),3.90(2H,t,J=7.0Hz),4.31(2H,d,J=5.8Hz),6.80(1H,dd,J=1.4Hz,6.8Hz),7.01(1H,brs),7.06(1H,d,J=1.9Hz),7.42(1H,dd,J=2.5Hz,8.3Hz),7.53(1H,d,J=2.0Hz),7.57(1H,d,J=8.3Hz),7.77(1H,d,J=7.3Hz),8.34(1H,t,J=5.9Hz),13.03(1H,brs)
MS(m/z):454(M+)。
6-(ジフルオロメトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロベンジル)プロピオンアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.02(3H,t,J=7.8Hz),2.16(2H,q,J=7.8Hz),4.31(2H,d,J=6.4Hz),7.08(1H,brs),7.20(1H,d,J=8.8Hz),7.43(1H,dd,J=1.9Hz,8.3Hz),7.5-7.7(2H,m),7.77(1H,t,J=72.7Hz),8.3-8.4(1H,m),8.54(1H,dd,J=2.5Hz,8.8Hz),8.95(1H,d,J=2.0Hz),12.95(1H,brs)
MS(m/z):434(M+)。
6-(シクロプロピルメトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロベンジル)プロピオンアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.3-0.4(2H,m),0.5-0.6(2H,m),1.02(3H,t,J=7.3Hz),1.2-1.4(1H,m),2.16(2H,q,J=7.8Hz),4.16(2H,d,J=7.3Hz),4.32(2H,d,J=5.9Hz),6.91(1H,d,J=8.8Hz),6.95(1H,brs),7.43(1H,dd,J=2.0Hz,8.8Hz),7.5-7.6(2H,m),8.2-8.4(2H,m),8.85(1H,d,J=2.0Hz),12.80(1H,brs)
MS(m/z):438(M+)。
6-(ジフルオロメトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロベンジル)ブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.85(3H,t,J=7.3Hz),1.4-1.6(2H,m),2.13(2H,t,J=7.3Hz),4.32(2H,d,J=5.8Hz),7.08(1H,brs),7.20(1H,d,J=8.7Hz),7.43(1H,dd,J=1.9Hz,8.3Hz),7.5-7.7(2H,m),7.77(1H,t,J=72.2Hz),8.3-8.5(1H,m),8.54(1H,dd,J=2.5Hz,8.8Hz),8.95(1H,d,J=2.5Hz),12.98(1H,brs)
MS(m/z):448(M+)。
6-(2-プロポキシエトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロベンジル)ブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.8-0.9(6H,m),1.4-1.6(4H,m),2.13(2H,t,J=7.3Hz),3.40(2H,t,J=6.8Hz),3.6-3.8(2H,m),4.32(2H,d,J=6.3Hz),4.4-4.5(2H,m),6.92(1H,d,J=8.8Hz),6.96(1H,brs),7.3-7.7(3H,m),8.2-8.5(2H,m),8.87(1H,d,J=2.0Hz),12.87(1H,brs)
MS(m/z):484(M+)。
5-フルオロピリジン-3-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.44(1H,sept,J=6.8Hz),4.32(2H,d,J=6.4Hz),7.19(1H,brs),7.43(1H,dd,J=2.0Hz,8.3Hz),7.5-7.7(2H,m),8.2-8.4(2H,m),8.70(1H,d,J=2.9Hz),9.14(1H,s),13.05(1H,brs)
MS(m/z):400(M+)。
6-(2,2,2-トリフルオロエトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロベンジル)プロピオンアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.02(3H,t,J=7.3Hz),2.16(2H,q,J=7.8Hz),4.32(2H,d,J=5.9Hz),5.07(2H,q,J=8.8Hz),7.02(1H,brs),7.10(1H,d,J=8.8Hz),7.43(1H,dd,J=1.9Hz,8.3Hz),7.5-7.6(2H,m),8.3-8.4(1H,m),8.44(1H,dd,J=2.4Hz,8.8Hz),8.91(1H,d,J=2.5Hz),12.83(1H,brs)
MS(m/z):466(M+)。
5-(ジフルオロメトキシ)ピリジン-2-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロベンジル)ブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.85(3H,t,J=7.8Hz),1.4-1.6(2H,m),2.13(2H,t,J=7.3Hz),4.33(2H,d,J=5.9Hz),7.18(1H,brs),7.41(1H,t,J=72.8Hz),7.44(1H,dd,J=2.0Hz,8.3Hz),7.5-7.7(2H,m),7.80(1H,dd,J=2.4Hz,8.3Hz),8.30(1H,d,J=8.8Hz),8.38(1H,t,J=5.9Hz),8.63(1H,d,J=2.9Hz),13.04(1H,brs)
MS(m/z):448(M+)。
5-クロロピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),2.46(1H,sept,J=6.9Hz),4.40(2H,d,J=5.8Hz),7.23(1H,brs),7.5-7.7(2H,m),7.90(1H,d,J=8.3Hz),8.3-8.5(1H,m),8.48(1H,s),8.74(1H,d,J=1.9Hz),9.19(1H,s),13.17(1H,brs)
MS(m/z):450(M+)。
5-フルオロピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),2.46(1H,sept,J=6.8Hz),4.41(2H,d,J=5.8Hz),7.21(1H,brs),7.5-7.7(2H,m),7.90(1H,d,J=8.3Hz),8.28(1H,d,J=9.8Hz),8.3-8.5(1H,m),8.70(1H,d,J=2.9Hz),9.13(1H,s),13.16(1H,brs)
MS(m/z):434(M+)。
5-(ジフルオロメトキシ)ピリジン-2-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロベンジル) プロピオンアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(3H,t,J=7.8Hz),2.16(2H,q,J=7.3Hz),4.32(2H,d,J=5.8Hz),7.19(1H,brs),7.42(1H,t,J=73.3Hz),7.44(1H,dd,J=2.5Hz,8.8Hz),7.5-7.7(2H,m),7.80(1H,dd,J=2.4Hz,8.3Hz),8.31(1H,d,J=8.8Hz),8.35(1H,t,J=5.8Hz),8.63(1H,d,J=2.4Hz),12.96(1H,brs)
MS(m/z):434(M+)。
5-メトキシピリジン-3-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),3.90(3H,s),4.32(2H,d,J=5.9Hz),7.14(1H,brs),7.42(1H,dd,J=2.4Hz,8.3Hz),7.5-7.7(2H,m),7.94(1H,d,J=2.2Hz),8.34(1H,t,J=5.9Hz),8.40(1H,d,J=3.0Hz),8.85(1H,d,J=1.9Hz),12.98(1H,brs)
MS(m/z):412(M+)。
5-メトキシピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),2.46(1H,sept,J=6.8Hz),3.88(3H,s),4.40(2H,d,J=5.8Hz),7.17(1H,brs),7.5-7.7(2H,m),7.8-8.0(2H,m),8.3-8.5(2H,m),8.83(1H,s),13.04(1H,brs)
MS(m/z):446(M+)。
6-プロポキシピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロベンジル)プロピオンアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.9-1.1(6H,m),1.6-1.8(2H,m),2.16(2H,q,J=7.8Hz),4.2-4.4(4H,m),6.89(1H,d,J=8.8Hz),6.95(1H,brs),7.43(1H,dd,J=2.0Hz,8.3Hz),7.5-7.6(2H,m),8.2-8.4(2H,m),8.86(1H,d,J=2.5Hz),12.85(1H,brs)
MS(m/z):426(M+)。
6-(2,2-ジフルオロエトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロベンジル)プロピオンアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.02(3H,t,J=7.8Hz),2.16(2H,q,J=7.3Hz),4.32(2H,d,J=5.9Hz),4.64(2H,dt,J=3.4Hz,15.1Hz),6.41(1H,tt,J=3.6Hz,54.7Hz),7.00(1H,brs),7.03(1H,d,J=8.8Hz),7.43(1H,dd,J=1.9Hz,8.3Hz),7.5-7.6(2H,m),8.35(1H,t,J=5.9Hz),8.40(1H,dd,J=2.5Hz,8.8Hz),8.90(1H,d,J=2.0Hz),12.89(1H,brs)
MS(m/z):448(M+)。
5-メチルピリジン-3-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),2.36(3H,s),2.3-2.5(1H,m),4.32(2H,d,J=5.9Hz),7.05(1H,brs),7.42(1H,dd,J=1.9Hz,8.3Hz),7.5-7.6(2H,m),8.23(1H,s),8.35(1H,t,J=5.8Hz),8.52(1H,s),9.03(1H,d,J=1.4Hz),12.95(1H,brs)
MS(m/z):396(M+)。
5-メチルピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),2.35(3H,s),2.4-2.6(1H,m),4.40(2H,d,J=6.4Hz),7.08(1H,brs),7.5-7.7(2H,m),7.89(1H,d,J=7.8Hz),8.21(1H,s),8.40(1H,t,J=5.9Hz),8.51(1H,s),9.02(1H,s),13.01(1H,brs)
MS(m/z):430(M+)。
5-メチルピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),2.36(3H,s),2.3-2.6(1H,m),4.32(2H,d,J=5.9Hz),7.11(1H,brs),7.4-7.6(2H,m),8.21(1H,s),8.36(1H,t,J=5.4Hz),8.52(1H,s),9.01(1H,d,J=1.2Hz),13.17(1H,brs)
MS(m/z):414(M+)。
5-メトキシピリジン-2-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.44(1H,sept,J=6.8Hz),3.90(3H,s),4.32(2H,d,J=5.9Hz),7.12(1H,brs),7.42(1H,dd,J=2.4Hz,8.3Hz),7.50(1H,dd,J=3.0Hz,8.8Hz),7.5-7.6(2H,m),8.21(1H,d,J=8.8Hz),8.34(1H,t,J=5.9Hz),8.43(1H,d,J=3.0Hz),12.84(1H,brs)
MS(m/z):412(M+)。
1-イソプロピル-1H-ピラゾール-4-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),1.42(6H,d,J=6.4Hz),2.43(1H,sept,J=6.8Hz),4.30(2H,d,J=5.8Hz),4.52(1H,sept,J=6.3Hz),6.62(1H,brs),7.39(1H,dd,J=1.9Hz,8.3Hz),7.47(1H,d,J=1.9Hz),7.54(1H,d,J=8.3Hz),8.00(1H,s),8.2-8.4(2H,m),12.39(1H,brs)
MS(m/z):413(M+)。
1-プロピル-1H-ピラゾール-4-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.82(3H,t,J=7.6Hz),1.03(6H,d,J=6.8Hz),1.7-1.9(2H,m),2.43(1H,sept,J=6.8Hz),4.08(2H,t,J=6.8Hz),4.30(2H,d,J=6.3Hz),6.61(1H,brs),7.39(1H,dd,J=1.9Hz,8.3Hz),7.48(1H,d,J=2.5Hz),7.54(1H,d,J=7.8Hz),8.01(1H,s),8.2-8.4(2H,m),12.13(1H,brs)
MS(m/z):413(M+)。
6-(ジフルオロメトキシ)ピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(ジフルオロメトキシ)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),4.32(2H,d,J=6.4Hz),6.9-8.0(7H,m),8.34(1H,t,J=5.9Hz),8.56(1H,dd,J=2.4Hz,8.8Hz),8.97(1H,d,J=2.0Hz),12.77(1H,brs)
MS(m/z):480(M+)。
6-[2-(2-メトキシエトキシ)エトキシ]ピリジン-3-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),3.24(3H,s),3.4-3.6(4H,m),3.7-3.8(2H,m),4.31(2H,d,J=5.8Hz),4.4-4.5(2H,m),6.92(1H,d,J=8.8Hz),6.96(1H,brs),7.41(1H,dd,J=1.9Hz,8.3Hz),7.5-7.6(2H,m),8.2-8.4(2H,m),8.87(1H,d,J=1.9Hz),12.86(1H,brs)
MS(m/z):500(M+)。
6-{2-[2-(2-エトキシエトキシ)エトキシ]エトキシ}ピリジン-3-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),1.08(3H,t,J=6.8Hz),2.43(1H,sept,J=6.8Hz),3.3-3.8(12H,m),4.31(2H,d,J=5.8Hz),4.4-4.5(2H,m),6.92(1H,d,J=8.8Hz),6.96(1H,brs),7.42(1H,dd,J=2.0Hz,8.3Hz),7.5-7.6(2H,m),8.2-8.4(2H,m),8.87(1H,d,J=2.4Hz),12.84(1H,brs)
MS(m/z):558(M+)。
6-(6-メチルピリジン-2-イルメトキシ)ピリジン-3-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),2.47(3H,s),4.31(2H,d,J=5.8Hz),5.44(2H,s),6.97(1H,brs),7.04(1H,d,J=8.8Hz),7.18(1H,d,J=7.8Hz),7.24(1H,d,J=7.3Hz),7.41(1H,dd,J=1.9Hz,8.3Hz),7.5-7.6(2H,m),7.68(1H,t,J=7.8Hz),8.33(1H,t,J=5.8Hz),8.38(1H,dd,J=2.4Hz,8.8Hz),8.87(1H,d,J=2.4Hz),12.71(1H,brs)
MS(m/z):503(M+)。
6-(2-プロポキシエトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロベンジル)プロピオンアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.86(3H,t,J=7.3Hz),1.02(3H,t,J=7.6Hz),1.4-1.6(2H,m),2.16(2H,q,J=7.8Hz),3.40(2H,t,J=6.8Hz),3.6-3.8(2H,m),4.32(2H,d,J=5.9Hz),4.4-4.5(2H,m),6.93(1H,d,J=8.8Hz),6.96(1H,brs),7.43(1H,dd,J=2.0Hz,8.3Hz),7.5-7.6(2H,m),8.3-8.4(2H,m),8.87(1H,d,J=2.4Hz),12.74(1H,brs)
MS(m/z):470(M+)。
6-(2-エトキシエトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロベンジル)ブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.85(3H,t,J=8.1Hz),1.12(3H,t,J=7.8Hz),1.4-1.6(2H,m),2.13(2H,t,J=7.3Hz),3.49(2H,q,J=7.3Hz),3.6-3.8(2H,m),4.32(2H,d,J=5.8Hz),4.3-4.5(2H,m),6.93(1H,d,J=8.8Hz),6.96(1H,brs),7.43(1H,dd,J=2.0Hz,8.3Hz),7.5-7.7(2H,m),8.2-8.5(2H,m),8.87(1H,d,J=2.4Hz),12.87(1H,brs)
MS(m/z):470(M+)。
6-(2-フルオロエトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロベンジル)ブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.85(3H,t,J=7.3Hz),1.4-1.6(2H,m),2.13(2H,t,J=7.1Hz),4.32(2H,d,J=5.8Hz),4.5-4.9(4H,m),6.97(1H,d,J=8.3Hz),6.97(1H,brs),7.43(1H,dd,J=2.5Hz,8.3Hz),7.5-7.6(2H,m),8.3-8.5(2H,m),8.88(1H,d,J=2.5Hz),12.87(1H,brs)
MS(m/z):444(M+)。
6-(3-フルオロプロポキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロベンジル)プロピオンアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.02(3H,t,J=7.8Hz),2.0-2.3(4H,m),4.32(2H,d,J=6.4Hz),4.43(2H,t,J=6.3Hz),4.55(1H,t,J=6.4Hz),4.66(1H,t,J=5.9Hz),6.92(1H,d,J=8.8Hz),6.96(1H,brs),7.43(1H,dd,J=2.0Hz,8.3Hz),7.5-7.6(2H,m),8.3-8.4(2H,m),8.88(1H,d,J=2.5Hz),12.87(1H,brs)
MS(m/z):444(M+)。
6-(2-エトキシエトキシ)ピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=7.2Hz),1.12(3H,t,J=7.2Hz),2.46(1H,sept,J=7.2Hz),3.49(2H,q,J=7.2Hz),3.7-3.8(2H,m),4.3-4.4(4H,m),6.92(1H,d,J=8.8Hz),6.96(1H,s),7.5-7.6(2H,m),7.88(1H,d,J=8.0Hz),8.31(1H,d,J=8.8Hz),8.39(1H,t,J=6.0Hz),8.84(1H,s),12.97(1H,s)
MS(m/z):504(M+)。
6-(2-プロポキシエトキシ)ピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.85(3H,t,J=7.2Hz),1.05(6H,d,J=7.2Hz),1.5-1.6(2H,m),2.46(1H,sept,J=6.8Hz),3.40(2H,t,J=6.8Hz),3.6-3.7(2H,m),4.4-4.5(4H,m),6.92(1H,d,J=8.4Hz),6.97(1H,s),7.5-7.6(2H,m),7.88(1H,d,J=8.0Hz),8.31(1H,d,J=8.0Hz),8.39(1H,t,J=6.0Hz),8.85(1H,s),12.97(1H,s)
MS(m/z):518(M+)。
6-シクロプロピルピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.0-1.1(10H,m),2.1-2.2(1H,m),2.4-2.6(1H,m),4.40(2H,d,J=6.0Hz),7.01(1H,s),7.39(1H,d,J=8.0Hz),7.5-7.6(2H,m),7.88(1H,d,J=8.0Hz),8.23(1H,d,J=6.8Hz),8.39(1H,t,J=6.0Hz),9.04(1H,s),13.00(1H,s)
MS(m/z):456(M+)。
6-(2-ブトキシエトキシ)ピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.86(3H,t,J=7.2Hz),1.05(6H,d,J=6.8Hz),1.2-1.3(2H,m),1.4-1.5(2H,m),2.4-2.6(1H,m),3.43(2H,t,J=6.8Hz),3.6-3.7(2H,m),4.4-4.5(4H,m),6.91(1H,d,J=8.8Hz),6.96(1H,s),7.5-7.6(2H,m),7.88(1H,d,J=8.0Hz),8.31(1H,d,J=8.8Hz),8.39(1H,t,J=6.0Hz),8.84(1H,s),12.96(1H,s)
MS(m/z):532(M+)。
6-(3-メトキシプロポキシ)ピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=7.2Hz),1.96(2H,quin,J=6.8Hz),2.4-2.6(1H,m),3.24(3H,s),3.46(2H,t,J=6.4Hz),4.36(2H,t,J=6.8Hz),4.40(2H,d,J=5.6Hz),6.89(1H,d,J=8.8Hz),6.96(1H,s),7.5-7.6(2H,m),7.88(1H,d,J=8.4Hz),8.30(1H,d,J=8.4Hz),8.39(1H,t,J=6.4Hz),8.84(1H,s),12.97(1H,s)
MS(m/z):504(M+)。
ピリジン-3-カルバルデヒドを用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),2.4-2.6(1H,m),4.32(2H,d,J=6.0Hz),7.09(1H,s),7.42(1H,dd,J=2.0Hz,8.4Hz),7.5-7.6(3H,m),8.34(1H,t,J=6.0Hz),8.4-8.5(1H,m),8.68(1H,dd,J=1.6Hz,4.8Hz),9.24(1H,d,J=2.0Hz),12.99(1H,s)
MS(m/z):382(M+)。
6-メトキシピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-メチルベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),2.3-2.6(4H,m),3.92(3H,s),4.28(2H,d,J=6.0Hz), 6.9-7.0(2H,m),7.2-7.3(2H,m),7.42(1H,s),8.24(1H,t,J=6.0Hz),8.34(1H,dd,J=2.4Hz,8.8Hz),8.89(1H,d,J=2.0Hz),12.65(1H,s)
MS(m/z):392(M+)。
2-(トリフルオロメチル)ピリジン-4-カルバルデヒドを用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),4.32(2H,d,J=6.0Hz),7.36(1H,s),7.44(1H,dd,J=2.0Hz,8.4Hz),7.5-7.6(2H,m),8.3-8.4(2H,m),8.44(1H,s),8.91(1H,d,J=5.6Hz),13.19(1H,s)
MS(m/z):450(M+)。
6-(トリフルオロメチル)ピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(ジフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),2.4-2.6(1H,m),4.39(2H,d,J=6.0Hz),7.26(1H,s),7.43(1H,m),7.58(1H,d,J=8.0Hz),7.68(1H,t,J=98.4Hz),7.80(1H,d,J=8.0Hz),8.05(1H,d,J=8.4Hz),8.34(1H,t,J=5.6Hz),8.72(1H,d,J=7.2Hz),9.44(1H,s),13.17(1H,s)
MS(m/z):466(M+)。
2-(シクロプロピルメトキシ)ピリジン-4-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.3-0.4(2H,m),0.5-0.6(2H,m),1.05(6H,d,J=6.8Hz),1.2-1.3(1H,m),2.4-2.6(1H,m),4.13(2H,d,J=6.8Hz),4.40(2H,d,J=6.0Hz),7.14(1H,s),7.40(1H,s),7.5-7.7(3H,m),7.89(1H,d,J=8.0Hz),8.23(1H,d,J=5.6Hz),8.39(1H,t,J=6.4Hz),13.13(1H,s)
MS(m/z):486(M+)。
6-(シクロプロピルメトキシ)ピリダジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.4-0.6(4H,m),1.05(6H,d,J=7.2Hz),1.3-1.4(1H,m),2.45(1H,sept,J=6.8Hz),4.03(2H,d,J=7.6Hz),4.40(2H,d,J=5.6Hz),7.0-7.1(2H,m),7.6-7.7(2H,m),7.88(1H,d,J=8.4Hz),8.0-8.1(1H,m),8.40(1H,t,J=6.4Hz),13.10(1H,s)
MS(m/z):487(M+)。
4-ホルミル-N,N-ジメチルベンズアミド及びN-(3-カルバミミドイル-4-クロロベンジル)-3,3,3-トリフルオロ-2,2-ジメチルプロピオンアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.38(6H,s),2.92(3H,s),3.00(3H,s),4.37(2H,d,J=6.0Hz),7.00(1H,s),7.40(1H,dd,J=2.0Hz,8.4Hz),7.49(2H,d,J=8.4Hz),7.55(1H,d,J=2.0Hz),7.58(1H,d,J=8.4Hz),8.13(2H,d,J=8.0Hz),8.61(1H,t,J=6.0Hz),12.89(1H,brs)
MS(m/z):520(M+)。
6-(ジフルオロメトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-2,4-ジフルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.4-2.6(1H,m),4.32(2H,d,J=5.6Hz),7.12(1H,s),7.20(1H,d,J=8.8Hz),7.29(1H,t,J=8.8Hz),7.4-7.6(1H,m),7.77(1H,t,J=72.8Hz),8.33(1H,t,J=5.6Hz),8.52(1H,dd,J=2.0Hz,8.8Hz),8.93(1H,d,J=1.6Hz),13.23(1H,brs)
MS(m/z):450(M+)。
2-メトキシピリミジン-5-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),2.46(1H,sept,J=6.8Hz),3.99(3H,s),4.40(2H,d,J=6.0Hz),7.10(1H,s),7.6-7.7(2H,m),7.89(1H,d,J=8.4Hz),8.39(1H,t,J=6.0Hz),9.19(2H,s),13.05(1H,brs)
MS(m/z):447(M+)。
5-クロロピリジン-3-カルバルデヒドを用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=7.2Hz),2.4-2.6(1H,m),4.32(2H,d,J=6.0Hz),7.19(1H,s),7.43(1H,dd,J=2.0Hz,8.4Hz),7.5-7.6(2H,m),8.34(1H,t,J=5.6Hz),8.50(1H,s),8.75(1H,d,J=2.0Hz),9.21(1H,s),13.08(1H,brs)
MS(m/z):416(M+)。
6-シクロプロピルピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.9-1.1(4H,m),1.04(6H,d,J=6.8Hz),2.1-2.2(1H,m),2.4-2.6(1H,m),4.32(2H,d,J=5.6Hz),7.04(1H,s),7.39(1H,d,J=8.4Hz),7.4-7.5(2H,m),8.23(1H,dd,J=2.0Hz,8.4Hz),8.35(1H,t,J=5.6Hz),9.03(1H,s),13.13(1H,brs)
MS(m/z):440(M+)。
2-シクロプロピルピリミジン-5-カルバルデヒドを用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=7.2Hz),1.0-1.2(4H,m),2.2-2.3(1H,m),2.43(1H,sept,J=6.8Hz),4.31(2H,d,J=6.4Hz),7.10(1H,s),7.42(1H,dd,J=2.0Hz,8.4Hz),7.5-7.6(2H,m),8.33(1H,t,J=6.0Hz),9.21(2H,s),13.01(1H,brs)
MS(m/z):423(M+)。
6-(シクロプロピルメトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.3-0.4(2H,m),0.5-0.6(2H,m),1.04(6H,d,J=6.8Hz),1.2-1.3(1H,m),2.4-2.6(1H,m),4.16(2H,d,J=7.2Hz),4.32(2H,d,J=5.6Hz),6.90(1H,d,J=8.4Hz),7.00(1H,s),7.4-7.5(2H,m),8.30(1H,dd,J=2.4Hz,8.8Hz),8.35(1H,t,J=5.6Hz),8.82(1H,d,J=2.0Hz),13.06(1H,brs)
MS(m/z):470(M+)。
6-(2-エトキシエトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),1.10(3H,t,J=6.8Hz),2.45(1H,sept,J=6.8Hz),3.49(2H,q,J=6.8Hz),3.71(2H,t,J=4.8Hz),4.32(2H,d,J=5.6Hz),4.43(2H,t,J=4.4Hz),6.92(1H,d,J=8.8Hz),7.00(1H,s),7.4-7.5(2H,m),8.3-8.4(2H,m),8.84(1H,d,J=1.6Hz),13.10(1H,brs)
MS(m/z):488(M+)。
6-(シクロプロピルメトキシ)ピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.3-0.4(2H,m),0.5-0.6(2H,m),1.05(6H,d,J=7.2Hz),1.2-1.3(1H,m),2.45(1H,sept,J=6.8Hz),4.16(2H,d,J=6.8Hz),4.40(2H,d,J=5.6Hz),6.90(1H,d,J=8.8Hz),6.95(1H,s),7.5-7.7(2H,m),7.88(1H,d,J=8.4Hz),8.30(1H,d,J=7.2Hz),8.39(1H,t,J=5.6Hz),8.83(1H,s),12.95(1H,brs)
MS(m/z):486(M+)。
6-(2-プロポキシエトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.85(3H,t,J=7.2Hz),1.04(6H,d,J=6.8Hz),1.51(2H,sext,J=7.2Hz),2.45(1H,sept,J=6.8Hz),3.40(2H,t,J=6.8Hz),3.71(2H,t,J=4.8Hz),4.32(2H,d,J=6.0Hz),4.44(2H,t,J=4.8Hz),6.92(1H,d,J=8.8Hz),7.02(1H,s),7.4-7.5(2H,m),8.31(1H,dd,J=2.8Hz,8.8Hz),8.36(1H,t,J=6.0Hz),8.84(1H,d,J=2.4Hz),13.00(1H,brs)
MS(m/z):502(M+)。
6-エトキシピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),1.33(3H,t,J=6.8Hz),2.45(1H,sept,J=6.8Hz),4.32(2H,d,J=5.2Hz),4.37(2H,q,J=6.8Hz),6.88(1H,d,J=8.8Hz),7.00(1H,s),7.4-7.5(2H,m),8.30(1H,dd,J=2.4Hz,8.8Hz),8.36(1H,t,J=5.6Hz),8.84(1H,d,J=2.0Hz),13.08(1H,brs)
MS(m/z):444(M+)。
5-(トリフルオロメチル)ピリジン-2-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),2.4-2.6(1H,m),4.33(2H,d,J=5.6Hz),7.34(1H,s),7.4-7.6(2H,m),8.3-8.5(3H,m),9.13(1H,s),13.42(1H,brs)
MS(m/z):468(M+)。
6-(2-エトキシエトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-2,4-ジフルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),1.12(3H,t,J=6.8Hz),2.45(1H,sept,J=6.8Hz),3.49(2H,q,J=6.8Hz),3.71(2H,t,J=4.8Hz),4.32(2H,d,J=5.6Hz),4.44(2H,t,J=4.8Hz),6.93(1H,d,J=8.8Hz),7.00(1H,s),7.28(1H,t,J=8.8Hz),7.4-7.6(1H,m),8.3-8.4(2H,m),8.85(1H,s),13.11(1H,brs)
MS(m/z):472(M+)。
6-(シクロプロピルメトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-2,4-ジフルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.3-0.4(2H,m),0.5-0.6(2H,m),1.04(6H,d,J=6.8Hz),1.2-1.3(1H,m),2.45(1H,sept,J=6.8Hz),4.16(2H,d,J=7.6Hz),4.32(2H,d,J=5.6Hz),6.91(1H,d,J=8.8Hz),6.98(1H,s),7.28(1H,t,J=8.8Hz),7.4-7.6(1H,m),8.3-8.4(2H,m),8.83(1H,d,J=1.6Hz),13.10(1H,brs)
MS(m/z):454(M+)。
6-(ジフルオロメトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-2-クロロ-4-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.07(6H,d,J=6.8Hz),2.4-2.6(1H,m),4.34(2H,d,J=5.2Hz),7.13(1H,s),7.18(1H,d,J=8.8Hz),7.4-7.6(2H,m),7.76(1H,t,J=72.8Hz),8.37(1H,t,J=6.0Hz),8.51(1H,dd,J=2.4Hz,8.4Hz),8.92(1H,d,J=2.4Hz),13.22(1H,brs)
MS(m/z):466(M+)。
6-(シクロプロピルメトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-2-クロロ-4-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.3-0.4(2H,m),0.5-0.6(2H,m),1.07(6H,d,J=7.2Hz),1.2-1.3(1H,m),2.4-2.6(1H,m),4.16(2H,d,J=6.8Hz),4.34(2H,d,J=5.6Hz),6.90(1H,d,J=8.8Hz),7.00(1H,s),7.4-7.6(2H,m),8.30(1H,dd,J=2.4Hz,8.8Hz),8.37(1H,t,J=5.6Hz),8.82(1H,d,J=2.4Hz),12.95(1H,brs)
MS(m/z):470(M+)。
6-(2,2,2-トリフルオロエトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.4-2.6(1H,m),4.32(2H,d,J=6.0Hz),5.07(2H,q,J=8.8Hz),7.0-7.1(2H,m),7.4-7.6(2H,m),8.36(1H,t,J=6.0Hz),8.41(1H,d,J=8.0Hz),8.88(1H,s),13.16(1H,brs)
MS(m/z):498(M+)。
5-クロロピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),2.45(1H,sept,J=6.8Hz),4.33(2H,d,J=6.0Hz),7.25(1H,s),7.4-7.6(2H,m),8.36(1H,t,J=6.0Hz),8.4-8.5(1H,m),8.75(1H,d,J=2.4Hz),9.18(1H,d,J=2.0Hz),13.29(1H,brs)
MS(m/z):434(M+)。
2-[3-クロロ-2-フルオロ-6-(トリフルオロメチル)フェニル]-6-[6-(トリフルオロメチル)ピリジン-3-イル]ピリミジン-4(3H)-オン109mg、カリウム N-[(トリフルオロボレート)メチル]イソブチルアミド104mg、ビス(ジベンジリデンアセトン)パラジウム(0)7.2mg、2-ジシクロヘキシルホスフィノ-2',6'-ジイソプロポキシ-1,1'-ビフェニル12mg、炭酸ナトリウム53mg、1,4-ジオキサン4mL、水0.4mLを混ぜ、マイクロ波をかけ100分間130℃で反応させた。反応後、酢酸エチルで抽出し、硫酸マグネシウムで乾燥した。溶媒を留去した後、シリカゲルカラムクロマトグラフィーで精製して表題化合物35mgを得た。
1H-NMR(d6-DMSO,δ):1.06(6H,d,J=6.8Hz),2.48(1H,sept,J=6.8Hz),4.41(2H,d,J=5.6Hz),7.31(1H,s),7.67(1H,t,J=8.0Hz),7.79(1H,d,J=8.4Hz),8.01(1H,d,J=8.4Hz),8.40(1H,t,J=6.0Hz),8.64(1H,d,J=7.6Hz),9.36(1H,s),13.38(1H,brs)
MS(m/z):502(M+)。
6-(2,2,2-トリフルオロエトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-2-クロロ-4-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.07(6H,d,J=7.2Hz),2.4-2.6(1H,m),4.34(2H,d,J=6.0Hz),5.06(2H,q,J=9.2Hz),7.0-7.1(2H,m),7.4-7.6(2H,m),8.38(1H,t,J=6.0Hz),8.41(1H,dd,J=2.0Hz,8.8Hz),8.88(1H,d,J=2.0Hz),13.15(1H,brs)
MS(m/z):498(M+)。
5-クロロピリジン-2-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),2.45(1H,sept,J=6.8Hz),4.33(2H,d,J=5.6Hz),7.24(1H,s),7.4-7.6(2H,m),8.06(1H,dd,J=2.4Hz,8.8Hz),8.22(1H,d,J=8.8Hz),8.37(1H,t,J=5.6Hz),8.79(1H,d,J=2.4Hz),13.31(1H,brs)
MS(m/z):434(M+)。
6-(3,3,3-トリフルオロプロポキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.45(1H,sept,J=6.8Hz),2.7-2.9(2H,m),4.32(2H,d,J=6.0Hz),4.56(2H,t,J=5.6Hz),6.93(1H,d,J=8.8Hz),7.02(1H,s),7.4-7.5(2H,m),8.3-8.4(2H,m),8.87(1H,d,J=2.0Hz),13.12(1H,brs)
MS(m/z):512(M+)。
5-(トリフルオロメチル)ピリジン-2-カルバルデヒド及びN-(3-カルバミミドイル-2-クロロ-4-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.07(6H,d,J=6.8Hz),2.4-2.6(1H,m),4.35(2H,d,J=5.6Hz),7.35(1H,s),7.4-7.6(2H,m),8.34(1H,dd,J=2.0Hz,8.8Hz),8.3-8.5(2H,m),9.13(1H,s),13.38(1H,brs)
MS(m/z):468(M+)。
2-[3-クロロ-2-フルオロ-6-(トリフルオロメチル)フェニル]-6-[6-(ジフルオロメトキシ)ピリジン-3-イル]ピリミジン-4(3H)-オンを用い、実施例169と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.06(6H,d,J=6.8Hz),2.48(1H,sept,J=6.8Hz),4.40(2H,d,J=5.6Hz),7.14(1H,s),7.20(1H,d,J=8.8Hz),7.66(1H,t,J=7.6Hz),7.77(1H,t,J=72.0Hz),7.79(1H,d,J=8.0Hz),8.44(1H,t,J=5.6Hz),8.49(1H,d,J=7.2Hz),8.91(1H,s),13.29(1H,brs)
MS(m/z):500(M+)。
6-(2-プロポキシエトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.86(3H,t,J=7.6Hz),1.05(6H,d,J=7.2Hz),1.4-1.6(2H,m),2.46(1H,sept,J=6.8Hz),3.42(2H,t,J=6.8Hz),3.74(2H,t,J=4.4Hz),4.26(2H,t,J=4.4Hz),4.33(2H,d,J=6.0Hz),7.13(1H,s),7.4-7.6(3H,m),8.15(1H,d,J=8.8Hz),8.36(1H,t,J=6.0Hz),8.44(1H,d,J=2.8Hz),13.13(1H,brs)
MS(m/z):502(M+)。
2-[3-クロロ-2-フルオロ-6-(トリフルオロメチル)フェニル]-6-[6-(2-エトキシエトキシ)ピリジン-3-イル]ピリミジン-4(3H)-オンを用い、実施例169と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.06(6H,d,J=6.8Hz),1.12(3H,t,J=7.2Hz),2.48(1H,sept,J=6.8Hz),3.49(2H,q,J=6.8Hz),3.70(2H,t,J=4.8Hz),4.4-4.5(4H,m),6.92(1H,d,J=8.8Hz),7.01(1H,s),7.65(1H,t,J=7.6Hz),7.78(1H,d,J=7.6Hz),8.29(1H,d,J=8.8Hz),8.43(1H,t,J=6.0Hz),8.82(1H,s),13.17(1H,brs)
MS(m/z):522(M+)。
6-(2,2-ジフルオロエトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.45(1H,sept,J=6.8Hz),4.32(2H,d,J=6.0Hz),4.60-4.68(2H,m),6.2-6.6(1H,m),7.02(1H,d,J=8.0Hz),7.05(1H,s),7.4-7.5(2H,m),8.3-8.4(2H,m),8.87(1H,d,J=2.0Hz),13.12(1H,brs)
MS(m/z):480(M+)。
6-(2,2-ジフルオロエトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-2-クロロ-4-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.07(6H,d,J=7.2Hz),2.4-2.6(1H,m),4.34(2H,d,J=6.0Hz),4.6-4.7(2H,m),6.2-6.6(1H,m),7.02(1H,d,J=8.8Hz),7.04(1H,s),7.4-7.6(2H,m),8.3-8.4(2H,m),8.86(1H,d,J=2.0Hz),13.14(1H,brs)
MS(m/z):480(M+)。
5-(ジフルオロメトキシ)ピリジン-2-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=7.2Hz),2.46(1H,sept,J=6.8Hz),4.33(2H,d,J=6.0Hz),7.21(1H,s),7.42(1H,t,J=73.2Hz),7.4-7.6(2H,m),7.78(1H,dd,J=2.8Hz,8.4Hz),8.27(1H,d,J=8.4Hz),8.37(1H,t,J=6.0Hz),8.63(1H,d,J=2.8Hz),13.27(1H,brs)
MS(m/z):466(M+)。
5-(2-エトキシエトキシ)ピリジン-2-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=7.2Hz),1.13(3H,t,J=7.2Hz),2.46(1H,sept,J=7.2Hz),3.51(2H,q,J=7.2Hz),3.73(2H,t,J=4.4Hz),4.25(2H,t,J=4.4Hz),4.33(2H,d,J=5.6Hz),7.14(1H,s),7.4-7.6(3H,m),8.15(1H,d,J=8.8Hz),8.36(1H,t,J=6.0Hz),8.44(1H,d,J=2.8Hz),13.12(1H,brs)
MS(m/z):488(M+)。
5-クロロピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=7.2Hz),2.44(1H,sept,J=6.8Hz),4.33(2H,d,J=5.6Hz),7.19(1H,s),7.3-7.4(1H,m),7.4-7.6(1H,m),7.74(1H,d,J=6.4Hz),8.35(1H,t,J=5.6Hz),8.54(1H,t,J=2.0Hz),8.76(1H,d,J=2.0Hz),9.24(1H,d,J=1.6Hz),12.93(1H,brs)
MS(m/z):400(M+)。
2-[3-クロロ-2-フルオロ-6-(トリフルオロメチル)フェニル]-6-[5-(トリフルオロメチル)ピリジン-2-イル]ピリミジン-4(3H)-オンを用い、実施例169と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.06(6H,d,J=6.8Hz),2.4-2.6(1H,m),4.41(2H,d,J=5.6Hz),7.35(1H,s),7.67(1H,t,J=7.2Hz),7.80(1H,d,J=8.4Hz),8.36(2H,s),8.45(1H,t,J=5.6Hz),9.13(1H,s),13.49(1H,brs)
MS(m/z):502(M+)。
5-(シクロプロピルメトキシ)ピリジン-2-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.3-0.4(2H,m),0.5-0.7(2H,m),1.05(6H,d,J=7.6Hz),1.1-1.4(1H,m),2.46(1H,sept,J=7.2Hz),3.97(2H,d,J=6.8Hz),4.32(2H,d,J=6.0Hz),7.13(1H,s),7.45-7.50(3H,m),8.14(1H,d,J=8.4Hz),8.36(1H,t,J=5.6Hz),8.42(1H,d,J=3.2Hz),13.12(1H,brs)
MS(m/z):470(M+)。
5-フルオロピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.45(1H,sept,J=6.8Hz),4.33(2H,d,J=5.6Hz),7.24(1H,s),7.4-7.6(2H,m),8.29(1H,d,J=9.6Hz),8.36(1H,t,J=5.6Hz),8.71(1H,d,J=2.8Hz),9.11(1H,s),13.30(1H,brs)
MS(m/z):418(M+)。
6-(2-エトキシエトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-2-クロロ-4-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.07(6H,d,J=7.2Hz),1.12(3H,t,J=6.8Hz),2.4-2.6(1H,m),3.49(2H,q,J=6.8Hz),3.71(2H,t,J=4.4Hz),4.34(2H,d,J=6.0Hz),4.43(2H,t,J=4.4Hz),6.92(1H,d,J=8.8Hz),7.01(1H,s),7.4-7.6(2H,m),8.31(1H,dd,J=2.4Hz,8.8Hz),8.37(1H,t,J=6.0Hz),8.83(1H,d,J=2.0Hz),13.09(1H,brs)
MS(m/z):488(M+)。
5-(シクロプロピルメトキシ)ピリジン-2-カルバルデヒド及びN-(3-カルバミミドイル-2-クロロ-4-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.3-0.4(2H,m),0.5-0.7(2H,m),1.07(6H,d,J=6.8Hz),1.2-1.3(1H,m),2.4-2.6(1H,m),3.97(2H,d,J=7.6Hz),4.35(2H,d,J=6.0Hz),7.14(1H,s),7.41-7.51(3H,m),8.14(1H,d,J=8.8Hz),8.38(1H,t,J=5.6Hz),8.42(1H,d,J=2.8Hz),13.11(1H,brs)
MS(m/z):470(M+)。
6-(3,3,3-トリフルオロプロポキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-2-クロロ-4-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.07(6H,d,J=6.8Hz),2.4-2.6(1H,m),2.7-2.9(2H,m),4.34(2H,d,J=5.6Hz),4.56(2H,t,J=6.0Hz),6.92(1H,d,J=8.8Hz),7.02(1H,s),7.4-7.6(2H,m),8.34(1H,dd,J=2.8Hz,8.8Hz),8.37(1H,t,J=6.0Hz),8.86(1H,d,J=1.6Hz),13.11(1H,brs)
MS(m/z):512(M+)。
6-(テトラヒドロピラン-4-イルメトキシ)ピリジン-3-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),1.33(2H,dq,J=4.4Hz,12.2Hz),1.66(2H,dd,J=2.0Hz,12.7Hz),1.9-2.1(1H,m),2.43(1H,sept,J=6.8Hz),3.2-3.4(2H,m),3.87(2H,dd,J=3.0Hz,11.8Hz),4.19(2H,d,J=6.4Hz),4.31(2H,t,J=5.8Hz),6.90(1H,d,J=8.8Hz),6.95(1H,brs),7.41(1H,dd,J=1.9Hz,8.3Hz),7.5-7.6(2H,m),8.2-8.4(2H,m),8.86(1H,d,J=2.5Hz),12.83(1H,brs)
MS(m/z):496(M+)。
6-(テトラヒドロピラン-4-イルメトキシ)ピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),1.32(2H,dq,J=4.4Hz,12.2Hz),1.6-1.7(2H,m),1.9-2.1(1H,m),2.46(1H,sept,J=6.8Hz),3.2-3.4(2H,m),3.87(2H,dd,J=3.4Hz,11.2Hz),4.18(2H,d,J=6.3Hz),4.40(2H,d,J=6.3Hz),6.90(1H,d,J=8.8Hz),6.97(1H,brs),7.5-7.7(2H,m),7.88(1H,d,J=8.3Hz),8.31(1H,d,J=8.8Hz),8.39(1H,t,J=5.9Hz),8.84(1H,d,J=2.5Hz),12.94(1H,brs)
MS(m/z):530(M+)。
6-(テトラヒドロピラン-4-イルメトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロベンジル)ブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.85(3H,t,J=7.3Hz),1.33(2H,dq,J=4.4Hz,12.2Hz),1.4-1.7(4H,m),1.9-2.1(1H,m),2.13(2H,t,J=7.3Hz),3.2-3.4(2H,m),3.87(2H,dd,J=3.0Hz,11.3Hz),4.19(2H,d,J=6.9Hz),4.32(2H,t,J=5.8Hz),6.90(1H,d,J=8.8Hz),6.95(1H,brs),7.43(1H,dd,J=2.0Hz,8.3Hz),7.5-7.6(2H,m),8.33(1H,dd,J=2.4Hz,8.8Hz),8.38(1H,t,J=5.8Hz),8.86(1H,d,J=2.5Hz),12.87(1H,brs)
MS(m/z):496(M+)。
4-トリフルオロメチルチアゾール-2-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),2.45(1H,sept,J=6.8Hz),4.33(2H,d,J=5.8Hz),7.05(1H,brs),7.4-7.6(2H,m),8.37(1H,t,J=5.4Hz),8.76(1H,s),13.51(1H,brs)
MS(m/z):474(M+)。
5-エチニルピリジン-3-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.44(1H,sept,J=6.8Hz),4.32(2H,d,J=5.8Hz),4.52(1H,s),7.17(1H,brs),7.43(1H,dd,J=1.9Hz,8.3Hz),7.5-7.7(2H,m),8.34(1H,t,J=5.8Hz),8.49(1H,s),8.78(1H,d,J=1.9Hz),9.24(1H,d,J=2.0Hz),13.05(1H,brs)
MS(m/z):406(M+)。
5-(1-プロピニル)ピリジン-3-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.10(3H,s),2.44(1H,sept,J=6.8Hz),4.32(2H,d,J=5.8Hz),7.14(1H,brs),7.43(1H,dd,J=2.0Hz,8.3Hz),7.5-7.7(2H,m),8.35(1H,t,J=5.8Hz),8.39(1H,s),8.68(1H,d,J=2.0Hz),9.17(1H,d,J=1.5Hz),13.02(1H,brs)
MS(m/z):420(M+)。
6-(3-メチルオキセタン-3-イルメトキシ)ピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),1.35(3H,s),2.46(1H,sept,J=6.9Hz),4.30(2H,d,J=5.8Hz),4.3-4.5(4H,m),4.50(2H,d,J=5.9Hz),6.95(1H,d,J=9.0Hz),6.99(1H,brs),7.5-7.7(2H,m),7.88(1H,d,J=8.3Hz),8.33(1H,dd,J=1.9Hz,8.8Hz),8.39(1H,t,J=5.4Hz),8.86(1H,d,J=1.5Hz),12.90(1H,brs)
ESI(+)-MS:517(M++1)。
5-エチニルピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),2.46(1H,sept,J=6.9Hz),4.41(2H,d,J=5.8Hz),4.51(1H,s),7.20(1H,brs),7.5-7.7(2H,m),7.89(1H,d,J=8.3Hz),8.40(1H,t,J=6.3Hz),8.47(1H,s),8.77(1H,d,J=2.0Hz),9.22(1H,d,J=2.0Hz),13.12(1H,brs)
MS(m/z):440(M+)。
6-(3-メチルオキセタン-3-イルメトキシ)ピリジン-3-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),1.36(3H,s),2.43(1H,sept,J=6.8Hz),4.2-4.4(4H,m),4.43(2H,s),4.50(2H,d,J=5.8Hz),6.9-7.1(2H,m),7.42(1H,dd,J=2.5Hz,8.3Hz),7.5-7.6(2H,m),8.2-8.4(2H,m),8.88(1H,d,J=2.4Hz),12.86(1H,brs)
ESI(+)-MS:483(M++1)。
5-(1-プロピニル)ピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),2.10(3H,s),2.46(1H,sept,J=6.8Hz),4.41(2H,d,J=5.8Hz),7.17(1H,brs),7.5-7.7(2H,m),7.89(1H,d,J=7.8Hz),8.3-8.5(2H,m),8.67(1H,d,J=1.9Hz),9.15(1H,d,J=2.0Hz),13.10(1H,brs)
MS(m/z):454(M+)。
5-(トリフルオロメチル)ピリジン-3-カルバルデヒドを用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),2.3-2.6(1H,m),4.32(2H,d,J=6.4Hz),7.31(1H,s).7.44(1H,dd,J=2.4Hz,8.4Hz),7.5-7.6(2H,m),8.34(1H,t,J=6.0Hz),8.73(1H,s),9.10(1H,d,J=1.2Hz),9.54(1H,d,J=1.2Hz),13.11(1H,s)
MS(m/z):450(M+)。
6-(3-エトキシプロポキシ)ピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=7.6Hz),1.10(3H,t,J=6.8Hz),1.95(2H,quin,J=6.4Hz),2.4-2.6(1H,m),3.42(2H,q,J=6.8Hz),3.50(2H,t,J=6.4Hz),4.36(2H,t,J=6.8Hz),4.40(2H,d,J=6.0Hz),6.89(1H,d,J=8.4Hz),6.96(1H,s),7.6-7.7(2H,m),7.88(1H,d,J=8.0Hz),8.30(1H,d,J=8.8Hz),8.39(1H,t,J=6.0Hz),8.85(1H,s),12.97(1H,s)
MS(m/z):518(M+)。
6-(2,2-ジフルオロエトキシ)ピリジン-3-カルバルデヒドを用い、実施例4と同様の操作を行い,表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),2.4-2.6(1H,m),4.31(2H,d,J=6.0Hz),4.63(2H,dt,J=3.6Hz,15.2Hz),6.41(1H,tt,J=3.6Hz,54.4Hz),6.96(1H,s),7.02(1H,d,J=8.8Hz),7.40(1H,dd,J=2.0Hz,8.0Hz),7.5-7.6(2H,m),8.34(1H,t,J=6.0Hz),8.39(1H,dd,J=2.4Hz,8.8Hz),8.89(1H,d,J=2.0Hz),12.86(1H,s)
MS(m/z):462(M+)。
6-(2,2-ジフルオロエトキシ)ピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い,実施例4と同様の操作を行い,表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=7.6Hz),2.4-2.6(1H,m),4.40(2H,d,J=6.0Hz),4.64(2H,dt,J=3.2Hz,15.2Hz),6.41(1H,tt,J=3.2Hz,54.8Hz),7.02(2H,d,J=8.8Hz),7.5-7.6(2H,m),7.88(1H,d,J=8.4Hz),8.3-8.4(2H,m),8.87(1H,d,J=2.0Hz),12.96(1H,s)
MS(m/z):496(M+)。
6-(2,2,2-トリフルオロエトキシ)ピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い,実施例4と同様の操作を行い,表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),2.4-2.6(1H,m),4.40(2H,d,J=6.4Hz),5.06(2H,q,J=8.8Hz),7.04(1H,s),7.09(1H,d,J=8.8Hz),7.5-7.6(2H,m),7.88(1H,d,J=8.4Hz),8.3-8.4(2H,m),8.89(1H,d,J=1.2Hz),13.01(1H,s)
MS(m/z):514(M+)。
6-(3,3,3-トリフルオロプロポキシ)ピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い,実施例4と同様の操作を行い,表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),2.46(1H,sept,J=6.8Hz),2.8-2.9(2H,m),4.40(2H,d,J=6.0Hz),4.56(2H,t,J=6.0Hz),6.93(1H,d,J=8.8Hz),6.98(1H,s),7.6-7.7(2H,m),7.88(1H,d,J=8.4Hz),8.34(1H,d,J=7.6Hz),8.39(1H,t,J=6.0Hz),8.87(1H,s),12.99(1H,s)
MS(m/z):528(M+)。
6-(2-フルオロエトキシ)ピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い,実施例4と同様の操作を行い,表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),2.4-2.6(1H,m),4.40(2H,d,J=6.0Hz),4.5-4.9(4H,m),6.9-7.0(2H,m),7.5-7.6(2H,m),7.88(1H,d,J=8.4Hz),8.34(1H,d,J=8.8Hz),8.39(1H,t,J=6.0Hz),8.86(1H,s),12.98(1H,s)
MS(m/z):478(M+)。
6-(3-フルオロプロポキシ)ピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い,実施例4と同様の操作を行い,表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=7.2Hz),2.0-2.2(2H,m),2.4-2.6(1H,m),4.3-4.7(6H,m),6.91(1H,d,J=8.8Hz),6.98(1H,s),7.6-7.7(2H,m),7.88(1H,d,J=8.4Hz),8.32(1H,dd,J=2.0Hz,8.8Hz),8.39(1H,t,J=6.0Hz),8.86(1H,d,J=2.0Hz),12.96(1H,s)
MS(m/z):492(M+)。
2-(ジフルオロメトキシ)ピリジン-4-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い,実施例4と同様の操作を行い,表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),2.46(1H,sept,J=6.8Hz),4.40(2H,d,J=5.6Hz),7.25(1H,s),7.6-7.7(3H,m),7.73(1H,t,J=72.8Hz),7.8-7.9(2H,m),8.3-8.4(2H,m),13.23(1H,s)
MS(m/z):482(M+)。
5-(トリフルオロメチル)ピリジン-2-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い,実施例4と同様の操作を行い,表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),2.4-2.6(1H,m),4.41(2H,d,J=5.6Hz),7.33(1H,s),7.6-7.7(2H,m),7.90(1H,d,J=8.4Hz),8.3-8.4(3H,m),9.12(1H,s),13.23(1H,s)
MS(m/z):484(M+)。
5-クロロピリジン-2-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い,実施例4と同様の操作を行い,表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=7.2Hz),2.4-2.6(1H,m),4.40(2H,d,J=6.0Hz),7.21(1H,s),7.6-7.7(2H,m),7.89(1H,d,J=7.6Hz),8.08(1H,dd,J=2.8Hz,8.8Hz),8.19(1H,d,J=8.0Hz),8.40(1H,t,J=6.0Hz),8.78(1H,d,J=2.4Hz),13.17(1H,s)
MS(m/z):450(M+)。
5-(プロポキシエトキシ)ピリジン-2-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い,実施例4と同様の操作を行い,表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.86(3H,t,J=7.2Hz),1.05(6H,d,J=7.2Hz),1.52(2H,sext,J=7.2Hz),2.4-2.6(1H,m),3.41(2H,t,J=7.2Hz),3.7-3.8(2H,m),4.2-4.3(2H,m),4.40(2H,d,J=6.4Hz),7.11(1H,s),7.52(1H,dd,J=3.2Hz,8.8Hz),7.6-7.7(2H,m),7.88(1H,d,J=8.4Hz),8.14(1H,d,J=8.8Hz),8.39(1H,t,J=6.0Hz),8.43(1H,d,J=3.2Hz),12.98(1H,s)
MS(m/z):518(M+)。
5-(ジフルオロメトキシ)ピリジン-2-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い,実施例4と同様の操作を行い,表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),2.4-2.6(1H,m),4.40(2H,d,J=6.0Hz),7.18(1H,s),7.41(1H,t,J=73.2Hz),7.6-7.7(2H,m),7.80(1H,dd,J=3.2Hz,8.8Hz),7.89(1H,d,J=8.4Hz),8.24(1H,d,J=8.4Hz),8.40(1H,t,J=6.0Hz),8.63(1H,d,J=2.4Hz),13.14(1H,s)
MS(m/z):482(M+)。
5-(シクロプロピルメトキシ)ピリジン-2-カルバルデヒドを用い,実施例4と同様の操作を行い,表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.3-0.4(2H,m),0.5-0.6(2H,m),1.04(6H,d,J=7.2Hz),1.2-1.3(1H,m),2.4-2.6(1H,m),3.98(2H,d,J=7.2Hz),4.31(2H,d,J=5.6Hz),7.10(1H,s),7.41(1H,dd,J=2.0Hz,8.4Hz),7.48(1H,dd,J=2.8Hz,8.4Hz),7.5-7.6(2H,m),8.18(1H,d,J=8.8Hz),8.34(1H,t,J=5.6Hz),8.42(1H,d,J=2.8Hz)12.86(1H,s)
MS(m/z):452(M+)。
5-(シクロプロピルメトキシ)ピリジン-2-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い,実施例4と同様の操作を行い,表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.3-0.4(2H,m),0.5-0.6(2H,m),1.05(6H,d,J=7.2Hz),1.2-1.3(1H,m),2.4-2.6(1H,m),3.97(2H,d,J=6.8Hz),4.40(2H,d,J=6.0Hz),7.11(1H,s),7.48(1H,dd,J=2.8Hz,8.4Hz),7.6-7.7(2H,m),7.88(1H,d,J=8.4Hz),8.13(1H,d,J=8.4Hz),8.3-8.4(2H,m),12.97(1H,s)
MS(m/z):486(M+)。
6-(トリフルオロメチル)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)ブチルアミド塩酸塩を用い,実施例4と同様の操作を行い,表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.87(3H,t,J=7.2Hz),1.55(2H,sext,J=7.2Hz),2.14(2H,t,J=7.2Hz),4.33(2H,d,J=6.0Hz),7.31(1H,s),7.4-7.5(2H,m),8.02(1H,d,J=8.4Hz),8.40(1H,t,J=6.0Hz),8.67(1H,d,J=8.0Hz),9.39(1H,s),13.34(1H,s)
MS(m/z):468(M+)。
6-(ジフルオロメトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)ブチルアミド塩酸塩を用い,実施例4と同様の操作を行い,表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.87(3H,t,J=7.6Hz),1.55(2H,sext,J=7.6Hz),2.14(2H,t,J=7.6Hz),4.33(2H,d,J=5.2Hz),7.13(1H,s),7.19(1H,d,J=8.4Hz),7.4-7.5(2H,m),7.77(1H,t,J=76.4Hz),8.40(1H,t,J=5.2Hz),8.51(1H,dd,J=0.8Hz,8.8Hz),8.92(1H,s),13.19(1H,s)
MS(m/z):466(M+)。
2-(シクロプロピルメトキシ)ピリミジン-5-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い,実施例4と同様の操作を行い,表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.3-0.4(2H,m),0.5-0.6(2H,m),1.05(6H,d,J=6.8Hz),1.2-1.3(1H,m),2.4-2.6(1H,m),4.22(2H,d,J=6.8Hz),4.40(2H,d,J=6.0Hz),7.09(1H,s),7.5-7.6(2H,m),7.89(1H,d,J=8.4Hz),8.39(1H,t,J=6.0Hz),9.1-9.2(2H,m),13.07(1H,s)
MS(m/z):487(M+)。
6-ブトキシピリダジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い,実施例4と同様の操作を行い,表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.93(3H,t,J=7.6Hz),1.05(6H,d,J=7.2Hz),1.34(2H,sext,J=7.6Hz),1.77(2H,quin,J=7.2Hz),2.4-2.6(1H,m),4.17(2H,t,J=7.6Hz),4.39(2H,d,J=6.0Hz),6.96(1H,s),7.03(1H,d,J=10.0Hz),7.5-7.7(2H,m),7.88(1H,d,J=8.4Hz),7.99(1H,d,J=9.6Hz),8.39(1H,t,J=6.0Hz),13.17(1H,s)
MS(m/z):489(M+)。
2-(トリフルオロメチル)ピリミジン-5-カルバルデヒドを用い,実施例4と同様の操作を行い,表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),4.32(2H,d,J=6.0Hz),7.34(1H,s),7.44(1H,dd,J=2.0Hz,8.0Hz),7.5-7.6(2H,m),8.34(1H,t,J=6.0Hz),9.63(2H,s),13.21(1H,s)
MS(m/z):451(M+)。
2-(シクロプロピルメトキシ)ピリジン-4-カルバルデヒドを用い,実施例4と同様の操作を行い,表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.3-0.4(2H,m),0.5-0.6(2H,m),1.04(6H,d,J=6.8Hz),1.2-1.3(1H,m),2.4-2.6(1H,m),4.14(2H,d,J=7.2Hz),4.32(2H,d,J=6.4Hz),7.11(1H,s),7.4-7.5(2H,m),7.5-7.6(3H,m),8.24(1H,d,J=5.6Hz),8.34(1H,t,J=5.6Hz),13.05(1H,s)
MS(m/z):452(M+)。
5-フルオロピリジン-2-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=7.2Hz),2.45(1H,sept,J=6.8Hz),4.33(2H,d,J=6.0Hz),7.21(1H,s),7.4-7.6(2H,m),7.84(1H,dt,J=2.8Hz,8.8Hz),8.2-8.3(1H,m),8.37(1H,t,J=6.0Hz),8.74(1H,d,J=3.2Hz),13.28(1H,brs)
MS(m/z):418(M+)。
2-[3-クロロ-2-フルオロ-6-(トリフルオロメチル)フェニル]-6-(6-メトキシピリジン-3-イル)ピリミジン-4(3H)-オンを用い、実施例169と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.06(6H,d,J=6.8Hz),2.48(1H,sept,J=6.8Hz),3.91(3H,s),4.40(2H,d,J=6.0Hz),6.91(1H,d,J=8.8Hz),7.01(1H,s),7.65(1H,t,J=8.0Hz),7.78(1H,d,J=7.6Hz),8.30(1H,d,J=8.4Hz),8.44(1H,t,J=6.0Hz),8.85(1H,s),13.17(1H,brs)
MS(m/z):464(M+)。
6-(シクロプロピルエチニル)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.8-1.0(4H,m),1.04(6H,d,J=6.8Hz),1.6-1.7(1H,m),2.45(1H,sept,J=6.8Hz),4.32(2H,d,J=5.6Hz),7.14(1H,s),7.4-7.5(3H,m),8.3-8.4(2H,m),9.13(1H,d,J=1.6Hz),13.22(1H,brs)
MS(m/z):464(M+)。
5-クロロピリジン-2-カルバルデヒド及びN-(3-カルバミミドイル-2-クロロ-4-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.07(6H,d,J=6.8Hz),2.4-2.6(1H,m),4.35(2H,d,J=6.0Hz),7.25(1H,s),7.4-7.5(2H,m),8.05(1H,dd,J=2.4Hz,8.4Hz),8.21(1H,d,J=8.4Hz),8.38(1H,t,J=6.0Hz),8.79(1H,d,J=2.4Hz),13.29(1H,brs)
MS(m/z):434(M+)。
4-ホルミルベンゾニトリル及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.45(1H,sept,J=6.8Hz),4.32(2H,d,J=6.0Hz),7.17(1H,s),7.4-7.5(2H,m),7.95(2H,d,J=8.4Hz),8.24(2H,d,J=8.4Hz),8.36(1H,t,J=6.0Hz),13.27(1H,brs)
MS(m/z):424(M+)。
6-フェニルピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),2.46(1H,sept,J=6.8Hz),4.34(2H,d,J=5.6Hz),7.20(1H,s),7.4-7.5(5H,m),8.09(1H,d,J=8.4Hz),8.1-8.2(2H,m),8.37(1H,t,J=5.6Hz),8.48(1H,dd,J=2.0Hz,8.0Hz),9.31(1H,d,J=1.6Hz),13.17(1H,brs)
MS(m/z):476(M+)。
5-(トリフルオロメチル)ピリジン-2-カルバルデヒド及びN-(3-カルバミミドイル-2,4-ジフルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),2.45(1H,sept,J=6.8Hz),4.33(2H,d,J=6.0Hz),7.30(1H,t,J=8.8Hz),7.35(1H,s),7.53(1H,q,J=8.0Hz),8.3-8.4(3H,m),9.13(1H,s),13.40(1H,brs)
MS(m/z):452(M+)。
5-クロロピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-2,4-ジフルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.45(1H,sept,J=6.8Hz),4.32(2H,d,J=6.0Hz),7.24(1H,s),7.29(1H,t,J=8.8Hz),7.4-7.5(1H,m),8.33(1H,t,J=5.6Hz),8.49(1H,s),8.75(1H,d,J=2.4Hz),9.18(1H,d,J=1.6Hz),13.31(1H,brs)
MS(m/z):418(M+)。
6-(ジフルオロメチル)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.45(1H,sept,J=6.8Hz),4.33(2H,d,J=6.0Hz),7.04(1H,t,J=54.8Hz),7.25(1H,s),7.4-7.5(2H,m),7.81(1H,d,J=8.4Hz),8.39(1H,t,J=6.0Hz),8.60(1H,d,J=8.0Hz),9.31(1H,s),13.35(1H,brs)
MS(m/z):450(M+)。
6-(シクロプロピルエチニル)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-2-クロロ-4-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.8-1.0(4H,m),1.07(6H,d,J=6.8Hz),1.6-1.7(1H,m),2.4-2.6(1H,m),4.34(2H,d,J=6.0Hz),7.14(1H,s),7.4-7.5(3H,m),8.3-8.4(2H,m),9.13(1H,d,J=1.6Hz),13.21(1H,brs)
MS(m/z):464(M+)。
5-(ジフルオロメチル)ピリジン-2-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=7.2Hz),2.46(1H,sept,J=6.8Hz),4.33(2H,d,J=6.0Hz),7.23(1H,t,J=55.2Hz),7.32(1H,s),7.4-7.6(2H,m),8.15(1H,d,J=7.6Hz),8.3-8.4(2H,m),8.93(1H,s),13.33(1H,brs)
MS(m/z):450(M+)。
5-クロロピリジン-2-カルバルデヒド及びN-(3-カルバミミドイル-2,4-ジフルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.45(1H,sept,J=6.8Hz),4.32(2H,d,J=6.0Hz),7.23(1H,s),7.29(1H,t,J=8.8Hz),7.4-7.6(1H,m),8.08(1H,dd,J=2.4Hz,8.4Hz),8.22(1H,d,J=8.4Hz),8.34(1H,t,J=6.0Hz),8.78(1H,d,J=2.4Hz),13.32(1H,brs)
MS(m/z):418(M+)。
6-(トリフルオロメチル)ピリジン-2-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=7.2Hz),2.46(1H,sept,J=6.8Hz),4.33(2H,d,J=5.6Hz),7.26(1H,s),7.4-7.5(2H,m),8.05(1H,d,J=7.6Hz),8.25(1H,t,J=8.0Hz),8.37(1H,t,J=5.6Hz),8.47(1H,d,J=8.0Hz),13.40(1H,brs)
MS(m/z):468(M+)。
4-(トリフルオロメチル)チアゾール-2-カルバルデヒド及びN-(3-カルバミミドイル-2-クロロ-4-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.07(6H,d,J=7.2Hz),2.4-2.6(1H,m),4.35(2H,d,J=6.0Hz),7.05(1H,s),7.4-7.6(2H,m),8.39(1H,t,J=6.0Hz),8.76(1H,s),13.51(1H,brs)
MS(m/z):474(M+)。
2-(シクロプロピルエチニル)チアゾール-5-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.8-1.0(4H,m),1.04(6H,d,J=6.8Hz),1.6-1.7(1H,m),2.45(1H,sept,J=6.8Hz),4.31(2H,d,J=6.0Hz),7.07(1H,s),7.4-7.5(2H,m),8.36(1H,t,J=5.6Hz),8.59(1H,s),13.22(1H,brs)
MS(m/z):470(M+)。
5-(シクロプロピルエチニル)ピリジン-2-カルバルデヒド及びN-(3-カルバミミドイル-2-クロロ-4-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.8-1.0(4H,m),1.07(6H,d,J=7.2Hz),1.6-1.7(1H,m),2.4-2.6(1H,m),4.34(2H,d,J=6.0Hz),7.23(1H,s),7.4-7.5(2H,m),7.88(1H,dd,J=2.0Hz,8.4Hz),8.15(1H,d,J=8.4Hz),8.38(1H,t,J=6.0Hz),8.69(1H,d,J=2.0Hz),13.26(1H,brs)
MS(m/z):464(M+)。
6-(3-エチルオキセタン-3-イルメトキシ)ピリジン-3-カルバルデヒドを用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.90(3H,t,J=7.8Hz),1.04(6H,d,J=6.8Hz),1.77(2H,q,J=7.3Hz),2.43(1H,sept,J=6.8Hz),4.2-4.6(8H,m),6.9-7.0(2H,m),7.42(1H,dd,J=2.0Hz,8.3Hz),7.5-7.6(2H,m),8.2-8.4(2H,m),8.89(1H,d,J=2.2Hz),12.85(1H,brs)
ESI(+)-MS:497(M++1)。
6-(3-エチルオキセタン-3-イルメトキシ)ピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.90(3H,t,J=7.3Hz),1.05(6H,d,J=6.8Hz),1.77(2H,q,J=7.3Hz),2.46(1H,sept,J=6.8Hz),4.33(2H,d,J=5.9Hz),4.40(2H,d,J=5.9Hz),4.45(2H,d,J=5.9Hz),4.48(2H,s),6.9-7.0(2H,m),7.5-7.7(2H,m),7.87(1H,d,J=7.8Hz),8.32(1H,dd,J=2.4Hz,8.7Hz),8.40(1H,t,J=5.9Hz),8.86(1H,d,J=2.0Hz),12.92(1H,brs)
ESI(+)-MS:531(M++1)。
4-メチルチアゾール-2-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),2.45(1H,sept,J=6.8Hz),2.47(3H,s),4.33(2H,d,J=5.9Hz),6.96(1H,brs),7.4-7.6(2H,m),7.59(1H,s),8.37(1H,t,J=6.1Hz),13.31(1H,brs)
MS(m/z):420(M+)。
4-(1-プロピニル)チアゾール-2-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.09(3H,s),2.45(1H,sept,J=6.8Hz),4.33(2H,d,J=5.9Hz),6.99(1H,brs),7.4-7.6(2H,m),8.10(1H,s),8.36(1H,t,J=5.8z),13.39(1H,brs)
MS(m/z):444(M+)。
5-(シクロプロピルエチニル)チアゾール-2-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.7-1.0(4H,m),1.05(6H,d,J=6.8Hz),1.6-1.7(1H,s),2.45(1H,sept,J=6.8Hz),4.33(2H,d,J=5.9Hz),6.99(1H,brs),7.4-7.6(2H,m),8.13(1H,s),8.37(1H,t,J=6.1Hz),13.38(1H,brs)
MS(m/z):470(M+)。
4-(シクロプロピルエチニル)チアゾール-2-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.7-1.0(4H,m),1.04(6H,d,J=6.8Hz),1.5-1.7(1H,m),2.45(1H,sept,J=6.8Hz),4.32(2H,d,J=5.9Hz),6.98(1H,brs),7.4-7.6(2H,m),8.08(1H,s),8.36(1H,t,J=5.4Hz),13.39(1H,brs)
MS(m/z):470(M+)。
5-(シクロプロピルエチニル)チアゾール-2-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.7-1.0(4H,m),1.05(6H,d,J=6.8Hz),1.5-1.7(1H,m),2.46(1H,sept,J=6.8Hz),4.40(2H,d,J=5.9Hz),6.94(1H,brs),7.5-7.7(2H,m),7.89(1H,d,J=8.3Hz),8.11(1H,s),8.40(1H,t,J=5.8Hz),13.23(1H,brs)
MS(m/z):486(M+)。
6-(シクロプロピルエチニル)ピリジン-2-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.8-1.0(4H,m),1.05(6H,d,J=6.8Hz),1.5-1.7(1H,m),2.46(1H,sept,J=6.8Hz),4.40(2H,d,J=6.4Hz),7.18(1H,brs),7.54(1H,dd,J=0.9Hz,7.8Hz),7.5-7.7(2H,m),7.8-8.0(2H,m),8.10(1H,d,J=7.4Hz),8.40(1H,t,J=5.8Hz),13.11(1H,brs)
MS(m/z):480(M+)。
5-(シクロプロピルエチニル)ピリジン-3-カルバルデヒドを用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.7-1.0(4H,m),1.04(6H,d,J=6.8Hz),1.5-1.7(1H,m),2.44(1H,sept,J=6.8Hz),4.32(2H,d,J=5.9Hz),7.13(1H,brs),7.43(1H,dd,J=2.5Hz,8.3Hz),7.5-7.7(2H,m),8.3-8.4(2H,m),8.65(1H,d,J=1.9Hz),9.15(1H,d,J=2.0Hz),13.02(1H,brs)
MS(m/z):446(M+)。
5-(シクロプロピルエチニル)ピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.7-1.0(4H,m),1.05(6H,d,J=6.8Hz),1.5-1.7(1H,m),2.46(1H,sept,J=6.8Hz),4.40(2H,d,J=5.9Hz),7.16(1H,brs),7.5-7.7(2H,m),7.89(1H,d,J=8.3Hz),8.34(1H,s),8.40(1H,t,J=5.8Hz),8.64(1H,d,J=2.0Hz),9.13(1H,d,J=1.5Hz),13.11(1H,brs)
MS(m/z):480(M+)。
6-(3-モルホリン-4-イルプロポキシ)ピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=7.2Hz),1.89(2H,sext,J=6.8Hz),2.3-2.6(7H,m),3.56(4H,t,J=4.8Hz),4.35(2H,t,J=6.8Hz),4.40(2H,d,J=5.6Hz),6.88(1H,d,J=8.8Hz),6.98(1H,s),7.5-7.6(2H,m),7.88(1H,d,J=7.6Hz),8.30(1H,dd,J=2.4Hz,8.8Hz),8.39(1H,t,J=6.0Hz),8.85(1H,d,J=2.4Hz),12.90(1H,s)
MS(m/z):559(M+)。
5-(トリフルオロメチル)ピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),2.46(1H,sept,J=6.8Hz),4.41(2H,d,J=5.6Hz),7.35(1H,s),7.6-7.7(2H,m),7.91(1H,d,J=8.0Hz),8.42(1H,t,J=6.0Hz),8.73(1H,s),9.10(1H,s),9.54(1H,s),13.23(1H,s)
MS(m/z):484(M+)。
5-(トリフルオロメチル)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.43(1H,sept,J=6.8Hz),4.33(2H,d,J=6.0Hz),7.36(1H,s),7.4-7.5(2H,m),8.36(1H,t,J=6.0Hz),8.70(1H,s),9.10(1H,d,J=1.2Hz),9.51(1H,d,J=1.6Hz),13.33(1H,s)
MS(m/z):468(M+)。
2-ブチルピリミジン-5-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.90(3H,t,J=7.2Hz),1.05(6H,d,J=6.8Hz),1.34(2H,sext,J=7.6Hz),1.76(2H,quin,J=7.6Hz),2.46(1H,sept,J=6.8Hz),2.93(2H,t,J=7.2Hz),4.40(2H,d,J=6.0Hz),7.17(1H,s),7.6-7.7(2H,m),7.89(1H,d,J=8.4Hz),8.39(1H,t,J=6.4Hz),9.28(2H,s),13.15(1H,s)
MS(m/z):473(M+)。
5-(トリフルオロメチル)ピリジン-2-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]ブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.86(3H,t,J=7.2Hz),1.55(2H,sext,J=7.2Hz),2.15(2H,t,J=7.2Hz),4.42(2H,d,J=6.0Hz),7.31(1H,s),7.6-7.7(2H,m),7.90(1H,d,J=7.6Hz),8.38(2H,s),8.44(1H,t,J=6.0Hz),9.12(1H,s),13.26(1H,s)
MS(m/z):484(M+)。
5-(トリフルオロメチル)ピリジン-2-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)ブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.87(3H,t,J=7.2Hz),1.55(2H,sext,J=7.2Hz),2.14(2H,t,J=7.2Hz),4.34(2H,d,J=6.0Hz),7.36(1H,s),7.5-7.6(2H,m),8.3-8.5(3H,m),9.13(1H,d,J=1.2Hz),13.38(1H,s)
MS(m/z):468(M+)。
6-プロピルピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.91(3H,t,J=7.2Hz),1.04(6H,d,J=6.8Hz),1.07(2H,sext,J=7.2Hz),2.45(1H,sept,J=6.8Hz),2.76(2H,t,J=7.6Hz),4.32(2H,d,J=6.0Hz),7.09(1H,s),7.36(1H,d,J=7.6Hz),7.4-7.5(2H,m),8.29(1H,dd,J=2.4Hz,8.0Hz),8.36(1H,t,J=6.0Hz)9.11(1H,d,J=2.0Hz),13.10(1H,s)
MS(m/z):442(M+)。
6-プロピルピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.91(3H,t,J=7.2Hz),1.05(6H,d,J=7.2Hz),1.71(2H,sext,J=7.2Hz),2.4-2.6(1H,m),2.76(2H,t,J=7.2Hz),4.40(2H,d,J=6.0Hz),7.05(1H,s),7.35(1H,d,J=8.4Hz),7.6-7.7(2H,m),7.88(1H,d,J=8.0Hz),8.29(1H,dd,J=2.4Hz,8.4Hz),8.39(1H,t,J=6.0Hz),9.12(1H,d,J=1.6Hz),13.00(1H,s)
MS(m/z):458(M+)。
2-(3,3-ジメチル-1-ブチニル)ピリミジン-5-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=7.2Hz),1.33(9H,s),2.4-2.6(1H,m),4.40(2H,d,J=6.4Hz),7.24(1H,s),7.6-7.7(2H,m),7.89(1H,d,J=7.6Hz),8.40(1H,t,J=6.0Hz),9.32(2H,s),13.19(1H,s)
MS(m/z):497(M+)。
2-(3,3-ジメチル-1-ブチニル)ピリミジン-5-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),1.33(9H,s),2.45(1H,sept,J=6.8Hz),4.32(2H,d,J=5.6Hz),7.28(1H,s),7.4-7.5(2H,m),8.36(1H,t,J=6.0Hz),9.31(2H,s),13.31(1H,s)
MS(m/z):481(M+)。
5-(シクロプロピルエチニル)ピリジン-2-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.8-1.0(4H,m),1.04(6H,d,J=6.8Hz),1.6-1.7(1H,m),2.45(1H,sept,J=6.8Hz),4.32(2H,d,J=6.0Hz),7.23(1H,s),7.4-7.5(2H,m),7.89(1H,dd,J=2.0Hz,8.4Hz),8.15(1H,d,J=8.0Hz),8.36(1H,t,J=5.6Hz),8.69(1H,d,J=2.0Hz),13.26(1H,brs)
MS(m/z):464(M+)。
6-(1-プロピニル)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.11(3H,s),2.45(1H,sept,J=6.8Hz),4.32(2H,d,J=6.0Hz),7.14(1H,s),7.4-7.6(3H,m),8.3-8.4(2H,m),9.15(1H,s),13.23(1H,brs)
MS(m/z):438(M+)。
6-(2-プロポキシエトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-2,4-ジフルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.85(3H,t,J=7.2Hz),1.04(6H,d,J=6.8Hz),1.51(2H,sext,J=7.2Hz),2.45(1H,sept,J=6.8Hz),3.40(2H,t,J=6.8Hz),3.71(2H,t,J=4.4Hz),4.32(2H,d,J=6.0Hz),4.44(2H,t,J=4.4Hz),6.92(1H,d,J=8.8Hz),7.00(1H,s),7.28(1H,t,J=8.8Hz),7.4-7.6(1H,m),8.3-8.4(2H,m),8.85(1H,s),13.11(1H,brs)
MS(m/z):486(M+)。
6-メトキシピリジン-2-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=7.2Hz),2.45(1H,sept,J=6.8Hz),3.98(3H,s),4.33(2H,d,J=6.0Hz),6.9-7.0(1H,m),7.29(1H,s),7.4-7.5(2H,m),7.8-7.9(2H,m),8.37(1H,t,J=6.0Hz),13.15(1H,brs)
MS(m/z):430(M+)。
2-[3-クロロ-2-フルオロ-6-(トリフルオロメチル)フェニル]-6-(5-フルオロピリジン-3-イル)ピリミジン-4(3H)-オンを用い、実施例169と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.06(6H,d,J=6.8Hz),2.48(1H,sept,J=6.8Hz),4.41(2H,d,J=5.6Hz),7.25(1H,s),7.66(1H,t,J=7.2Hz),7.80(1H,d,J=8.0Hz),8.27(1H,d,J=10.4Hz),8.44(1H,t,J=5.6Hz),8.71(1H,d,J=2.4Hz),9.10(1H,s),13.38(1H,brs)
MS(m/z):452(M+)。
6-[(1-ヒドロキシシクロヘキシル)エチニル]ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),1.2-1.3(1H,m),1.4-1.7(7H,m),1.8-1.9(2H,m),2.45(1H,sept,J=6.8Hz),4.32(2H,d,J=6.0Hz),5.58(1H,s),7.16(1H,s),7.4-7.5(2H,m),7.57(1H,d,J=8.0Hz),8.3-8.4(2H,m),9.19(1H,s),13.25(1H,brs)
MS(m/z):522(M+)。
5-(1-プロピニル)ピリジン-2-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.12(3H,s),2.45(1H,sept,J=6.8Hz),4.32(2H,d,J=6.0Hz),7.24(1H,s),7.4-7.5(2H,m),7.92(1H,dd,J=2.0Hz,8.4Hz),8.17(1H,d,J=8.4Hz),8.36(1H,t,J=5.6Hz),8.72(1H,d,J=2.0Hz),13.27(1H,brs)
MS(m/z):438(M+)。
2-[3-クロロ-2-フルオロ-6-(トリフルオロメチル)フェニル]-6-(6-エトキシピリジン-3-イル)ピリミジン-4(3H)-オンを用い、実施例169と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.06(6H,d,J=6.8Hz),1.33(3H,t,J=6.8Hz),2.48(1H,sept,J=6.8Hz),4.3-4.5(4H,m),6.88(1H,d,J=8.8Hz),7.00(1H,s),7.65(1H,t,J=8.0Hz),7.78(1H,d,J=8.4Hz),8.28(1H,d,J=8.4Hz),8.43(1H,t,J=5.6Hz),8.83(1H,s),13.16(1H,brs)
MS(m/z):478(M+)。
1H-NMR(CDCl3,δ):1.20(6H,d,J=5.8Hz),3.49(1H,sept,J=6.3Hz),3.7-3.9(2H,m),4.5-4.7(2H,m),6.89(1H,d,J=8.8Hz),8.06(1H,dd,J=2.5Hz,8.8Hz),8.61(1H,d,J=1.9Hz),9.95(1H,s)
MS(m/z):210(M++1) 。
1H-NMR(CDCl3,δ):3.94(2H,q,J=8.3Hz),4.01(2H,t,J=4.4Hz),4.5-4.7(2H,m),6.90(1H,d,J=8.3Hz),8.09(1H,dd,J=1.9Hz,8.3Hz),8.61(1H,d,J=2.0Hz),9.97(1H,s)
MS(m/z):249(M+) 。
1H-NMR(CDCl3,δ):1.38(9H,s),4.04(3H,s),8.67(1H,d,J=1.2Hz),9.21(1H,d,J=1.2Hz)
MS(m/z):218(M+)。
1H-NMR(CDCl3,δ):1.17(9H,s),3.7-3.8(1H,m),4.82(2H,d,J=8.4Hz),8.4-8.6(2H,m)
MS(m/z):190(M+)。
1H-NMR(CDCl3,δ):1.19(9H,s),8.64(1H,d,J=0.8Hz),9.06(1H,d,J=1.2Hz),10.11(1H,s)
MS(m/z):188(M+)。
1H-NMR(CDCl3,δ):0.9-1.1(4H,m),1.5-1.6(1H,m),4.03(3H,s),8.65(1H,d,J=1.6Hz),9.19(1H,d,J=1.6Hz)
MS(m/z):202(M+)。
1H-NMR(CDCl3,δ):0.5-0.7(2H,m),0.9-1.0(2H,m),1.6-1.7(1H,m),3.7-3.8(1H,m),4.7-4.8(2H,m),8.3-8.6(2H,m)
MS(m/z):174(M+)。
1H-NMR(CDCl3,δ):0.7-0.8(2H,m),0.9-1.1(2H,m),1.7-1.8(1H,m),8.53(1H,d,J=1.6Hz),9.01(1H,d,J=1.2Hz),10.08(1H,s)
MS(m/z):172(M+)。
1H-NMR(CDCl3,δ):1.09(6H,d,J=6.0Hz),2.03(1H,sept,J=6.8Hz),2.43(2H,d,J=6.4Hz),9.12(2H,s),10.13(1H,s)
MS(m/z):188(M+)。
1H-NMR(CDCl3,δ):2.18(3H,s),8.34(1H,s),10.00(1H,s)
MS(m/z):151(M+)。
1H-NMR(d6-DMSO,δ):7.29(1H,s),7.87(1H,d,J=8.8Hz),8.0-8.2(3H,m),8.79(1H,d,J=2.4Hz),13.40(1H,brs)
MS(m/z):403(M+)。
1H-NMR(d6-DMSO,δ):2.12(3H,s),7.29(1H,s),7.86(1H,d,J=8.4Hz),7.94(1H,dd,J=2.0Hz,8.0Hz),8.0-8.2(2H,m),8.73(1H,d,J=2.0Hz),13.37(1H,brs)
MS(m/z):407(M+)。
1H-NMR(d6-DMSO,δ):0.7-1.0(4H,m),1.5-1.7(1H,m),7.19(1H,s),7.52(1H,d,J=8.4Hz),7.86(1H,d,J=8.8Hz),8.09(1H,t,J=7.2Hz),8.33(1H,d,J=8.4Hz),9.13(1H,s),13.32(1H,brs)
MS(m/z):433(M+)。
1H-NMR(d6-DMSO,δ):0.85(3H,t,J=7.2Hz),1.51(2H,sext,J=7.2Hz),3.40(2H,t,J=6.8Hz),3.71(2H,t,J=4.8Hz),4.44(2H,t,J=4.8Hz),6.93(1H,d,J=8.8Hz),7.06(1H,s),7.85(1H,d,J=8.8Hz),8.08(1H,t,J=8.4Hz),8.30(1H,dd,J=2.0Hz,8.8Hz),8.84(1H,s),13.19(1H,brs)
MS(m/z):471(M+)。
1H-NMR(d6-DMSO,δ):1.09(6H,d,J=6.0Hz),3.61(1H,sept,J=6.0Hz),3.70(2H,t,J=4.8Hz),4.41(2H,t,J=4.8Hz),6.93(1H,d,J=8.8Hz),7.07(1H,s),7.85(1H,d,J=8.4Hz),8.08(1H,t,J=8.4Hz),8.30(1H,dd,J=2.0Hz,8.8Hz),8.84(1H,d,J=1.6Hz),13.18(1H,brs)
MS(m/z):471(M+)。
1H-NMR(d6-DMSO,δ):0.8-1.1(4H,m),1.6-1.8(1H,m),7.13(1H,s),7.85(1H,d,J=8.0Hz),8.09(1H,t,J=8.0Hz),8.60(1H,s),13.31(1H,brs)
MS(m/z):439(M+)。
1H-NMR(d6-DMSO,δ):3.95(2H,t,J=4.0Hz),4.14(2H,q,J=9.2Hz),4.48(2H,t,J=4.4Hz),6.95(1H,d,J=8.8Hz),7.08(1H,s),7.85(1H,d,J=8.8Hz),8.08(1H,t,J=8.4Hz),8.31(1H,dd,J=2.4Hz,8.8Hz),8.84(1H,d,J=2.0Hz),13.15(1H,brs)
MS(m/z):511(M+)。
1H-NMR(CDCl3,δ):3.55(2H,q,10.8Hz),7.44(2H,s),7.92(1H,dd,J=1.6Hz,8.0Hz),8.33(1H,d,J=8.4Hz),8.81(1H,d,J=2.0Hz)
MS(m/z):383(M+)。
1H-NMR(CDCl3,δ):3.42(3H,s),3.45(2H,q,10.8Hz),3.76(3H,s),7.6-7.8(2H,m),8.55(1H,s)
MS(m/z):217(M+-31)。
1H-NMR(CDCl3,δ):3.51(2H,q,10.8Hz),7.85(1H,d,J=7.2Hz),7.99(1H,d,J=8.0Hz),8.73(1H,d,J=1.2Hz),10.10(1H,s)
MS(m/z):189(M+)。
1H-NMR(d6-DMSO,δ):0.7-1.0(4H,m),1.5-1.7(1H,m),7.28(1H,s),7.86(1H,d,J=8.8Hz),7.91(1H,dd,J=2.0Hz,8.4Hz),8.0-8.2(2H,m),8.69(1H,d,J=1.2Hz),13.35(1H,brs)
MS(m/z):433(M+)。
ベンゾチアゾール-2-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),2.48(1H,sept,J=6.8Hz),4.35(2H,d,J=5.9Hz),7.23(1H,brs),7.4-7.7(4H,m),8.1-8.3(2H,m),8.38(1H,t,J=5.4Hz),13.50(1H,brs)
MS(m/z):456(M+)。
6-(2-イソプロポキシエトキシ)ピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),1.09(6H,d,J=5.9Hz),2.46(1H,sept,J=6.8Hz),3.61(1H,sept,J=6.4Hz),3.6-3.8(2H,m),4.3-4.5(4H,m),6.92(1H,d,J=8.8Hz),6.98(1H,brs),7.5-7.7(2H,m),7.88(1H,d,J=7.8Hz),8.31(1H,dd,J=1.9Hz,8.8Hz),8.39(1H,t,J=5.8Hz),8.85(1H,d,J=1.5Hz),12.95(1H,brs)
MS(m/z):518(M+)。
6-(2-イソプロポキシエトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),1.10(6H,d,J=5.9Hz),2.45(1H,sept,J=6.8Hz),3.61(1H,sept,J=6.3Hz),3.70(2H,t,J=4.9Hz),4.32(2H,d,J=5.8Hz),4.41(2H,t,J=4.9Hz),6.92(1H,d,J=8.8Hz),7.01(1H,brs),7.4-7.6(2H,m),8.31(1H,dd,J=2.4Hz,8.7Hz),8.36(1H,t,J=5.8Hz),8.84(1H,d,J=2.0Hz),13.08(1H,brs)
MS(m/z):502(M+)。
6-(2-イソプロポキシエトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-2,4-ジフルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=7.3Hz),1.10(6H,d,J=6.4Hz),2.45(1H,sept,J=6.8Hz),3.62(1H,sept,J=6.3Hz),3.70(2H,t,J=4.9Hz),4.32(2H,d,J=5.9Hz),4.41(2H,t,J=5.4Hz),6.92(1H,d,J=8.8Hz),7.01(1H,brs),7.28(1H,t,J=8.8Hz),7.50(1H,dd,J=7.9Hz),8.2-8.4(2H,m),8.85(1H,d,J=1.9Hz),13.02(1H,brs)
MS(m/z):486(M+)。
6-(2-イソプロポキシエトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-2-クロロ-4-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.07(6H,d,J=6.8Hz),1.09(6H,d,J=6.4Hz),2.4-2.6(1H,m),3.61(1H,sept,J=5.9Hz),3.70(2H,t,J=4.9Hz),4.34(2H,d,J=5.8Hz),4.41(2H,t,J=5.4Hz),6.91(1H,d,J=8.8Hz),7.01(1H,brs),7.3-7.6(2H,m),8.31(1H,dd,J=2.4Hz,8.8Hz),8.37(1H,t,J=5.9Hz),8.84(1H,d,J=2.0Hz),13.06(1H,brs)
MS(m/z):502(M+)。
6-(テトラヒドロピラン-4-イルメトキシ)ピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]ブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.86(3H,t,J=7.3Hz),1.2-1.4(2H,m),1.55(2H,sext,J=7.3Hz),1.65(2H,d,J=2.7Hz),1.9-2.1(1H,m),2.15(2H,t,J=7.3Hz),3.2-3.5(2H,m),3.87(2H,dd,J=2.9Hz,11.2Hz),4.18(2H,d,J=6.3Hz),4.41(2H,d,J=5.4Hz),6.90(1H,d,J=8.8Hz),6.98(1H,s),7.5-7.7(2H,m),7.87(1H,d,J=8.3Hz),8.30(1H,dd,J=2.0Hz,8.3Hz),8.43(1H,t,J=5.8Hz),8.84(1H,d,J=2.0Hz),12.54(1H,brs)
MS(m/z):530(M+)。
6-(2-イソプロポキシエトキシ)ピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]ブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.86(3H,t,J=7.3Hz),1.09(6H,d,J=5.9Hz),1.55(2H,sext,J=7.3Hz),2.15(2H,t,J=7.3Hz),3.61(1H,sept,J=5.9Hz),3.6-3.8(2H,m),4.3-4.5(4H,m),6.92(1H,d,J=8.8Hz),6.98(1H,brs),7.5-7.7(2H,m),7.88(1H,d,J=8.8Hz),8.31(1H,dd,J=2.4Hz,8.8Hz),8.43(1H,t,J=5.8Hz),8.85(1H,d,J=2.7Hz),12.81(1H,brs)
MS(m/z):518(M+)。
6-(2-エトキシエトキシ)ピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]ブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.86(3H,t,J=7.3Hz),1.12(3H,t,J=7.3Hz),1.55(2H,sext,J=7.3Hz),2.15(2H,t,J=7.6Hz),3.49(2H,q,J=6.9Hz),3.6-3.8(2H,m),4.3-4.5(4H,m),6.92(1H,d,J=8.8Hz),6.98(1H,brs),7.5-7.7(2H,m),7.88(1H,d,J=8.3Hz),8.2-8.4(1H,m),8.43(1H,t,J=5.8Hz),8.85(1H,brs),12.95(1H,brs)
MS(m/z):504(M+)。
6-(2-プロポキシエトキシ)ピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]ブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.8-0.9(6H,m),1.4-1.7(4H,m),2.15(2H,t,J=7.6Hz),3.40(2H,t,J=6.9Hz),3.6-3.8(2H,m),4.3-4.5(4H,m),6.92(1H,d,J=8.3Hz),6.98(1H,brs),7.5-7.7(2H,m),7.88(1H,d,J=8.4Hz),8.31(1H,dd,J=1.9Hz,8.8Hz),8.43(1H,t,J=5.8Hz),8.85(1H,d,J=1.5Hz),12.93(1H,brs)
MS(m/z):518(M+)。
ベンゾチアゾール-2-カルバルデヒド及びN-(3-カルバミミドイル-2,4-ジフルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),2.46(1H,sept,J=6.8Hz),4.34(2H,d,J=5.3Hz),7.23(1H,brs),7.32(1H,t,J=8.8Hz),7.5-7.7(3H,m),8.1-8.3(2H,m),8.35(1H,t,J=5.6Hz),13.48(1H,brs)
MS(m/z):440(M+)。
ベンゾチアゾール-2-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.06(6H,d,J=6.8Hz),2.47(1H,sept,J=6.8Hz),4.42(2H,d,J=5.9Hz),7.20(1H,brs),7.5-7.8(4H,m),7.92(1H,d,J=8.3Hz),8.1-8.3(2H,m),8.41(1H,t,J=5.9Hz),13.35(1H,brs)
MS(m/z):472(M+)。
6-(2-プロポキシエトキシ)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-2-クロロ-4-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.85(3H,t,J=7.3Hz),1.07(6H,d,J=6.8Hz),1.51(2H,sext,J=7.3Hz),2.4-2.6(1H,m),3.40(2H,t,J=6.3Hz),3.6-3.8(2H,m),4.35(2H,d,J=5.9Hz),4.4-4.5(2H,m),6.91(1H,d,J=8.8Hz),7.01(1H,brs),7.3-7.6(2H,m),8.31(1H,dd,J=2.4Hz,8.8Hz),8.37(1H,t,J=5.9Hz),8.84(1H,d,J=2.4Hz),13.10(1H,brs)
MS(m/z):502(M+)。
4-(トリフルオロメチル)チアゾール-2-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),2.46(1H,sept,J=6.8Hz),4.41(2H,d,J=6.8Hz),7.01(1H,brs),7.5-7.7(2H,m),7.91(1H,d,J=8.3Hz),8.41(1H,t,J=5.8Hz),8.73(1H,s),13.36(1H,brs)
MS(m/z):490(M+)。
5-エチニルピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行って表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),2.46(1H,sept,J=6.8Hz),4.33(2H,d,J=5.9Hz),4.52(1H,s),7.22(1H,brs),7.4-7.6(2H,m),8.36(1H,t,J=5.8Hz),8.4-8.5(1H,m),8.78(1H,d,J=2.0Hz),9.22(1H,d,J=2.0Hz),13.23(1H,brs)
MS(m/z):424(M+)。
6-[2-(2,2,2-トリフルオロエトキシ)エトキシ]ピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),2.46(1H,sept,J=6.8Hz),3.95(2H,t,J=4.7Hz),4.14(2H,q,J=9.3Hz),4.40(2H,d,J=5.9Hz),4.4-4.6(2H,m),6.94(1H,d,J=8.8Hz),6.99(1H,brs),7.5-7.7(2H,m),7.88(1H,d,J=8.3Hz),8.33(1H,dd,J=2.0Hz,8.3Hz),8.39(1H,t,J=5.9Hz),8.86(1H,d,J=2.0Hz),12.95(1H,brs)
MS(m/z):558(M+)。
6-[2-(2,2,2-トリフルオロエトキシ)エトキシ]ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=7.3Hz),2.45(1H,sept,J=6.8Hz),3.9-4.0(2H,m),4.14(2H,q,J=9.7Hz),4.32(2H,d,J=5.8Hz),4.4-4.6(2H,m),6.94(1H,d,J=8.8Hz),7.02(1H,brs),7.4-7.6(2H,m),8.2-8.4(2H,m),8.85(1H,d,J=1.9Hz),13.05(1H,brs)
MS(m/z):542(M+)。
6-[2-(2,2,2-トリフルオロエトキシ)エトキシ]ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-2,4-ジフルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.45(1H,sept,J=6.8Hz),3.9-4.0(2H,m),4.14(2H,q,J=9.8Hz),4.32(2H,d,J=5.9Hz),4.4-4.6(2H,m),6.95(1H,d,J=8.8Hz),7.01(1H,brs),7.28(1H,t,J=8.8Hz),7.51(1H,q,J=8.4Hz),8.2-8.4(2H,m),8.86(1H,d,J=2.0Hz),13.12(1H,brs)
MS(m/z):526(M+)。
6-[2-(2,2,2-トリフルオロエトキシ)エトキシ]ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-2-クロロ-4-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.07(6H,d,J=6.8Hz),2.4-2.6(1H,m),3.9-4.0(2H,m),4.14(2H,q,J=9.7Hz),4.34(2H,d,J=5.8Hz),4.4-4.6(2H,m),6.93(1H,d,J=8.8Hz),7.01(1H,brs),7.3-7.6(2H,m),8.32(1H,dd,J=2.4Hz,8.8Hz),8.37(1H,t,J=5.9Hz),8.84(1H,d,J=1.9Hz),13.10(1H,brs)
MS(m/z):542(M+)。
5-(シクロプロピルエチニル)ピリジン-2-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]ブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.7-0.9(2H,m),0.86(3H,t,J=7.2Hz),0.9-1.0(2H,m),1.5-1.7(3H,m),2.15(2H,t,J=7.2Hz),4.41(2H,d,J=5.6Hz),7.21(1H,s),7.6-7.7(2H,m),7.8-8.0(2H,m),8.13(1H,d,J=8.4Hz),8.43(1H,t,J=5.6Hz),8.68(1H,d,J=1.6Hz),13.06(1H,s)
MS(m/z):480(M+)。
5-(シクロプロピルエチニル)ピリジン-2-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)ブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.7-0.9(2H,m),0.87(3H,t,J=7.2Hz),0.9-1.0(2H,m),1.4-1.7(3H,m),2.14(2H,t,J=6.8Hz),4.33(2H,d,J=5.6Hz),7.24(1H,s),7.4-7.6(2H,m),7.89(1H,dd,J=2.8Hz,8.4Hz),8.15(1H,d,J=8.4Hz),8.40(1H,t,J=6.0Hz),8.69(1H,d,J=2.0Hz),13.20(1H,s)
MS(m/z):464(M+)。
5-(3,3-ジメチル-1-ブチニル)ピラジン-2-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=6.8Hz),1.14(9H,s),2.4-2.6(1H,m),4.41(2H,d,J=5.6Hz),7.17(1H,s),7.6-7.7(2H,m),7.91(1H,d,J=8.0Hz),8.40(1H,t,J=5.6Hz),8.81(1H,s),9.19(1H,s),13.18(1H,s)
MS(m/z):497(M+)。
5-(シクロプロピルエチニル)ピラジン-2-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.6-0.7(2H,m),0.8-1.0(2H,m),1.05(6H,d,J=6.8Hz),1.6-1.8(1H,m),2.4-2.6(1H,m),4.41(2H,d,J=6.0Hz),7.15(1H,s),7.6-7.7(2H,m),7.90(1H,d,J=8.0Hz),8.40(1H,t,J=6.0Hz),8.73(1H,s),9.14(1H,s),13.17(1H,s)
MS(m/z):481(M+)。
2-(4-メチル-1-ペンチニル)ピリミジン-5-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.02(6H,d,J=6.8Hz),1.05(6H,d,J=7.2Hz),1.91(1H,sept,J=6.8Hz),2.4-2.6(3H,m)4.40(2H,d,J=6.0Hz),7.23(1H,s),7.6-7.7(2H,m),7.89(1H,d,J=8.0Hz),8.40(1H,t,J=6.0Hz),9.32(2H,s),13.19(1H,s)
MS(m/z):497(M+)。
5-プロピルピリジン-2-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.91(3H,t,J=7.2Hz),1.05(6H,d,J=7.2Hz),1.71(2H,sext,J=7.2Hz),2.46(1H,sept,J=6.8Hz),2.76(2H,t,J=7.2Hz),4.40(2H,d,J=6.0Hz),7.05(1H,s),7.35(1H,d,J=8.4Hz),7.5-7.7(2H,m),7.88(1H,d,J=8.0Hz),8.29(1H,dd,J=2.0Hz,8.0Hz),8.39(1H,t,J=6.0Hz),9.12(1H,d,J=1.2Hz),12.98(1H,s)
MS(m/z):458(M+)。
5-プロピルピリジン-2-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.91(3H,t,J=7.2Hz),1.05(6H,d,J=6.8Hz),1.71(2H,m),2.3-2.6(1H,m),2.76(2H,t,J=7.6Hz),4.32(2H,d,J=4.8Hz),7.09(1H,s),7.36(1H,d,J=8.0Hz),7.4-7.6(2H,m),8.2-8.5(2H,m),9.11(1H,s),12.99(1H,s)
MS(m/z):442(M+)。
2-(シクロプロピルメトキシ)ピリミジン-5-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.3-0.4(2H,m),0.5-0.7(2H,m),1.04(6H,d,J=6.4Hz),1.2-1.4(1H,m),2.3-2.6(1H,m),4.22(2H,d,J=7.2Hz),4.32(2H,d,J=4.8Hz),7.13(1H,s),7.4-7.6(2H,m),8.3-8.4(1H,m),9.1-9.2(2H,m),13.01(1H,s)
MS(m/z):471(M+)。
2-(シクロプロピルメトキシ)ピリミジン-5-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]ブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.3-0.4(2H,m),0.5-0.6(2H,m),0.86(3H,t,J=7.2Hz),1.2-1.4(1H,m),1.55(2H,sext,J=7.2Hz),2.15(2H,t,J=7.2Hz),4.22(2H,d,J=7.2Hz),4.41(2H,d,J=5.6Hz),7.10(1H,s),7.6-7.7(2H,m),7.88(1H,d,J=7.6Hz),8.43(1H,t,J=5.6Hz),9.1-9.2(2H,m),12.74(1H,s)
MS(m/z):487(M+)。
[4,5'-ビピリミジン]-2-イル]-2-フルオロベンジル}ブチルアミド
2-(シクロプロピルメトキシ)ピリミジン-5-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)ブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.3-0.4(2H,m),0.5-0.6(2H,m),0.87(3H,t,J=7.2Hz),1.2-1.4(1H,m),1.55(2H,sext,J=7.2Hz),2.14(2H,t,J=7.2Hz),4.22(2H,d,J=7.2Hz),4.33(2H,d,J=5.6Hz),7.12(1H,s),7.4-7.6(2H,m),8.39(1H,t,J=4.8Hz),9.17(2H,s),12.43(1H,s)
MS(m/z):471(M+)。
5-(シクロプロピルメトキシ)ピラジン-2-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.3-0.4(2H,m),0.5-0.6(2H,m),1.05(6H,d,J=6.8Hz),1.2-1.3(1H,m),2.4-2.6(1H,m),4.21(2H,d,J=7.6Hz),4.40(2H,d,J=5.6Hz),7.06(1H,s),7.5-7.7(2H,m),7.90(1H,d,J=8.0Hz),8.3-8.5(2H,m),8.8-8.9(1H,m),13.05(1H,s)
MS(m/z):487(M+)。
2-(1-プロピニル)チアゾール-5-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.04(6H,d,J=6.8Hz),2.17(3H,s),2.45(1H,sept,J=6.8Hz),4.31(2H,d,J=6.0Hz),7.08(1H,s),7.4-7.5(2H,m),8.36(1H,t,J=6.0Hz),8.61(1H,s),13.23(1H,brs)
MS(m/z):444(M+)。
2-(シクロプロピルエチニル)チアゾール-5-カルバルデヒド及びN-(3-カルバミミドイル-2-クロロ-4-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.8-1.1(4H,m),1.07(6H,d,J=6.8Hz),1.6-1.8(1H,m),2.4-2.6(1H,m),4.33(2H,d,J=6.0Hz),7.07(1H,s),7.4-7.6(2H,m),8.37(1H,t,J=6.0Hz),8.59(1H,s),13.22(1H,brs)
MS(m/z):470(M+)。
5-(シクロプロピルエチニル)ピリジン-2-カルバルデヒド及びN-(3-カルバミミドイル-2,4-ジフルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.7-1.0(4H,m),1.04(6H,d,J=6.8Hz),1.5-1.7(1H,m),2.45(1H,sept,J=6.8Hz),4.32(2H,d,J=5.6Hz),7.23(1H,s),7.28(1H,t,J=8.8Hz),7.4-7.6(1H,m),7.91(1H,dd,J=2.4Hz,8.4Hz),8.17(1H,d,J=8.0Hz),8.33(1H,t,J=5.6Hz),8.69(1H,d,J=1.2Hz),13.26(1H,brs)
MS(m/z):448(M+)。
6-(シクロプロピルエチニル)ピリジン-3-カルバルデヒド及びN-(3-カルバミミドイル-2,4-ジフルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.8-1.0(4H,m),1.04(6H,d,J=6.8Hz),1.5-1.7(1H,m),2.44(1H,sept,J=6.8Hz),4.32(2H,d,J=5.6Hz),7.14(1H,s),7.28(1H,t,J=8.8Hz),7.4-7.6(2H,m),8.3-8.4(2H,m),9.14(1H,d,J=2.0Hz),13.22(1H,brs)
MS(m/z):448(M+)。
2-[3-クロロ-2-フルオロ-6-(トリフルオロメチル)フェニル]-6-(5-クロロピリジン-2-イル)ピリミジン-4(3H)-オンを用い、実施例169と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.03(6H,d,J=6.8Hz),1.06(6H,d,J=6.8Hz),2.3-2.6(2H,m),4.34(2H,d,J=5.6Hz),4.41(2H,d,J=5.6Hz),7.24(1H,s),7.66(1H,t,J=8.0Hz),7.7-7.9(2H,m),8.11(1H,d,J=7.6Hz),8.35(1H,t,J=5.6Hz),8.45(1H,t,J=6.0Hz),8.60(1H,d,J=1.6Hz),13.30(1H,brs)
MS(m/z):533(M+)。
2-[3-クロロ-2-フルオロ-6-(トリフルオロメチル)フェニル]-6-[5-(1-プロピニル)ピリジン-2-イル]ピリミジン-4(3H)-オンを用い、実施例169と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.06(6H,d,J=6.8Hz),2.12(3H,s),2.48(1H,sept,J=6.8Hz),4.41(2H,d,J=5.6Hz),7.24(1H,s),7.66(1H,t,J=7.6Hz),7.79(1H,d,J=7.6Hz),7.93(1H,dd,J=2.0Hz,8.0Hz),8.12(1H,d,J=8.0Hz),8.44(1H,t,J=5.6Hz),8.72(1H,d,J=2.0Hz),13.34(1H,brs)
MS(m/z):472(M+)。
2-[3-クロロ-2-フルオロ-6-(トリフルオロメチル)フェニル]-6-[6-(シクロプロピルエチニル)ピリジン-3-イル]ピリミジン-4(3H)-オンを用い、実施例169と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.7-1.0(4H,m),1.06(6H,d,J=7.2Hz),1.5-1.7(1H,m),2.48(1H,sept,J=6.8Hz),4.40(2H,d,J=6.0Hz),7.15(1H,s),7.51(1H,d,J=8.4Hz),7.65(1H,t,J=8.0Hz),7.78(1H,d,J=8.4Hz),8.33(1H,d,J=8.4Hz),8.43(1H,t,J=6.0Hz),9.12(1H,s),13.29(1H,brs)
MS(m/z):498(M+)。
6-(シクロプロピルエチニル)ピリジン-3-カルバルデヒド及びN-[3-カルバミミドイル-4-(トリフルオロメチル)ベンジル]イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.7-1.0(4H,m),1.05(6H,d,J=7.2Hz),1.5-1.7(1H,m),2.45(1H,sept,J=6.8Hz),4.40(2H,d,J=6.0Hz),7.11(1H,s),7.5-7.7(3H,m),7.88(1H,d,J=8.4Hz),8.34(1H,dd,J=2.0Hz,8.4Hz),8.39(1H,t,J=6.0Hz),9.14(1H,s),13.06(1H,brs)
MS(m/z):480(M+)。
2-[3-クロロ-2-フルオロ-6-(トリフルオロメチル)フェニル]-6-[6-(2-プロポキシエトキシ)ピリジン-3-イル]ピリミジン-4(3H)-オンを用い、実施例169と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.85(3H,t,J=7.6Hz),1.06(6H,d,J=6.8Hz),1.51(2H,sext,J=7.6Hz),2.48(1H,sept,J=6.8Hz),3.39(2H,t,J=6.8Hz),3.71(2H,t,J=4.8Hz),4.40(2H,d,J=6.0Hz),4.43(2H,t,J=4.4Hz),6.92(1H,d,J=8.8Hz),7.02(1H,s),7.65(1H,t,J=7.6Hz),7.79(1H,d,J=8.0Hz),8.30(1H,d,J=8.4Hz),8.46(1H,t,J=6.0Hz),8.83(1H,s),13.20(1H,brs)
MS(m/z):536(M+)。
2-[3-クロロ-2-フルオロ-6-(トリフルオロメチル)フェニル]-6-[6-(2-イソプロポキシエトキシ)ピリジン-3-イル]ピリミジン-4(3H)-オンを用い、実施例169と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.0-1.2(12H,m),2.48(1H,sept,J=6.8Hz),3.61(1H,sept,J=6.0Hz),3.70(2H,t,J=4.8Hz),4.3-4.5(4H,m),6.92(1H,d,J=8.8Hz),7.01(1H,s),7.65(1H,t,J=8.0Hz),7.78(1H,d,J=8.0Hz),8.29(1H,d,J=8.4Hz),8.43(1H,t,J=6.0Hz),8.83(1H,s),13.17(1H,brs)
MS(m/z):536(M+)。
2-[3-クロロ-2-フルオロ-6-(トリフルオロメチル)フェニル]-6-[2-(シクロプロピルエチニル)チアゾール-5-イル]ピリミジン-4(3H)-オンを用い、実施例169と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.8-1.1(4H,m),1.06(6H,d,J=6.8Hz),1.6-1.8(1H,m),2.47(1H,sept,J=6.8Hz),4.40(2H,d,J=5.6Hz),7.08(1H,s),7.65(1H,t,J=7.6Hz),7.77(1H,d,J=8.0Hz),8.43(1H,t,J=5.6Hz),8.59(1H,s),13.29(1H,brs)
MS(m/z):504(M+)。
2-[3-クロロ-2-フルオロ-6-(トリフルオロメチル)フェニル]-6-{6-[2-(2,2,2-トリフルオロエトキシ)エトキシ]ピリジン-3-イル}ピリミジン-4(3H)-オンを用い、実施例169と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.06(6H,d,J=6.8Hz),2.48(1H,sept,J=6.8Hz),3.95(2H,t,J=4.4Hz),4.14(2H,q,J=9.2Hz),4.40(2H,d,J=5.2Hz),4.48(2H,t,J=4.4Hz),6.94(1H,d,J=8.8Hz),7.02(1H,s),7.65(1H,t,J=7.6Hz),7.78(1H,d,J=8.0Hz),8.31(1H,d,J=7.6Hz),8.43(1H,t,J=5.6Hz),8.83(1H,s),13.18(1H,brs)
MS(m/z):576(M+)。
5-(2,2,2-トリフルオロエチル)ピリジン-2-カルバルデヒド及びN-(3-カルバミミドイル-4-クロロ-2-フルオロベンジル)イソブチルアミド塩酸塩を用い、実施例4と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):1.05(6H,d,J=7.2Hz),2.46(1H,sept,J=6.8Hz),3.84(2H,q,J=11.2Hz),4.33(2H,d,J=6.0Hz),7.28(1H,s),7.4-7.6(2H,m),7.95(1H,dd,J=2.0Hz,8.0Hz),8.23(1H,d,J=7.6Hz),8.37(1H,t,J=6.0Hz),8.72(1H,d,J=1.6Hz),13.28(1H,brs)
MS(m/z):482(M+)。
2-[3-クロロ-2-フルオロ-6-(トリフルオロメチル)フェニル]-6-[5-(シクロプロピルエチニル)ピリジン-2-イル]ピリミジン-4(3H)-オンを用い、実施例169と同様の操作を行い、表題化合物を得た。
1H-NMR(d6-DMSO,δ):0.7-1.0(4H,m),1.06(6H,d,J=6.8Hz),1.5-1.7(1H,m),2.48(1H,sept,J=6.8Hz),4.40(2H,d,J=6.0Hz),7.23(1H,s),7.66(1H,t,J=8.0Hz),7.79(1H,d,J=8.4Hz),7.89(1H,dd,J=2.0Hz,8.0Hz),8.10(1H,d,J=8.0Hz),8.44(1H,t,J=6.0Hz),8.69(1H,d,J=1.2Hz),13.33(1H,brs)
MS(m/z):498(M+)。
ヒトmPGES-1 cDNAをコードするプラスミドを一過性にトランスフェクトしたCOS-1細胞からミクロソームを調製し、mPGES-1酵素として用いた。mPGES-1酵素を還元型グルタチオン(2.5 mM)及びEDTA(1 mM)を含んだリン酸ナトリウム緩衝液(pH 7.2)にて希釈し、DMSO又は試験化合物のDMSO溶液(DMSOの終濃度1%)を加え、4℃で15分間プレインキュベートした。次に、基質であるPGH2を終濃度1μMとなるよう添加して酵素反応を開始させ、4℃で4分間インキュベートした後、塩化第二鉄(25 mM)及びクエン酸(50 mM)溶液を加えて酵素反応を停止させた。生成したPGE2をProstaglandin E2 Express EIA kit (Cayman Chemical)を用いて測定した。標準的な方法を用いてIC50値を測定した。結果を以下の表2-1〜表2-5に示す。
Claims (13)
- 下記の一般式(1):
- Xがカルボニル基である請求項1に記載の一般式(1)で表される化合物又はその塩。
- R6が分枝鎖C1-6アルキル基(該アルキル基はC1-6アルコキシ基で置換されていてもよい)である請求項1又は2に記載の一般式(1)で表される化合物又はその塩。
- R4及びR5が共に水素原子である請求項1乃至3のいずれか1項に記載の一般式(1)で表される化合物又はその塩。
- R3が1個または2個のハロゲン原子又はハロゲン原子で置換されてもよいアルキル基である請求項1乃至4のいずれか1項に記載の一般式(1)で表される化合物又はその塩。
- R1が水素原子、アルキル基、又はシアノ基である請求項1乃至5のいずれか1項に記載の一般式(1)で表される化合物又はその塩。
- R2が置換基を有していてもよい飽和若しくは部分飽和の単環性3〜7員環状炭化水素基、置換基を有していてもよいフェニル基、置換基を有していてもよい飽和若しくは部分飽和の単環性3〜7員複素環基(該複素環基は1乃至3個の環構成ヘテロ原子を含む)、又は置換基を有していてもよい単環性芳香族複素環基(該複素環基は1乃至3個の環構成ヘテロ原子を含む)である請求項1乃至6のいずれか1項に記載の一般式(1)で表される化合物又はその塩。
- R2が置換基を有していてもよいフェニル基、又は置換基を有してもよいピリジル基である請求項1乃至7のいずれかに1項に記載の一般式(1)で表される化合物又はその塩。
- N-(4-クロロ-3-[4-[6-(ジフルオロメトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-2-フルオロベンジル)イソブチルアミド、
N-(3-[4-[6-(2-エトキシエトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-4-(トリフルオロメチル)ベンジル)イソブチルアミド、
N-(3-[6-オキソ-4-[6-(2-プロポキシエトキシ)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル]-4-(トリフルオロメチル)ベンジル)イソブチルアミド、
N-(4-クロロ-3-[4-[6-(シクロプロピルメトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-2-フルオロベンジル)イソブチルアミド、
N-(4-クロロ-2-フルオロ-3-[6-オキソ-4-[5-(トリフルオロメチル)ピリジン-2-イル]-1,6-ジヒドロピリミジン-2-イル]ベンジル)イソブチルアミド、
N-(3-[4-[6-(シクロプロピルメトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-2,4-ジフルオロベンジル)イソブチルアミド、
N-(4-クロロ-2-フルオロ-3-[6-オキソ-4-[6-(2,2,2-トリフルオロエトキシ)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル]ベンジル)イソブチルアミド、
N-[4-クロロ-3-[4-(5-クロロピリジン-2-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-2-フルオロベンジル]イソブチルアミド、
N-(4-クロロ-2-フルオロ-3-[6-オキソ-4-[6-(3,3,3-トリフルオロプロポキシ)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル]ベンジル)イソブチルアミド、
N-(2-クロロ-4-フルオロ-3-[6-オキソ-4-[5-(トリフルオロメチル)ピリジン-2-イル]-1,6-ジヒドロピリミジン-2-イル]ベンジル)イソブチルアミド、
N-(3-[4-[6-(ジフルオロメトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-2-フルオロ-4-(トリフルオロメチル)ベンジル)イソブチルアミド、
N-(3-[4-[6-(2-エトキシエトキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-2-フルオロ-4-(トリフルオロメチル)ベンジル)イソブチルアミド、
N-(2-フルオロ-3-[6-オキソ-4-[5-(トリフルオロメチル)ピリジン-2-イル]-1,6-ジヒドロピリミジン-2-イル]-4-(トリフルオロメチル)ベンジル)イソブチルアミド、
N-(3-[6-オキソ-4-[6-(テトラヒドロピラン-4-イルメトキシ)ピリジン-3-イル]-1,6-ジヒドロピリミジン-2-イル]-4-(トリフルオロメチル)ベンジル)イソブチルアミド、
N-(3-[4-[6-(3-エトキシプロポキシ)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-4-(トリフルオロメチル)ベンジル)イソブチルアミド、
N-[2-フルオロ-3-[4-(6-メトキシピリジン-3-イル)-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-4-(トリフルオロメチル)ベンジル]イソブチルアミド、又は
N-(4-クロロ-3-[4-[6-(シクロプロピルエチニル)ピリジン-3-イル]-6-オキソ-1,6-ジヒドロピリミジン-2-イル]-2-フルオロベンジル)イソブチルアミドである請求項1に記載の一般式(1)で表される化合物又はその塩。 - 請求項1乃至9のいずれか1項に記載の上記一般式(1)で表される化合物又はその塩を含むmPGES-1阻害剤。
- 請求項1乃至9のいずれか1項に記載の上記一般式(1)で表される化合物又はその塩を含むPGE2生合成阻害剤。
- 請求項1乃至9のいずれか1項に記載の上記一般式(1)で表される化合物又は生理学的に許容されるその塩を含む医薬。
- 炎症、疼痛、リウマチ、変形性関節症、発熱、アルツハイマー病、多発性硬化症、動脈硬化、高眼圧症、虚血性網膜疾患、全身性強皮症、悪性腫瘍、過活動膀胱、前立腺肥大に伴う排尿障害、夜間頻尿、尿失禁、神経因性膀胱、間質性膀胱炎、膀胱痛症候群、尿路結石、前立腺肥大症、又はPGE2産生抑制が有効性を示す疾患の予防及び/又は治療に用いるための請求項12に記載の医薬。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015212920 | 2015-10-29 | ||
JP2015212920 | 2015-10-29 | ||
JP2016078697 | 2016-04-11 | ||
JP2016078697 | 2016-04-11 | ||
PCT/JP2016/081993 WO2017073709A1 (ja) | 2015-10-29 | 2016-10-28 | ピリミジン誘導体 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2017073709A1 JPWO2017073709A1 (ja) | 2018-08-23 |
JP6817952B2 true JP6817952B2 (ja) | 2021-01-20 |
Family
ID=58630549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017547876A Active JP6817952B2 (ja) | 2015-10-29 | 2016-10-28 | ピリミジン誘導体 |
Country Status (11)
Country | Link |
---|---|
US (1) | US10710967B2 (ja) |
EP (1) | EP3372589B1 (ja) |
JP (1) | JP6817952B2 (ja) |
KR (1) | KR102649802B1 (ja) |
CN (1) | CN108137513B (ja) |
AU (1) | AU2016346557B2 (ja) |
CA (1) | CA3002632C (ja) |
DK (1) | DK3372589T3 (ja) |
ES (1) | ES2902127T3 (ja) |
SG (2) | SG10201913525QA (ja) |
WO (1) | WO2017073709A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019044868A1 (ja) * | 2017-08-30 | 2019-03-07 | あすか製薬株式会社 | ピリミジン誘導体 |
JP7499789B2 (ja) * | 2019-12-25 | 2024-06-14 | 日本新薬株式会社 | 慢性前立腺炎/慢性骨盤痛症候群の予防及び/又は治療剤 |
AU2022217610A1 (en) | 2021-02-02 | 2023-08-24 | Aska Pharmaceutical Co., Ltd. | Pyrimidine derivative |
TW202409037A (zh) * | 2022-07-06 | 2024-03-01 | 日商Aska製藥股份有限公司 | 嘧啶衍生物 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54113923A (en) | 1978-02-25 | 1979-09-05 | Sekisui Jushi Kk | Method of assembling partition wall |
JPS6310716Y2 (ja) | 1979-06-19 | 1988-03-30 | ||
JP2002514195A (ja) * | 1996-12-05 | 2002-05-14 | アムジエン・インコーポレーテツド | 置換ピリミジン化合物およびそれの使用 |
US6410729B1 (en) | 1996-12-05 | 2002-06-25 | Amgen Inc. | Substituted pyrimidine compounds and methods of use |
US6096753A (en) | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
AU733877C (en) * | 1996-12-05 | 2003-05-08 | Amgen, Inc. | Substituted pyrimidine compounds and their use |
US6087368A (en) * | 1998-06-08 | 2000-07-11 | Bristol-Myers Squibb Company | Quinazolinone inhibitors of cGMP phosphodiesterase |
CA2403382A1 (en) * | 2000-03-20 | 2001-09-27 | Teva Pharmaceutical Industries Ltd. | Novel processes for preparing torsemide intermediate |
EP1136485A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | Aminophenyl pyrimidone derivatives |
CN101747282A (zh) * | 2008-12-10 | 2010-06-23 | 上海特化医药科技有限公司 | 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途 |
UA108950C2 (uk) * | 2011-08-18 | 2015-06-25 | Гетероциклічна похідна і фармацевтичний засіб | |
TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲mPGES-1抑制劑之三唑酮化合物 |
WO2015059618A1 (en) | 2013-10-22 | 2015-04-30 | Glenmark Pharmaceuticals S.A. | SUBSTITUTED PYRIMIDINE COMPOUNDS AS mPGES-1 INHIBITORS |
TWI651310B (zh) * | 2014-02-20 | 2019-02-21 | 日商日本煙草產業股份有限公司 | 三化合物及其醫藥用途 |
PE20180951A1 (es) * | 2015-08-17 | 2018-06-11 | Japan Tobacco Inc | Compuestos de hidroxitriazina y usos medicos de los mismos |
-
2016
- 2016-10-28 CN CN201680063335.5A patent/CN108137513B/zh active Active
- 2016-10-28 DK DK16859937.1T patent/DK3372589T3/da active
- 2016-10-28 KR KR1020187014443A patent/KR102649802B1/ko active IP Right Grant
- 2016-10-28 US US15/770,002 patent/US10710967B2/en active Active
- 2016-10-28 AU AU2016346557A patent/AU2016346557B2/en active Active
- 2016-10-28 EP EP16859937.1A patent/EP3372589B1/en active Active
- 2016-10-28 SG SG10201913525QA patent/SG10201913525QA/en unknown
- 2016-10-28 CA CA3002632A patent/CA3002632C/en active Active
- 2016-10-28 ES ES16859937T patent/ES2902127T3/es active Active
- 2016-10-28 SG SG11201803357TA patent/SG11201803357TA/en unknown
- 2016-10-28 JP JP2017547876A patent/JP6817952B2/ja active Active
- 2016-10-28 WO PCT/JP2016/081993 patent/WO2017073709A1/ja active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CN108137513B (zh) | 2022-03-01 |
AU2016346557A1 (en) | 2018-05-31 |
CN108137513A (zh) | 2018-06-08 |
EP3372589A4 (en) | 2019-04-24 |
US20200071280A1 (en) | 2020-03-05 |
CA3002632A1 (en) | 2017-05-04 |
KR102649802B1 (ko) | 2024-03-20 |
EP3372589B1 (en) | 2021-10-20 |
WO2017073709A1 (ja) | 2017-05-04 |
EP3372589A1 (en) | 2018-09-12 |
US10710967B2 (en) | 2020-07-14 |
KR20180067678A (ko) | 2018-06-20 |
CA3002632C (en) | 2023-08-29 |
JPWO2017073709A1 (ja) | 2018-08-23 |
SG10201913525QA (en) | 2020-02-27 |
ES2902127T3 (es) | 2022-03-25 |
DK3372589T3 (da) | 2021-12-06 |
SG11201803357TA (en) | 2018-05-30 |
AU2016346557B2 (en) | 2020-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7001682B2 (ja) | 置換1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン及びGLUN2B受容体調節因子としてのそれらの使用 | |
AU2015335694B2 (en) | Indole carboxamide compounds useful as kinase inhibitors | |
US20230103791A1 (en) | 2,3-dihydroquinazolin compounds as nav1.8 inhibitors | |
AU2021400942A1 (en) | PRMT5 inhibitors | |
JP6923543B2 (ja) | Nr2b選択的nmda調節因子としての置換1,2,3−トリアゾール | |
JP5970003B2 (ja) | アミノピラジン化合物 | |
JP6817952B2 (ja) | ピリミジン誘導体 | |
WO2007037534A1 (ja) | 2-へテロアリール置換インドール誘導体 | |
NZ578310A (en) | Mapk/erk kinase inhibitors | |
TW201925187A (zh) | 經碸吡啶烷基醯胺取代之雜芳基化合物 | |
JP2018514537A (ja) | イミダゾピラジン及びピラゾロピリミジン、並びにampa受容体調節物質としてのこれらの使用 | |
TW201217362A (en) | Heteroaryls and uses thereof | |
JP2024505732A (ja) | ピリドピリミジノン系誘導体及びその製造方法と使用 | |
EP2091941B1 (en) | Mapk/erk kinase inhibitors | |
JP2020508327A (ja) | ジヒドロオロテートオキシゲナーゼ阻害剤としての1、4、6−トリ置換−2−アルキル−1H−ベンゾ[d]イミダゾール誘導体 | |
JP7237002B2 (ja) | ピリミジン誘導体 | |
CN112313207B (zh) | 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用 | |
JP2014101287A (ja) | インドール誘導体 | |
WO2019119481A1 (zh) | 吲唑类衍生物激酶抑制剂 | |
TW202409037A (zh) | 嘧啶衍生物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180425 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191010 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200901 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201023 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201208 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201225 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6817952 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |